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5Foreword
The prescription of substitution drugs, together with appropriate psychosocial 
support, is an integral part of today’s mainstream approach to treating heroin 
dependence. This has come about because over the last two decades, an increasing 
body of high-quality research has demonstrated the efficacy of using drugs such 
as methadone and buprenorphine to help stabilise and improve the health status of 
those dependent on illicit ‘street’ heroin. The weight of evidence has been sufficient 
to counterbalance legitimate concerns about the value of replacing one opioid 
drug with another. Most importantly, the development of good clinical practice 
and safeguards has ensured that any possible unintended negative consequences 
have been largely avoided. This is important for the prescription of medicines that 
themselves have considerable abuse potential.
Today, methadone and buprenorphine are among the first-line responses to the 
treatment of opioid dependence. However, as with other pharmacologically-based 
treatments across the medical spectrum, some patients are poor responders. 
A small, but important, minority of chronic heroin-dependent individuals repeatedly 
fail to benefit from this kind of intervention. This group may be a small one, but it 
is also one in which the negative health and social implications of long-term drug 
dependence are pronounced. The effective treatment of these individuals thus has a 
high relative potential to impact on the health costs associated with drug dependence 
and this is the underlying theme that this Insights publication addresses.
History has taught us that the introduction of effective interventions in the drugs field 
can sometimes, at first, seem counter-intuitive and be viewed as controversial. This is 
true of the subject of this publication and this is also the reason why the clear-headed 
evaluation of evidence is so important. Internationally, a number of experimental 
projects using robust research designs have been beginning to suggest that for 
some of those failing to respond to other approaches, the use of diamorphine as a 
substitution medicine may be an effective way forward. This is not simply a case of 
giving heroin to heroin addicts. Rather, studies have looked at the use of heroin as 
part of a highly regulated treatment regime, targeting a particularly difficult-to-treat 
group of patients.  
The EMCDDA is proud to have brought together here all the major contemporary 
studies on this topic, to address two key questions. Does the evidence available 
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now support the use of supervised injectable heroin treatment for those who have 
failed to respond adequately to other approaches? And if so, what are the clinical 
management issues necessary to ensure that this therapeutic option can be delivered 
in a manner that avoids the obvious risks associated with such an intervention? 
When addressing a topic of this sensitivity and importance, maintaining a high 
degree of scientific rigour is paramount. To ensure this, the review of evidence 
that underpins this publication has been conducted in close collaboration with the 
Cochrane Group. But if this kind of approach is to become more widely adopted, 
then the evidence must also speak to the wider policy and practice community. This is 
the purpose of this report. I believe that it provides the reader with an easy to access, 
state-of-the-art overview of the current development of science in this area, together 
with a more practically orientated discussion on service-delivery issues. Our purpose 
in doing this is to inform — not to advocate. National drug situations across the 
European Union differ considerably, as do the relative costs and benefits of pursuing 
different therapeutic approaches. It remains, therefore, the readers’ responsibility to 
draw their own conclusions about the appropriateness, or otherwise, of this kind of 
intervention for their use, within their own national context.
Wolfgang Götz
Director, EMCDDA
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Executive summary
Supervised injectable heroin (SIH) treatment has emerged over the last 15 years as 
a potentially important intensive second-line treatment for entrenched heroin addicts 
for whom previous orthodox treatments (i.e. oral methadone maintenance treatment 
(MMT) or residential rehabilitation) have produced little benefit. This treatment, by its 
very nature, attracts attention and controversy. Therefore, it is particularly important 
that there is a robust evidence base for its effectiveness and that the research 
evidence from international trials is brought together in one document and examined 
alongside the evidence from wider clinical experience in order to provide a complete 
picture of what we know about this treatment.
We now have the results from a series of well-designed randomised clinical trials, 
from Europe and Canada, which have been peer reviewed and published in high-
impact scientific journals, as well as steadily accumulating clinical experience of the 
development and provision of supervised injectable heroin treatment.
All of the available findings from randomised controlled trials (RCTs) published 
in academic papers and project reports have been examined in order to gauge 
the efficacy (against a range of outcomes) as well as the cost and cost utility of 
SIH treatment. Thus, this Insights gives a historical overview of SIH, including the 
international policy and legislation regarding this treatment, before moving on to 
examine the research evidence and clinical and policy experience with this new 
treatment.
Context and history
Supervised injectable heroin treatment was developed and initially introduced in 
Switzerland during the 1990s after a century of prescribing heroin for the treatment 
of addiction without direct supervision, mostly in the United Kingdom. Since the 
1990s, SIH treatment has been tested as a new clinical practice, sometimes in the 
context of clinical RCTs, in a number of European countries and in Canada.
Two common features characterise the new approach to heroin treatment. Firstly, 
SIH is not a first-line treatment, but rather is an option for patients who have not 
responded to standard treatments such as oral MMT or residential rehabilitation. 
Secondly, all injectable doses (typically, approximately 200 mg of diacetylmorphine 
per injection) are taken under direct medical or nursing supervision, thereby 
12
New heroin-assisted treatment
ensuring compliance, monitoring, safety and prevention of any possible diversion of 
prescribed diacetylmorphine to the illicit market: this requires the clinics to be open 
for several sessions per day, every day of the year.
Scientific evidence base
Over the past 15 years, six RCTs have been conducted involving more than 
1 500 patients, and they provide strong evidence, both individually and collectively, 
in support of the efficacy of treatment with fully supervised self-administered 
injectable heroin, when compared with oral MMT, for long-term refractory 
heroin-dependent individuals. These have been conducted in six countries: 
Switzerland (Perneger et al., 1998); the Netherlands (van den Brink et al., 2003); 
Spain (March et al., 2006); Germany (Haasen et al., 2007), Canada (Oviedo-Joekes 
et al., 2009) and England (Strang et al., 2010).
Across the trials, major reductions in the continued use of ‘street’ heroin occurred 
in those receiving SIH compared with control groups (most often receiving active 
MMT). These reductions occasionally included complete cessation of ‘street’ heroin 
use, although more frequently there was continued but reduced irregular use of ‘street’ 
heroin, at least through the trial period (ranging from 6 to 12 months). Reductions 
also occurred, but to a lesser extent, with the use of a range of other drugs, such as 
cocaine and alcohol. However, the difference between reductions in the SIH group 
and the various control groups was not as great (compared with major reductions in 
the use of ‘street’ heroin).
Patients receiving SIH treatment achieved gains in physical and mental health, as 
well as social functioning, although improvements in those receiving SIH were not 
consistently or significantly superior to the control group across all trials, particularly 
in relation to psychosocial functioning.
Reductions in the criminal activity of SIH patients were evident and were substantially 
greater when compared with patients under control conditions.
Retention in treatment varied substantially across the trials. The available evidence 
suggests added value of SIH alongside supplementary doses of methadone for long-
term treatment-refractory opioid users.
Furthermore, efficacy of heroin provision as a treatment modality on several 
outcomes (retention, mortality) was corroborated by a systematic review conducted 
by the Cochrane Group. Although the inclusion criteria of studies in the latter 
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review were stricter from a methodological point of view, converging conclusions 
on the efficacy of SIH further strengthens the current evidence of this. However, it 
is important to note that more serious adverse events have been reported to occur 
in patients receiving SIH than oral methadone. This suggests that SIH may be less 
safe and therefore require more resources and clinical attention in order to manage 
greater safety issues.
Finally, countries that have conducted longer term (up to six years) follow-up studies 
have seen a high retention in SIH (55 % at two years and 40 % at six years), with 
patients sustaining gains in reduced ‘street’ heroin use and marked improvements in 
social functioning (e.g. stable housing, drug-free social contacts and increased rate 
of employment).
Cost and economic evaluations
The reported cost per patient per year of an SIH maintenance programme, across 
the different countries, was between EUR 12 700 and EUR 20 400. The lowest cost 
was reported by Switzerland at between EUR 12 700 and EUR 14 500, depending 
on the capacity of the injectable maintenance clinic; Germany reported a cost of 
EUR 19 000 and the Netherlands a cost of EUR 20 400. The costs reported by the 
trials were consistently and substantially higher than the cost of oral MMT provision 
at EUR 3 500 (Germany) and EUR 1 600 (Netherlands). This was largely due to 
a higher staffing requirement for the SIH treatment provision — at least two staff 
members must be present at all times and no ‘take-home’ injectable heroin doses are 
permitted, with clinics needing to be open daily and for extended hours — as well as 
the higher cost of diacetylmorphine (see also Chapter 5).
The higher cost of SIH compared with optimised oral methadone (OOM) treatment 
provision was compensated for by the significant savings to society. In particular, a 
greater reduction in the costs of criminal procedures and imprisonment as a result of 
associated criminal behaviour was seen with SIH than with OOM treatment. It should 
be noted that the provision of a more standard treatment to a patient who derives 
little benefit cannot be cost-effective, no matter how cheaply it may be delivered.
Impact, clinical practice and challenges
At the time of writing, the number of people receiving SIH treatment is changing, 
but there are approximately 1 000 SIH patients in the European Union (EU) and a 
further 1 400 in Switzerland.
14
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In the United Kingdom, the medical use of heroin has been used in clinical practice 
since it was first synthesised — both for the relief of terminal pain and for the 
treatment of opioid dependence (even though it has rarely been used in recent years 
for the treatment of addiction (see Chapter 2)). In recent years, four other countries 
(Denmark, Germany, the Netherlands and Switzerland) have granted approval 
for diamorphine to be used as a medicinal product for the specific indication of 
treatment-refractory heroin addicts. In these countries, SIH clinics are now integrated 
into local addiction service networks and appear to successfully deliver important 
benefits to a small number of severely affected chronic heroin addicts. For these 
addicts, this new treatment delivers tangible benefit, for themselves, for their families 
and for society.
In Spain, one SIH clinic continues to provide treatment to participants enrolled 
in their trial, now operating under legal exemption, and Canada has approved 
diacetylmorphine for research trials only.
Supervised injectable heroin treatment inevitably stimulates public and political 
interest as well as clinical and scientific interest. As a result of the medicinal product 
being used in the treatment (diacetylmorphine, pharmaceutical heroin), there is 
bound to be special public and political interest. Consequently, precisely because of 
this, it is particularly important that science contributes evidence-based examination 
of evidence and objective analysis and critique.
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Chapter 1: Introduction to this EMCDDA Insights
The size of the heroin problem in Europe has continued to grow (EMCDDA, 2010) 
and has prompted the introduction and expansion of various treatment responses, 
notably opiate substitution treatment (OST) (EMCDDA, 2010), as has occurred in 
many other countries across the world. However, for a minority of heroin-addicted 
patients, often with deeply entrenched addiction problems, the expected benefits of 
these treatment responses have not been seen.
Across Europe over the last 15 years, and more recently also in Canada, a novel 
approach of supervised injectable heroin (SIH) prescribing has been developed, 
introduced and tested in well-designed research studies — in most instances, 
specifically for this population of severe and previously refractory heroin addicts. 
This innovation has been particularly led by clinicians, researchers and policymakers 
in Europe. Therefore, the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) asked a team of leading scientists in this area to produce a 
comprehensive and up-to-date overview that is relevant and accessible to a wide 
audience. Under the guidance of Professor John Strang, Dr Teodora Groshkova 
and Dr Nicola Metrebian, this publication was produced with the support of many 
national experts in the field. The evidence was described in close cooperation with 
the Cochrane Collaboration, the world’s leading institution in promoting evidence-
based healthcare by producing systematic reviews of evidence.
Diacetylmorphine, more commonly known as diamorphine or heroin, was first 
synthesised and used as a medicinal product in the late nineteenth century into the 
early twentieth century. After it was brought under international control, beginning 
with the Hague Convention in 1912, and its use was limited to ‘legitimate’ medical 
and scientific purposes, the drug continued to be abused by a small number of 
people in Europe. In the mid-1970s, use of the drug increased across Europe 
(Hartnoll, 1985), peaking during the 1980s and into the 1990s in western and 
southern European countries and more recently in the 1990s to early 2000s in 
eastern and central European countries, particularly after the political changes that 
took place in those parts of Europe (Hartnoll et al., 2010). Serious negative health 
consequences were linked to heroin use, in particular alarming increases in overdose 
deaths. Furthermore, the detection of large human immunodeficiency virus (HIV) 
epidemics among drug injectors, mostly heroin injectors, in many countries during 
the 1980s made heroin use a major public health concern. This led, among other 
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measures, to the adoption of OST, a treatment first developed in the 1960s in the 
United States, as a treatment modality in the European Union (EU) in the mid-1980s.
In many EU Member States, this modality has undergone a major scale-up since the 
mid-1990s. To date, OST constitutes the main modality for the treatment of opioid 
dependence in Europe and is part of a wider range of treatment options available 
to heroin users. It is estimated that more than half of the 1.3 million problem opioid 
users in Europe are receiving this treatment, a considerably high rate compared 
with most other world regions (EMCDDA, 2010). This achievement is supported by 
compelling scientific evidence accumulated over the last decades regarding the 
benefits of OST in treating opioid dependence and in improving its associated health 
and social consequences.
However, a certain percentage of problem opioid users turned out to be 
unresponsive to standard treatments, including OST. Furthermore, there was a strong 
belief that a considerable number of heroin users were not reached by the treatment 
services available. In order to address the needs of this target population, a few 
countries — nearly exclusively members of the EU — have taken steps to respond to 
these problems by developing a new clinical approach, namely SIH treatment.
This new approach was an adaptation from the concept of heroin prescription for 
the treatment of heroin dependence, provided unsupervised in the United States a 
century ago and most notably in the United Kingdom for more than a century. The 
new approach was developed during the mid-1990s and experimental trials started 
in order to gather evidence of its efficacy. Thus, 15 years of trials conducted first in 
Switzerland, followed by the Netherlands, Germany, Spain, the United Kingdom and 
outside Europe in Canada, yielded positive outcomes in a number of areas, which 
recently led Denmark, Germany and the Netherlands to officially adopt supervised 
heroin-assisted treatment (HAT) as a second-line treatment. Other Member States 
continue to offer it within the context of their research studies. While this treatment 
option has now gained acceptance in a number of EU Member States, it remains 
controversial in most other countries.
At European level and worldwide in general, today there is, however, a growing 
interest in this particular treatment option with ongoing discussions and pertinent 
questions on the evidence, the costs, the implementation or its legal basis. With 
Europe being at the forefront of implementing and investigating this clinical practice, 
the EMCDDA found it necessary and timely to provide a state-of-the-art overview on 
a number of relevant aspects of supervised heroin treatment for entrenched heroin 
20
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users. Besides an overview on the latest scientific evidence available, this publication 
aims to answer questions on SIH treatment implementation and service provision.
Thus, Chapter 2 of this publication introduces SIH treatment from a historical 
perspective and provides an overview of its development in Europe and beyond.
Chapter 3 provides a comprehensive review of the scientific evidence of SIH 
treatment that has been accumulated through clinical trials internationally over 
the last 15 years. The joint collaboration with the Cochrane Group on this chapter 
provides a high-quality systematic review of a number of relevant and informative 
outcomes of SIH treatment. Findings are presented study by study according to 
country of origin with a clear and user-friendly description of the methodologies 
applied. The evidence reviewed concerns retention in treatment, ‘street’ heroin use 
and other drug use, health and social functioning, criminal offence and safety of 
SIH treatment. It was also deemed necessary to provide a review of the long-term 
trajectories of patients receiving SIH, as well as their perspective on this treatment 
and the impact of supervised injectable maintenance clinics and service provision in 
local communities. It is worth mentioning that the joint work between the Cochrane 
Collaboration and the research team has also resulted in an update of the Cochrane 
Systematic Review on heroin maintenance for chronic heroin-dependent individuals 
(Ferri et al., 2011).
The high cost of implementing SIH may be considered as problematic, especially 
during the current economic turmoil in Europe. Chapter 4 deals with the economic 
evaluation of SIH treatment. It offers a detailed economic evaluation of heroin-
prescribing treatment from the German, Dutch and Swiss studies. Also of interest is 
the actual medicinal product used in supervised SIH treatment to substitute for ‘street’ 
heroin, namely diacetylmorphine. Hence, the different commercial pharmaceutical 
diacetylmorphine products that are currently available and utilised in the countries 
are briefly described in Chapter 5, as well as a list of key features of each product.
Finally, Chapter 6 describes the implementation and delivery of SIH treatment in 
each country where it is available. For this chapter, the authors collaborated with 
national key informants who are lead clinicians, researchers who have pioneered 
SIH treatment trials and practice or others with a strategic overview of this type 
of treatment in each country. Thus, national experts contributed by describing 
the implementation, operational delivery and clinical practice of SIH treatment 
as practised in Belgium, Denmark, Germany, Spain, the Netherlands, United 
Kingdom, Switzerland and Canada, as well as identifying aspects which helped or 
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presented challenges to delivering SIH treatment in each of these countries. While 
the described conditions may be unique to each country, interested countries may 
identify similarities with their national situation, offering the opportunity to translate 
experiences of these countries into their national situation.
This EMCDDA Insights guides the reader through the concepts and the operational 
aspects of providing supervised heroin treatment and presents the reader with an 
overview of the research findings from the series of randomised clinical trials and 
associated analyses. With this publication to hand, we can now contribute more 
constructively to the clinical, public and political discussions that are required to 
establish the proper place of this new form of treatment in the wider provision of 
care to those with heroin addiction problems.
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International policy and legislation regarding heroin treatment
Diacetylmorphine is derived from opium and was first synthesised at St Mary’s 
Hospital in London in 1874. In 1898, it was produced as a new therapeutic drug and 
named ‘heroin’ by the German pharmaceutical company Bayer. Initially, heroin was 
principally used as a cough suppressant and for alleviating respiratory difficulties 
associated with such illnesses as bronchitis, pneumonia and tuberculosis. It was 
also used, and in some countries still is, as an analgesic to relieve the severe acute 
pain caused by injury, surgery or heart attacks and in palliative care for terminal 
illness. Moreover, heroin was believed to be non-addictive and was considered as 
an effective cure for morphine addiction. However, heroin was soon found to have 
addictive properties itself.
An international drug control policy was set in motion, beginning with the 
Shanghai Commission in 1909 and followed by a series of conferences at the 
Hague in 1911–12, 1913 and 1914. The movement towards international drug 
control was originally driven by American missionary concern about opiate use 
in the Far East, alongside the American government’s strategic policy to extend its 
influence and economic opportunities in the Far East (Berridge, 1999; McAllister, 
2000). The International Opium Convention of 1912 (the Hague Convention) 
aimed to reduce the use of opium, morphine, heroin and cocaine by restricting 
the manufacture, trade, distribution and use of these drugs to ‘legitimate’ scientific 
and medical purposes only and to make the possession of these drugs for anything 
other than medical purposes illegal. All preparations containing more than 0.1 % of 
heroin were also to be controlled. Although signed by countries at the conference 
and subsequently put into force by some of them, the convention obtained near-
universal adherence in 1919 when countries, through signing the peace treaties 
following the First World War, also became party to the Hague Convention 
(Berridge, 1999; McAllister, 2000).
The Hague Convention did not create administrative machinery for the 
implementation of its principles. The League of Nations established after the First 
World War provided a centralised body for the administration of international drug 
control and it was under the League’s auspices that the second Geneva Convention 
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of 1925 was signed. The Convention required parties to the treaty to provide annual 
statistics on drug stocks and consumption; the production of raw opium and coca; 
and the manufacture and distribution of heroin, morphine and cocaine. A limitation 
on the manufacture of opiates to amounts necessary for medical and scientific 
purposes was imposed by the Limitation Convention of 1931 (McAllister, 2000).
Further international drug control protocols followed, and eventually all the existing 
drug control treaties were consolidated in the United Nations 1961 Single Convention 
on Narcotic Drugs. Heroin is listed in Schedule I of the convention, and the principal 
objectives of the convention are to limit the possession, use, trade, distribution, 
import, export, manufacture and production of drugs exclusively to medical and 
scientific purposes and to address drug trafficking through international cooperation 
to deter and discourage drug use. The Single Convention confirms the importance 
of the medical use of controlled narcotics and notes that ‘the medical use of narcotic 
drugs continues to be indispensable for the relief of pain and suffering and that 
adequate provision must be made to ensure the availability of narcotic drugs for 
such purposes’. Articles 1, 2, 4, 9, 12, 19 and 49 contain provisions relating to the 
‘medical and scientific’ use of controlled substances. In almost all cases, parties 
are permitted to allow dispensation and use of controlled substances under a 
prescription, subject to record-keeping requirements and other restrictions.
Heroin can be legally prescribed in the United Kingdom and Belgium for pain relief. 
It is available for prescription to long-term opiate users in Denmark, Germany, 
the Netherlands, the United Kingdom and Switzerland.
Brief history of heroin prescribing
Heroin prescribing in the United States
For a brief period in the early 1900s, many cities throughout the United States 
had clinics providing legal supplies of opiates to addicts, with some providing 
maintenance treatment. Records suggest that there were clinics in 34 cities in 
12 states, the largest number of clinics being in New York. Many kept records of 
the addicts they saw and some states required the addicts to be registered before 
receiving their prescriptions for opiates (Musto, 1987).
The 1912 Hague Convention did not indicate how the control over production and 
distribution of opiates was to be implemented in individual countries, but in 1914 
the United States Congress passed the Harrison Narcotic Act, which restricted the 
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administration of opiates (including morphine, heroin and opium) to doctors and 
pharmacists, requiring them to register with the Department of the Treasury, pay 
tax at a moderate rate and keep records of the medicines they dispensed. Doctors 
(and dentists and veterinary surgeons) had a right to prescribe heroin for medical 
purposes. However, the act contained some ambiguities (Courtwright, 1982); the 
most important involved the provision that doctors in their professional practice might 
prescribe narcotics to their patients. It was left unclear whether prescribing narcotics 
to an addict for the treatment of addiction was for legitimate medical purposes. 
Addiction was not seen as a disease, nor was the addict seen as a patient and thus 
opiates prescribed for him or her by a doctor might not be supplied ‘in the course 
of his professional practice’. This act was interpreted to mean that doctors could not 
prescribe for addiction and by 1919, doctors were prosecuted for prescribing opiates 
to drug users. Even those who escaped conviction had their careers ruined by the 
publicity (Courtwright, 1982). As a result, doctors discontinued prescribing heroin 
for this purpose for fear of being prosecuted. Furthermore, the medical use of heroin 
was withdrawn with the United States Narcotic Drug Control Act of 1956.
British heroin prescribing (without direct supervision)
The Dangerous Drugs Act 1920 enacted into United Kingdom domestic legislation 
the provisions of the Hague Convention, which came into force in 1919 when it 
was ratified under the Versailles Peace Treaty. The Dangerous Drugs Act also 
retained most of the provisions of the 1916 Defence of the Realm Act Regulation 40B 
(DORA 40B), wartime domestic legislation restricting cocaine and opium use. The 
Dangerous Drugs Act restricted the import, export, manufacture, sale, distribution 
and supply of morphine and heroin except by persons licensed by the Home 
Secretary or otherwise authorised. The supply of morphine and heroin was restricted 
to registered medical practitioners for the purpose of medical treatment (and dentists 
for dental treatment and veterinary surgeons for the treatment of animals). The act 
was intended to meet international obligations but to interfere as little as possible 
with medical use of these drugs. The act imposed no limitations on the circumstances 
under which doctors could prescribe heroin and morphine to their patients.
DORA 40B had given the British Home Office the central power over drug policy. The 
Home Office was uncertain whether prescribing heroin and morphine for the treatment 
of addiction fell legitimately under the 1920 Act. At the suggestion of the Home Office, 
the Ministry of Health convened an expert committee (Departmental Committee on 
Morphine and Heroin Addiction), chaired by Sir Humphrey Rolleston, the President of 
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the Royal College of Physicians, to consider and advise on the circumstances in which 
it was medically advisable to prescribe heroin or morphine to addicts. The report 
(Ministry of Health, 1926) produced by the committee (usually known as the Rolleston 
Report) recommended that these drugs could be prescribed in the following cases:
1. to persons suffering from addiction to morphine or heroin who are under 
treatment by the gradual reduction method; and
2. to two classes of persons, to whom the indefinitely prolonged administration of 
morphine or heroin may be necessary:
i. those in whom a complete withdrawal of morphine or heroin produces serious 
symptoms which cannot be treated satisfactorily under the ordinary conditions 
of private practice; and
ii. those who are capable of leading a fairly normal and useful life so long as 
they take a certain quantity, usually small, of their drug of addiction, but not 
otherwise (Ministry of Health, 1926).
The report suggested that opiate-dependent drug users receive a gradual withdrawal 
from heroin (or morphine), but recognised that there would be patients for whom 
abstinence was not possible. It recognised the need for doctors to maintain such 
opiate-dependent drug users on a prescription indefinitely while keeping the supply 
of the drug within the limits of what is necessary. The Rolleston Report reaffirmed the 
right of doctors to treat heroin dependence and established that this could be done 
by either long-term or maintenance prescribing of heroin.
Heroin prescription was the main medication used for the treatment of opiate addicts 
up until the 1960s. The number of addicts in treatment was small and most were 
middle class, addicted to morphine and in the medical and allied professions, or had 
become dependent in the course of medical treatment. However, largely prompted 
by concern about whether long-term prescribing was still appropriate more than 
30 years after the Rolleston Report, the Home Office convened the Interdepartmental 
Committee on Drug Addiction chaired by Sir Russell Brain to review the advice given 
by the Rolleston Report. The committee’s 1961 report concluded that the drug problem 
remained small and no changes in approach were needed. However, increasing 
evidence of a heroin epidemic in the United Kingdom involving younger heroin users 
led to the Second Interdepartmental Committee on Drug Addiction, again chaired 
by Brain. The committee concluded that the increase in heroin use had been fuelled 
by a small number of doctors who were overprescribing heroin. As a result, it was 
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recommended that restrictions should apply to the prescribing of heroin and cocaine 
and that new drug treatment centres should be set up (Ministry of Health and Scottish 
Home and Health Department, 1965). The recommendations were enacted in the 
Dangerous Drug Act 1967, which restricted the prescribing of heroin in the treatment 
of addiction to doctors licensed by the Home Office. The doctors who obtained 
licences were mostly psychiatrists in charge of drug treatment centres or clinics set up 
by the National Health Service (NHS) to meet the increase in heroin use. Prescribing 
heroin for the treatment of other medical conditions was unaffected.
The drug clinics took over the prescribing of heroin to patients previously prescribed 
by private doctors and NHS general practitioners. Heroin prescribing declined in the 
early 1970s as doctors at the drug clinics were uncomfortable doing so. Methadone 
had recently been developed in the United States as a new treatment specifically for 
opiate dependence, and oral methadone was considered by the clinic doctors to be a 
more suitable medication. The findings of a research trial conducted in the early 1970s 
comparing the effectiveness of heroin with oral methadone treatment showed there 
were advantages and disadvantages to both, and the authors were unable to conclude 
whether one treatment was more effective than the other (Hartnoll et al., 1980). 
This research was used as justification for the move away from prescribing heroin to 
oral methadone, which had already started (Stimson and Oppenheimer, 1982).
Nevertheless, heroin prescribing for the treatment of addiction continues to be a 
legal option for the treatment of heroin problems. The established method of heroin 
prescription in the United Kingdom has been as a ‘takeaway’ supply, which is then 
injected in an unsupervised context. In practice, since the early 1970s, few doctors 
have prescribed it and few patients have received it (Metrebian et al., 2002). 
Heroin prescribing has steadily decreased, owing to the potential for diversion on 
to the black market (with an increased risk of spread of abuse and addiction and 
the danger of overdose) and the lack of evidence for effectiveness, as well as the 
development of oral medications such as methadone (Metrebian et al., 2002, 2007; 
Mayet et al., 2010; Strang and Sheridan, 1997, 2003, 2006).
Interest in heroin prescribing treatment from Switzerland
In 1991, in light of increasing numbers of young addicts injecting heroin, emerging 
open drug scenes in Swiss cities and increasing human immunodeficiency virus 
(HIV) infection rates, a national drug policy was formulated, which contained a 
new element of harm reduction. Prescribing heroin was proposed as both a harm-
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reduction measure and a means of targeting those addicts with severe health and 
social problems who were not benefiting from conventional treatment.
In the early 1990s, senior clinical and academic experts in addiction from Switzerland 
visited the United Kingdom to look for a treatment that might be applied to heroin addicts 
who were not succeeding with orthodox oral methadone maintenance. Among the sites 
they visited was a clinic in the north of England led by a psychiatrist, Dr John Marks, 
where both smokable and injectable heroin were prescribed. Following this visit, Professor 
Ambros Uchtenhagen and colleagues concluded that they could reconceptualise the 
delivery of heroin prescribing so as to secure the positive advantages while avoiding the 
disadvantages by delivering heroin prescribing on a strictly medically supervised on-site 
clinic basis specifically to treat the most entrenched, treatment-resistant heroin addicts 
in their communities (Uchtenhagen, 2010). Consequently, new clinics, which would be 
open 365 days a year and where injectable prescriptions were consumed under medical 
supervision with no take-home doses, were established in Swiss cities and towns.
A scientific study to evaluate supervised injectable heroin treatment was designed. 
Findings from the study showed positive benefits and the World Health Organization 
(WHO) convened an international expert committee to review the design, 
implementation and findings of the study. The international expert committee 
confirmed the positive findings but felt that the research had limitations of design as it 
had not used a control group. The WHO recommended further studies, in particular 
randomised controlled trials (RCTs).
Movement towards renewed interest in supervised injectable heroin and 
development of evidence for such treatment
The research trials in Switzerland prompted a renewed interest in heroin prescribing 
delivered within new supervised injecting clinics, which was seen as a potential 
way to solve the heroin problem and improve the health and social well-being of 
entrenched heroin users for whom conventional treatments have repeatedly failed. 
Trials of heroin treatment delivered in the new European-style supervised injecting 
clinic were undertaken in Germany, Spain, the Netherlands, the United Kingdom and 
Canada. All the trials showed that such programmes can reduce illicit heroin use 
and criminal activity and improve the health of entrenched heroin users for whom 
conventional treatments repeatedly fail (Perneger et al., 1998; van den Brink et al., 
2003; March et al., 2006; Haasen et al., 2007; Oviedo-Joekes et al., 2009; Strang et 
al., 2010), providing a good evidence base for this treatment.
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However, the development of new supervised heroin treatment has not been solely 
influenced by the evidence for its effectiveness. The historical context, pressure from 
medical professionals and political considerations have all helped to shape these 
responses. Germany, the Netherlands, the United Kingdom and Switzerland have all 
been able to continue to provide supervised injectable heroin (SIH) as part of regular 
treatment. A trial of SIH treatment has just started in Belgium and in 2009, Denmark 
introduced SIH as a medical treatment for addiction. However, Spain and Canada 
have not been able to provide SIH despite evidence for its effectiveness in these 
countries, and the Australian government stopped a well-prepared and scientifically 
sound SIH study for political reasons in the mid-1990s.
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injectable heroin treatment
In this chapter, we present the scientific evidence for supervised injectable heroin 
(SIH) treatment that has been accumulated through randomised controlled trials 
(RCTs) internationally.
The methodology for this exercise was designed to collect evidence in a sequential 
and logical manner. It has a clear focus on evidence of SIH treatment efficacy and 
cost-effectiveness as well as allowing a broad scope for learning about current 
clinical practices of SIH treatment across Europe and Canada.
Comprehensive review of the scientific literature on supervised 
injectable heroin treatment trials
The following detailed database search strategies were used to identify studies 
for inclusion in the review: the Cochrane Central Register of Controlled Trials 
(CENTRAL) Issue 2, 2010; MEDLINE (1966–2010), EMBASE (1980–2010). 
There were no language or publication year restrictions. The following terms 
or combinations of these terms were used in the search strategy: ‘addiction’, 
‘assisted’, ‘supervised’, ‘dependence’, ‘diacetylmorphine’, ‘diamorphine’, ‘heroin’, 
‘maintenance’, ‘prescription’, ‘programme’, ‘provision’, ‘therapy’. The citations were 
reviewed by the research team based on their relevance to SIH treatment and 
the domains of its outcomes, efficacy and cost-effectiveness. Thus, papers which 
were primarily assessing unsupervised heroin treatment provision, focused on 
policy aspects, reporting profile of trial participant or which had no measures that 
related to drug use, physical health, psychological or social functioning, cost-
effectiveness or community impact were excluded. Table 1 shows the results of 
the search by topic area, and these articles provide the evidentiary base for the 
literature review.
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Table 1: Initial search yield
Subject Number of articles
SIH efficacy 7
SIH cost-effectiveness 1
Long-term SIH effects 5
Community impact 2
Patients’ perspective 2
Total 17
SIH: supervised injectable heroin.
In addition, we searched relevant categories of the United Kingdom’s NTA 
publications database, UK’s Drugscope Library, and the National Research Register, 
Meta-register of Controlled Trials, Clinical Trials and Trials Central registers to 
ensure that no trials that were under way were neglected, as well as including 
recently published or ‘in press’ academic research that may not have been picked 
up in the literature review. Also, we assembled a list of contacts and conducted 
a review of the full project reports, provided on a more confidential basis by the 
principal investigators of the SIH treatment trials conducted in the EU Member States 
(Germany, Spain, the Netherlands) and also in Switzerland and Canada. Finally, the 
Cochrane Review (Ferri et al., 2011) was consulted to ensure consistency of key data 
sources. No additional main trial papers were identified, and the evidence in the 
subsequent sections is thus based on papers summarised in Table 1.
Efficacy
This section sets out the findings of a review of the published papers and project 
reports from studies examining the efficacy of heroin treatment under conditions of 
supervised administration.
The RCT design is considered the ‘gold standard’ for the generation of scientific 
level-1 evidence (evidence obtained from at least one properly designed RCT) about 
the efficacy of treatments (Ashcroft et al., 1997; Glasziou et al., 2007). However, 
other study designs may enable other domains to be explored and other important 
questions to be answered. We therefore briefly outline the large cohort study 
conducted in Switzerland — a study that marks the beginning of the scientific interest 
in SIH treatment — but we then focus on the evidence derived from more rigorous 
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evaluations using the RCT design. Although the Hartnoll et al. (1980) study was the first 
RCT to examine heroin (diacetylmorphine) treatment versus oral methadone treatment, 
this study is not included in the evidence reported in this chapter because the study 
did not use heroin treatment for the same target group (i.e. ‘chronic heroin-dependent 
individuals’), as has been used in all of the new generations of SIH treatment trials 
(i.e. from Perneger et al., 1998 onwards). Furthermore, the heroin treatment that was 
provided in this first trial was very different from the heroin treatment provided in 
all of the subsequent heroin trials (i.e. Hartnoll et al., 1980: take-home unsupervised 
consumption-based provision vs. from Perneger et al., 1998 onwards: strictly medically 
supervised, injectable clinic-based heroin provision) (for further details, see Chapter 2).
The Swiss cohort studies
A series of five linked studies (the Swiss studies) on medical prescriptions of injectable 
opiates were designed and conducted in Switzerland between 1994 and 1996 
(Uchtenhagen et al., 1996, 1997). The Swiss studies were originally planned as RCTs to 
compare (i) intravenous heroin with intravenous morphine and intravenous methadone, 
(ii) intravenous heroin with intravenous morphine and (iii) intravenous heroin with a 
waiting list control. However, owing to difficulties in recruitment into the non-heroin 
component, among other issues, the studies evolved into an observational open-label-
type study following a single-group pre-post design. A total of 800 treatment slots 
were set up for heroin treatment in three different clinical contexts: (i) newly established 
clinics, (ii) existing outpatient methadone programmes and (iii) a medium-security prison 
with an inmate-run farm.
Between January 1994 and June 1996, 1 035 heroin-dependent individuals over 
18 years of age who were chronically dependent, suffering from health and social 
problems as a consequence of their heroin addiction and had, without success, 
engaged in other treatment programmes at least twice entered the programme at 
a number of treatment centres throughout Switzerland and were followed up at 
12 and 18 months. The first layer of analysis showed that, according to the entry 
criteria, a group of long-time opiate addicts with severe social and health problems 
could be reached and 76 % of them could be retained in SIH treatment over a 
12-month period (Uchtenhagen et al., 1999). In the SIH cohort, significant reductions 
were reported in illicit drug use and criminal behaviour, as well as improvements in 
physical health and psychosocial functioning. At entry, 81 % of the sample retained 
in treatment for at least 12 months were using heroin illicitly on a daily basis. Only 
6 % reported almost daily illicit heroin use at 6 months, with that reduction being 
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maintained over the remaining months of treatment. Overall, statistically significant 
reductions in consumption of cocaine, cannabis and benzodiazepines were reported. 
Criminal behaviour declined, with the proportion reporting an income from illicit 
sources reducing from 69 % to 10 %, with self-reported criminal activity verified by 
police records and official crime statistics (Killias and Rabasa, 1998).
Although patients prescribed SIH (alone or in combination with methadone or other 
medication) improved significantly in all key domains of substance use and functioning, 
in the absence of data from an appropriate control group, it was not possible to 
conclude that these improvements were caused or enhanced by the prescription of 
supervised injectable heroin, the provision of ancillary services or by the combination 
of these interventions. In the face of this major weakness, from a design point of view, 
commentators such as Ali et al. (1999) have suggested that some of the findings of the 
Swiss studies have been somewhat over-interpreted as favourable to SIH treatment.
Supervised injectable heroin randomised controlled trials’ overview of methods
To date, six RCTs have assessed the efficacy of SIH treatment. As Fischer et al. 
(2002) point out, each of the evaluations had a different profile and used different 
methodologies in terms of target population, nature of interventions and measures, 
often reflecting the different treatment systems and policy environments in the 
countries involved (see Chapter 6 of this publication). Nonetheless, the main 
underlying objective of the trials in Germany, Spain (Andalusia), the Netherlands, 
Switzerland, Canada and, most recently, the United Kingdom has been consistently 
similar — to determine the therapeutic value of medical heroin prescription as 
second-line treatment for high-risk heroin users for whom such benefits cannot be 
expected or achieved from existing treatment options (van den Brink et al., 1999; 
Fischer et al., 2002; Lintzeris et al., 2006).
Participants across the six trials were daily heroin users with a stipulated minimum 
history of opiate dependency ranging between two (Switzerland (1) and Spain) and 
five (the Netherlands, Germany, Canada) years, commonly between 18 and 65 years 
of age at enrolment, who were residents of the supervised injecting clinic area. Also, 
they had a history of at least two unsuccessful treatment attempts, although there was 
variation with regard to their current treatment status at the time of enrolment, with 
the differences across the trials described in more detail below. Exclusion criteria, 
(1) In the Swiss trial, this criterion was defined as ‘addiction to intravenous heroin’.
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where specified, included the presence of active symptoms of a severe psychiatric 
disorder, a pending prison sentence, a recent (past 12 months) episode of abstinence, 
a severe physical disorder or pregnancy.
The setting for treatment provision in all RCTs was an outpatient in supervised 
injecting clinics of varied size.
The duration of follow-up in each trial ranged from six to 12 months. The Swiss 
and the English trials were the shortest, with outcome assessment compared six 
months after commencing treatment. The Spanish trial followed up participants over 
nine months, and the trials conducted in Germany, the Netherlands and Canada 
continued for 12 months after allocation to the randomised treatment.
Primary outcomes to measure patients’ response to SIH varied across trials: four trials 
(Germany: Haasen et al., 2007; Spain: March et al., 2006; the Netherlands: van den 
Brink et al., 2003; and Canada: Oviedo-Joekes et al., 2009) used composite or multi-
domain outcomes including:
1. physical health, mental health status, and social functioning evaluated using 
validated indicators (van den Brink et al., 2003);
2. (i) health improvement (physical or mental) and (ii) decline in ‘street’ heroin use 
and concurrent non-increase of cocaine use (Haasen et al., 2007);
3. improvement in general health or psychological or family adjustment without a 
significant deterioration in any of these dimensions (March et al., 2006);
4. (i) retention in SIH at 12 months and (ii) reduction in drug use or criminal activity 
(or both) (Oviedo-Joekes et al., 2009).
The primary outcome measures in the Swiss trial included a reduction of self-
reported drug use, and improved health status and social functioning (Perneger 
et al., 1998); the United Kingdom’s Randomised Controlled Opioid Treatment Trial 
(RIOTT) measured a reduction of ‘street’ heroin use as a primary outcome (Strang et 
al., 2010). Secondary outcomes across trials included, but were not limited to, SIH 
safety, criminal activity, other drug use, physical health, and psychological and social 
functioning. A range of variables that were regarded as secondary outcomes in one 
trial were included as primary outcomes of patient treatment response in other trials. 
In some countries (e.g. the United Kingdom and Canada), community outcomes, such 
as levels and types of crime occurring in the community linked with heroin use, public 
safety and sensitivity, were also considered.
39
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
Additionally, research teams in Germany, the Netherlands and Switzerland assessed 
the cost-effectiveness of SIH treatment. More detail, where reported by trials, on 
secondary and other outcomes and the outcome measures used is provided in 
subsequent sections of this chapter.
All trials were analysed on an intention-to-treat basis — a method of analysis for 
randomised trials in which all patients randomly assigned to one of the treatments 
are analysed together, regardless of whether or not they completed or received the 
treatment.
Overview of treatment investigated
Five trials (van den Brink et al., 2003; March et al., 2006; Haasen et al., 2007; 
Oviedo-Joekes et al., 2009; Strang et al., 2010) compared supervised injectable 
heroin (plus flexible doses of oral methadone) with oral methadone treatment 
only (i.e. without additional heroin). In the Swiss trial (Perneger et al., 1998), 
injectable heroin was compared with a waiting list where control patients were 
encouraged to select any drug treatment programme that was available in Geneva 
and were enrolled straight after a place became available. A Dutch trial (van 
den Brink et al., 2003) was conducted over the same time period and included a 
comparison between inhalable heroin (plus flexible doses of oral methadone) and 
oral methadone alone, and in the English trial (Lintzeris et al., 2006), injectable 
methadone (plus flexible doses of oral methadone) was included as a second 
experimental treatment to be studied and was evaluated separately against 
optimised oral methadone maintenance treatment (MMT).
Overview of treatment regimes
Across the trials, the mean daily dose of injectable heroin ranged between 275 mg 
(Spain) and 392 mg (Canada), 399 mg (United Kingdom) and 442 mg (Germany), 
up to 509 mg (Switzerland) and 548 mg (the Netherlands). In the control groups, 
the mean dose of oral methadone was lowest in the Dutch trials (60 mg), within 
the optimised range in the German (99 mg) and the Canadian (96 mg) trials, and 
highest in the Spanish (Andalusian) (105 mg) and the British RIOTT (107 mg) trials.
Supervised self-administration of heroin in the newly established injecting clinics was 
the key common feature of treatment provision in all countries. No take-away doses 
of injectable medication were available to patients and the clinics were open for 
supervised injecting in two (Spain and the United Kingdom) to three (Germany, the 
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Netherlands, Switzerland and Canada) sessions per day (for 365 days per year). 
In all six trials, supervised treatment was combined with some form of psychosocial 
support.
Methodology and interventions: review by country 
Switzerland, 1998
The Swiss trial was conducted as part of the cohort studies in the national evaluation 
(Perneger et al., 1998). It recruited a total of 51 participants: 27 long-term dependent 
heroin injectors with two previous episodes of methadone treatment, but who were 
not in treatment at enrolment, were randomly allocated to receive diacetylmorphine 
prescription (with all at least occasionally also receiving methadone as a 
replacement drug) and 24 were put on a six-month waiting list for diacetylmorphine, 
during which time they received conventional treatment, with most (n = 19) receiving 
MMT. Participants were studied over a six-month period of randomisation.
Patients randomised to receive SIH attended a clinic for supervised injections up 
to three times daily and received an average daily dose of 509 mg, occasionally 
supplemented with oral methadone. All patients received psychological counselling, 
as well as social and legal support services.
Outcomes, compared at six months, included self-reported consumption of ‘street’ 
heroin and other drugs, frequency of overdoses, use of health services, health status, 
work status, living arrangements, quality of social relationships, monthly living and 
drug-related expenditures, sources of income and criminal behaviour.
Netherlands, 2003
Two separate RCTs were conducted — an injectable heroin trial and a parallel 
study examining inhalable heroin for heroin smokers; with each of the two forms of 
treatment compared with oral methadone substitution therapy. Participating patients 
have typically been prescribed ‘effective daily dose methadone’ — at least 60 mg 
(injectable trial) or 50 mg (inhalable trial) — for at least four consecutive weeks in the 
past five years and, despite being in regular contact with a methadone maintenance 
programme for at least six months prior to enrolment, were not well stabilised and 
were continuing to regularly use illicit heroin, had poor physical or mental health or 
poor social functioning, and had not voluntarily abstained from heroin for more than 
two months in the year prior to trial enrolment (van den Brink et al., 2003).
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The injectable heroin trial recruited a total of 174 participants, and the study of 
inhalable heroin had 375 participants taking part in it. Participants in the RCT with 
injectable heroin were allocated to one of the following treatment groups: (i) oral 
methadone over 12 months in combination with a standard package of psychosocial 
interventions (Group A; n = 98) or (ii) injectable heroin and co-prescribed oral 
methadone, plus equivalent package of psychosocial interventions for 12 months 
(Group B; n = 76).
Within the inhalable trial, 139 participants in Group A were allocated to receive oral 
methadone supplemented with psychosocial care for 12 months, and 117 participants 
in Group B were receiving inhalable heroin plus methadone plus psychosocial 
interventions for 12 months. Group C (n = 119), involving six months of methadone 
followed by six months of inhalable heroin with co-prescribed oral methadone, plus 
psychosocial interventions, was included to test whether six months would be long 
enough to result in stable positive outcomes. Group C is not reported in the present 
review and the focus is kept on SIH treatment.
Patients in Group B for 12 months and Group C for the last six months were 
attending for supervised heroin injections seven days a week, three times a day, 
and were receiving an average daily dose of 548 mg (a maximum of 1 000 mg 
per day and 400 mg, at the most, per visit). A daily dose of inhalable heroin 
averaged 502 mg. Oral methadone was delivered once a day (with a mean 
dose of 60 mg).
Primary outcomes included self-reported illicit drug use, physical health, mental 
status and social functioning. Treatment response in these areas was measured after 
12 months in treatment, using a dichotomous, multi-domain outcome index. Response 
to treatment was considered as an improvement of at least 40 % in month 12 of 
outcome assessment compared with patients’ situation at baseline in at least one of 
the areas in which they functioned poorly: physical health, psychiatric status, social 
functioning and substance use, with no substantial deterioration (> 40 %) in any of 
the domains compared with baseline and no increase (> 20 %) in the use of cocaine 
or amphetamines.
Secondary outcomes included (i) treatment completion, defined as the proportion of 
patients still in the index treatment at the end of the trial and (ii) sustained treatment 
response, where participants who had become responders before assessment in 
month 12 remained as responders during the course of the trial.
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Spain, 2006
The experimental drug-prescription programme in Andalusia (PEPSA) (March et al., 
2006) examined the efficacy of injectable heroin (in combination with methadone) 
compared with oral MMT alone in a study sample of 62 patients (31 per study 
group) with a history of, or current, unsuccessful addiction treatment attempts.
Oral methadone (at a mean daily dose of 105 mg) was dispensed to patients once 
a day. Patients in the SIH group attended twice a day and received a mean dose of 
275 mg per day supplemented with oral methadone (at a mean daily dose of 43 mg).
Outcomes were assessed at four stages in the trial — at baseline and at three-, 
six- and nine-month follow-up — using a composite score of measures of general 
health, self-reported ‘street’ heroin use, quality of life, drug addiction-related 
problems, risk behaviour for human immunodeficiency virus (HIV) and hepatitis 
C virus, psychological functioning, and social and family status as based on ASI 
(Addiction Severity Index; McLellan et al., 1992), OTI (Opiate Treatment Index; 
Darke et al., 1992), SCL-90 (Symptom Checklist-90; Derogatis and Cleary, 1997) 
and SF-12 (Short Form-12; Gandek et al., 1998).
Germany, 2007
The German SIH RCT consisted of several stratified components and was based 
on a sample of 1 032 participants — both regular injecting heroin users presently 
in treatment but not sufficiently responding to MMT (n1 = 492) and individuals 
who were currently not in substance misuse treatment but had a treatment history 
(n2 = 540). In order to separately assess the benefit and impact of psychosocial 
treatment, a 4 × 2 design was adopted, whereby participants in each group were 
randomised to one of two types of psychosocial care. Thus, participants from each 
target group were randomly allocated to receive 12-month treatment in one of four 
treatment groups: (i) heroin plus education (n1 = 127; n2 = 131), (ii) heroin plus case 
management (n1 = 119; n2 = 138), (iii) methadone plus education (n1 = 125; n2 = 130) 
and (iv) methadone plus case management (n1 = 116; n2 = 129).
Doses of injectable heroin ranged up to 1 000 mg per day (at a mean daily dose 
of 442 mg) administered up to three times a day under supervision in the injecting 
clinic, and could be supplemented with oral methadone doses (at a mean daily dose 
of 8 mg) for ‘take-home’ night use. Methadone (at a mean daily dose of 99 mg) was 
administered once a day.
43
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
Outcomes were assessed at 12 months using two response criteria: (i) improvement 
in physical and/or mental health and (ii) decrease in illicit drug use. For the primary 
outcome measure on health, participants were considered to be responders if they had 
shown at least a 20 % improvement, based on the OTI Health Scale (physical health) 
and/or at least 20 % improvement, based on the Global Severity Index (GSI) (mental 
health), either of which occurring in tandem with no deterioration of more than 20 % in 
other domains of health. For the second primary measure, participants were identified 
as responders if a reduction in ‘street’ heroin use was evidenced in at least three of five 
urine samples negative for the drug in the month prior to the 12-month assessment, in 
tandem with no increase in cocaine use, evidenced and confirmed by hair analysis.
Canada, 2009
The North American Opiate Medication Initiative (NAOMI; Oviedo-Joekes et al., 
2008, 2009) evaluated the feasibility and effectiveness of SIH in the Canadian 
context. The trial recruited a total of 251 entrenched opioid injectors, aged 25 years 
or older, who had used opioids for at least five years with at least two previous 
unsuccessful opiate addiction treatment attempts (including one oral methadone 
maintenance in which they received 60 mg or more of methadone daily), but who 
were not enrolled in treatment at the time of recruitment to the study (Schechter, 
2002, 2006). A total of 251 participants were randomly allocated to receive one of 
three treatments: SIH (n = 115), MMT (n = 111) or injectable hydromorphone (n = 25), 
all supplemented with psychosocial interventions, with hydromorphone used to 
validate the self-reported use of illicit heroin by means of urine testing.
The injectable medications could be received up to three times daily, with a 
maximum daily dose of 1 000 mg of heroin (at a mean daily dose of 392 mg) plus 
oral methadone (at a mean daily dose of 34 mg). Oral methadone (at a mean daily 
dose of 96 mg) was dispensed on a daily basis.
Participants were followed up for 12 months. Retention in treatment was adopted as 
the first primary outcome and defined as receipt of the study medication on at least 
10 of the 14 days before the 12-month assessment, or confirmation of retention in 
any other treatment programme or abstinence from opioids during this interval. The 
second primary outcome measure of patient response was a reduction in illicit drug 
use or criminal activity as based on the composite score of the European Addiction 
Severity Index (EUROP-ASI). Patients were considered responders at 12 months in 
treatment if they had an improvement of at least 20 % from the baseline score for 
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illicit drug use or legal status, or both, in tandem with a maximum of one of the 
remaining ASI composite scores (e.g. physical, mental health or social functioning) 
where there was a deterioration of 10 % or more.
United Kingdom, 2010
In the United Kingdom, RIOTT (Strang et al., 2010) recruited individuals who were 
currently in oral substitution treatment but were nevertheless still injecting illicit 
heroin on a regular basis. A total of 127 patients were randomised to one of 
three conditions: (i) optimised oral methadone treatment (control group, n = 42); 
(ii) injected methadone treatment (n = 42); or (iii) injected heroin treatment (n = 43) 
(with access to oral methadone doses).
Daily dose of injectable heroin (at a maximum daily dose of 900 mg) was divided into 
two (450 mg per injection). Patients in both injectable treatment groups were encouraged 
to take additional doses of oral methadone on a regular basis and instead of injectable 
medication if unable to attend the clinic. Supervised injectable methadone (at a mean 
daily dose of 31 mg) was administered once a day. Optimised oral methadone treatment 
involved once-daily doses of ≥ 80 mg (with a mean dose of 107 mg) consumed under 
direct nurse supervision at clinic sites ≥ 5 days per week for at least 3 months, with ‘take-
home’ doses for weekends, and a reduced frequency thereafter if clinically appropriate.
Participants were followed up within the randomised trial for six months, with 
between-group comparisons on an intention-to-treat basis across a range of 
outcome measures. The primary outcome was the reduction in regular use of ‘street’ 
heroin, defined as 50 % or more of urine drug screens testing negative for markers 
of illicit heroin during trial weeks 14–26. For the first time, the primary outcome 
was measured using objective measures rather than self-reported illicit heroin use. 
Secondary outcomes included measures of other drug use, injecting practices, health 
and psychosocial functioning, criminal activity, patient satisfaction and incremental 
cost-effectiveness (Lintzeris et al., 2006).
Overall international evidence on individual and community outcomes
Retention 
In the Swiss RCT, the retention rates at six-month follow-up in the SIH and methadone 
groups were high and not distinctively different — 93 % and 92 %, respectively 
(Perneger et al., 1998).
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Although completion rates in the Dutch trials were high in all treatment groups, 
at 12 months, patients who were randomly assigned to receive methadone alone 
were marginally more likely to be retained in treatment at 12 months than those 
receiving injectable heroin (oral methadone: 85 % vs. injectable heroin: 72 %; 
difference: 12.3 %; 95 % confidence interval (CI) 0.2–24.5 %). Similarly, 
after 12 months in the inhalable trial, 87 % of the oral methadone patients were 
still in treatment compared with 68 % of the group allocated to inhalable heroin 
plus methadone (difference: 18.7 %; 95 % CI 8.8–28.6 %) (van den Brink et al., 
2003). However, it was acknowledged by the authors that 7 % of the intention-to-
treat population in the experimental groups never started the heroin treatment and 
a further 6 % were expelled from heroin treatment because of repeated violation 
of the clinic rules.
March and colleagues (2006) reported a 74 % retention rate in the SIH group at nine 
months, which was higher, although not significantly so, than the retention of 68 % 
achieved in the oral methadone group for the same time period.
In the German model project, retention at 12 months, too, was higher in the SIH 
group than in the methadone group (67 % vs. 40 %). However, when only those 
patients initiating trial treatment were considered in the calculation, 68 % of the 
heroin group and 56 % of the methadone group completed study treatment, and 
these proportions did not differ between treatment groups (Haasen et al., 2007).
In the Canadian trial (Oviedo-Joekes et al., 2009), the retention rate at 12 months in the 
SIH group was significantly higher than in the methadone group (87.8 % vs. 54.1 %; 
P < 0.001).
Finally, the RIOTT group reported that 88 % of SIH patients and 69 % of optimised 
oral methadone patients had remained in the assigned treatment at six months. 
Patients on oral methadone were found to be significantly more likely not to start 
treatment than those on injectable heroin (P = 0.03). After the exclusion of those who 
had not started treatment, the proportions of participants retained at six months did 
not differ significantly between treatment groups.
Retention in treatment appears to be similar or greater for patients in SIH than 
those engaging in oral methadone substitution therapy. Although this effect varied 
significantly across the trials, trials consistently reported good retention in the SIH 
group. Retention in the control groups was more varied.
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‘Street’ heroin and other drug use
A measure of reduction of ‘street’ heroin and/or other drug use, rather than 
abstinence, was consistently used across the trials.
All trials gathered self-reported data on ‘street’ heroin use (these data from the UK 
RIOTT trial are not yet published in peer-reviewed journal form). Within the RIOTT, 
reduction in ‘street’ heroin use was measured by weekly urinalysis during weeks 
14–26. Urine samples were obtained from patients at random once a week for 
26 weeks and analysed with laboratory urinalysis using liquid chromatography mass 
spectrometry to detect opioid impurities (e.g. noscopine, papaverine), and thus it was 
possible to differentiate between the prescribed pharmaceutical diacetylmorphine 
and ‘street’ heroin. The German and Canadian trials also included objective 
laboratory test results for illicit heroin. These were, however, incorporated into the 
composite scores and were not reported separately.
In the Swiss trial (Perneger et al., 1998), compared with the control group, those in 
the diacetylmorphine group showed significant reductions in ‘street’ heroin use — only 
4 % compared with 48 % in the control group were still using ‘street’ heroin daily 
at the six-month follow-up point (P = 0.002; difference 44 %; 95 % CI 16–72 %). 
Although the use of other substances (e.g. alcohol, cannabis, cocaine, barbiturates, 
opiates other than heroin) was described as differential between the two groups at 
baseline and at the end of the follow-up period, no significant differences between 
the two groups were observed, with the exception of benzodiazepines, for which 
33 % in the control group still used at the time of follow-up compared with 0 % in the 
experimental group (P = 0.049).
For the Dutch trials, van den Brink et al. (2003) reported that at 12 months, SIH 
was significantly more effective than treatment with methadone alone — in relation 
to the pre-defined outcome parameter, that is a self-reported 40 % improvement 
in at least one domain (physical, mental, social) — both in the trial with injectable 
heroin (55.5 % vs. 31.2 %; difference 24.3 %; 95 % CI 9.6–39.0 %) and in the trial 
with inhalable heroin (response rate 49.7 % vs. 26.9 %; difference 22.8 %; 95 % CI 
11.0–34.6 %). Disaggregated data on changes in ‘street’ heroin and other drug use 
were, however, not available.
In the Spanish project, both the SIH and the control group were found to have 
achieved considerable improvements in relation to their ‘street’ heroin and other 
drug use. At follow-up, SIH patients reported significantly less use of non-prescribed 
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heroin and were engaging in lower-risk injecting behaviour, as measured by OTI 
(Darke et al., 1991) (baseline: 8.90; 9 months: 0.59; P = 0.001). In a between-group 
analysis, the rate of improvement, measured by EURO-ASI (McLellan et al., 1992) 
was higher in the SIH group than in the control group, with better EURO-ASI drug 
score indicators for heroin use (15.3 vs. 6.5; P = 0.020) and OTI HIV risk behaviour 
(general: 8.3 vs. 5.1; P = 0.012; drug-use related: 7.8 vs. 4.2; P = 0.004).
Haasen and colleagues (2007) reported significantly greater reductions over 12 months 
in illicit drug use (reduction in illicit heroin use and no increase in cocaine use) in the 
SIH group compared with the methadone group (69.1 % vs. 55.2 %; odds ratio (OR) 
1.85; 95 % CI 1.43–2.40; P < 0.001). The German research group also reported the 
results of a more conservative analysis strategy that it had used, whereby only patients 
responding on both primary outcome measures — illicit drug use and health — had 
been defined as responders. Using this strategy, both their intention-to-treat (ITT) and 
per protocol analysis showed a significantly better response rate for the heroin than the 
methadone group (ITT: 57.3 % vs. 44.8 %; OR 1.67; 95 % CI 1.30–2.14; P < 0.001; per-
protocol analysis: 63.6 % vs. 39.5 %; OR 2.73; 95 % CI 1.88–3.97; P < 0.001).
In the Canadian trial (Oviedo-Joekes et al., 2009), self-reported illicit heroin use in the 
past 30 days (mean days) had reduced from 27 at baseline to 5 days at 12-month 
follow-up (SIH group) versus 27 days at baseline to 12 days at follow-up (methadone 
group) (P < 0.001). Reduction in illicit drug use or other illegal activity was reported 
at 67.0 % (SIH) versus 47.7 % (MMT), with a relative risk of 1.40 (95 % CI 1.11–1.77; 
P = 0.004). The reduction in illicit drug use alone was 22.6 % (SIH) versus 13.5 % (MMT), 
and reduction in both illicit drug use and other illegal activity was reported at 43.5 % 
(SIH) versus 28.8 % (MMT). No change in cocaine use was reported in either group.
Strang et al. (2010) reported that after adjustment for treatment centre, regular crack use at 
baseline and other variables, 66 % of the injectable heroin versus 19 % of the optimised oral 
methadone patients were responders (P < 0.0001) at the six-month follow-up. Responders in 
this trial were patients achieving a reduction in regular use of ‘street’ heroin and providing 
50 % or more negative specimens on urinalysis during weeks 14–26.
Conclusion
Compared with oral methadone substitution, treatment with heroin brings about 
additional reductions in illicit heroin use, although in both treatments this is markedly 
reduced. Cocaine use, where it was reported, had either not changed or reduced at 
a comparable rate across the two treatment types.
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Health, health-related quality of life and social functioning (integration at work, 
family relationship)
In the Swiss cohort, mental health, role-emotional and social functioning, measured 
by means of an SF-36 health survey, significantly improved between baseline and the 
six-month follow-up in the SIH group (mean for mental health: 54.4; role-emotional: 
63.0; social functioning: 64.4) in comparison with the oral methadone group (mean 
mental health: 49.3; P = 0.025; role emotional: 43.9; P = 0.027; social functioning: 
61.9; P = 0.041). There were, however, no statistically significant differences between 
the groups on a number of other health and social functioning variables, such as 
being employed and having a stable partner, although the SIH group consistently 
showed improvements when compared with baseline data (Perneger et al., 1998).
For the Dutch trials (injected and inhaled heroin), no disaggregated data were 
available on health and social functioning outcomes.
For patients recruited to treatment in the Spanish trial, March and colleagues 
(2006) reported health and social functioning outcomes as mean scores in the ASI 
(Kokkevi and Hartgers, 1995) and the OTI (Darke et al., 1991, 1992). SIH patients 
showed an improvement in physical health (OTI: from 16.5 to 9.8; P = 0.001) and in 
respect to their psychological status and adjustment (composite ASI: from 0.5 to 0.3; 
P = 0.009). In the control group, similar improvements were observed in the mental 
health domain (composite ASI: from 0.5 to 0.4; P = 0.017). These improvements 
occurred in tandem with significant gains in the social and family areas: for the SIH 
group (ASI: from 0.4 to 0.3; P = 0.007; OTI: from 21.9 to 19.0; P = 0.009) and for the 
control group (ASI: from 0.5 to 0.3; P = 0.002; OTI: from 25.1 to 20.7; P = 0.002). In 
between-group comparison at nine months, however, only the general health status 
was significantly better in the SIH group when compared with the methadone group 
(OTI: 7.8 vs. 3.2; P = 0.034).
Unlike the other trials, where health was typically a secondary outcome measure, 
in the German model project, improvement in health was adopted, along with 
reduction in illicit drug use, as a primary outcome measure. Consistent with illicit 
drug-use results, the SIH group demonstrated a significantly greater response on 
the health outcome measure. The difference between the SIH and the methadone 
group in health improvement rate was significant, in both ITT (80.0 vs. 74.0; OR: 
1.41; 95 % CI 1.05–1.89; P = 0.023) and per-protocol (87.0 vs. 77.0; OR 2.05; 
95 % CI 1.28–3.27; P = 0.003) analyses (Haasen et al., 2007). An in-depth analysis 
of physical (e.g. nutritional status, cardiac function, infectious diseases) and mental 
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health functioning and quality of life, using a range of measures: OTI (Darke et al., 
1991, 1992); the body mass index (BMI); a 12-lead electroencephalogram (ECG); an 
echocardiogram; hepatitis B virus, hepatitis C virus and HIV serology; a tuberculin 
test (Mendel–Mantoux method); GAF (the Global Assessment of Functioning Scale; 
Jones et al., 1995) and Symptom Checklist 90-R (SCL-90-R).
Although improvements were observed and reported in patients receiving both the 
heroin and methadone treatment regarding OTI, BMI and SCL-90-R, these changes 
were greater in the heroin group (analysis of variance (ANOVA), all P < 0.0001). 
While there were significantly fewer pathological echocardiograms in the heroin 
group than in the methadone treatment group (χ2 test, P < 0.05), the occurrence rate 
of markers of pathological diseases and frequencies of pathological ECGs did not 
differ between the two treatment groups, or between baseline and the 12-month 
follow-up (Reimer et al., 2011). An increase was reported in the average quality of 
life scores, as measured by the MSQoL (Modular System for Quality of Life; Pukrop 
et al., 1999), from 3.3 to 4.1 in the heroin group and to 3.9 in the methadone group, 
but these differences were not statistically significant.
Regarding outcomes in the social functioning domain, Haasen and colleagues (2007) 
reported improved family relationships, with a baseline of around 30 % of patients 
having a stable relationship and a slight increase in both SIH (SIH plus education 
or case management) groups at month 12. In terms of housing, approximately 69 % 
of patients in either the SIH group or the oral methadone group had stable housing 
(e.g. own apartment, partner’s apartment, parents/relatives or flat sharing) at 
baseline, with these percentages increasing to 72.2 % and 67.7 % in the SIH and the 
methadone group, respectively.
For the Canadian trial, Oviedo-Joekes and colleagues (2008) reported the health 
and social outcome as a mean score change in the EuropASI (European Addiction 
Severity Index; Kokkevi and Hartgers, 1995). Mental health status was significantly 
improved at the 12-month follow-up in the SIH group in comparison with the 
methadone group (ASI score psychiatric status: SIH: 0.16 vs. methadone: 0.20; 
P < 0.01), and in the social domain, employment satisfaction and social 
reintegration showed significant improvement (employment satisfaction: SIH: 
0.10 vs. methadone: 0.11; P = 0.02; social reintegration: SIH: 0.09 vs. methadone: 
0.08; P = 0.05).
The impact of SIH treatment on health and social functioning is yet to be reported by 
some of the trials.
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Conclusion
Patients undergoing SIH treatment have experienced significant physical and mental 
health improvements compared with patients receiving conventional oral substitution 
prescribing. However, heroin treatment has not been consistently or substantially 
superior across all studies and outcomes, particularly the health and psychosocial 
functioning domains.
Criminal offences
Across the trials, criminal activity was commonly measured by self-report, although 
the German trial conducted an ambitious objective crime activity data collection, 
corroborating self-report data with data extracted from state criminal police records.
The Swiss SIH group showed significant reductions in criminal charges, including 
charges for drug use and/or possession (11 %) in comparison with the oral 
methadone group (38 %; P = 0.008), property theft (4 % vs. 24 %; P = 0.015), 
other offence/charge in the past six months (19 % vs. 57 %; P = 0.0004) and in 
income from drug dealing (passing from CHF 3 372 to CHF 331 in the SIH group at 
follow-up) versus CHF 3 123 to CHF 4 931 in the oral methadone group (P = 0.053) 
(Perneger et al., 1998). The trial did not report on incarceration or imprisonment.
For the Dutch trials (injected and inhaled heroin), no disaggregated data were 
available. Based on a subgroup of 430 patients (heroin plus methadone: n = 193; 
methadone only: n = 237) who were receiving their treatment for a 12-month 
follow-up period, Dijkgraaf et al. (2005) reported that participants in the heroin group 
engaged in criminal activities less often than those in the oral methadone group, with 
fewer reported days of crime against property (10.3 vs. 37.5), less frequent arrests 
(2.1 vs. 2.8 times a year) and less frequent convictions (0.25 vs. 0.54 times).
In the Spanish trial, although there were significant reductions in the number of days 
of involvement in illegal activities in both the SIH (11.5–0.6 days; n = 27; P = 0.001) 
and the control group (from 8.0 to 4.1 days; n = 23; P = 0.015) at nine months, there 
were no significant between-group differences in this outcome measure (March et al., 
2006).
Importantly, in the largest RCT thus far — the German model project (n = 1015) — 
the investigation of SIH treatment’s contribution to a reduced criminal activity, relative 
to oral MMT, was undertaken based on both self-reported criminal behaviour and 
police data collected for a subsample (n = 825) from the Landeskriminalämter (state 
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criminal police offices) of the federal states participating in the trial (Löbmann and 
Verthein, 2009). Although improvements were reported in both the SIH and the oral 
methadone group, the heroin group fared significantly better. The percentage of 
individuals who had committed at least one offence in the respective year dropped 
from 79 % to 45 % in the heroin group and from 79 % to 63 % in the methadone 
group (McNemar tests: heroin, χ2 = 129.36; P < 0.0001; methadone, χ2 = 42.95; 
P < 0.0001). The average number of offences also declined in the heroin group from 
76.7 to 26.8; this drop was greater than the drop in the methadone group, where 
it declined from 79.7 to 49.9 (treatment effect, F = 9.83; P = 0.002; effect of time, 
F = 179.40; P < 0.0001; and an interaction between the two factors, F = 11.53; 
P = 0.001). Although a similar trend, indicating the superiority of the SIH group, was 
evidenced by the analysis of police data on alleged criminals, the primary aim of the 
study was not validation of self-reported criminal data, because the crime categories 
built for the self-reported data did not correspond exactly to the categories for the 
police data.
Within the Canadian trial, the reduction in illegal activities was reported at 0.9 % 
(SIH) versus 5.4 % (MMT). The British research team is yet to report on crime 
outcomes of SIH treatment delivered within RIOTT.
Conclusion
Trials that have reported findings in the crime domain stated that crime — self-
reported or reported by official databases — had reduced, compared with levels 
at entry to SIH treatment and where available to controls (with the exception of the 
Spanish and the Canadian trials).
Safety
Across all trials, overdoses were registered as serious adverse events (SAEs) (2) when 
treatment with opioid antagonists was required, even when patients recuperated in a 
short space of time.
(2) An SAE is an unanticipated problem involving ‘risk’ to participants that ultimately 
results in harm to the participant (impacts on the participant’s morbidity and mortality) 
(e.g. unanticipated ‘risk’ requiring hospitalisation or prolongation of existing hospital 
stay) or to others.
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No deaths occurred in the Swiss trial and data on other SAEs were not available. 
In 2005, Rehm and colleagues published data on mortality in SIH in Switzerland 
over a 6-year time period (1994–2000) (Rehm et al., 2005). Data in their study were 
sourced from two doctoral dissertations (Ryser, 1999; Gacond, 2004) and records 
monitoring SIH treatment in this country. The authors reported death occurrence 
during SIH treatment episode, that is from admission to discharge, plus a timeframe 
of 30 days post-SIH treatment discharge. Their analysis yielded a total of 49 deaths 
in more than 4 600 person-years over the period 1994 and 2000 (Rehm et al., 
2005).
In the Dutch trials, the incidence of SAEs over the 12-month study period was similar 
across the treatment groups (van den Brink et al., 2003). Two SAEs were reported 
as probably or definitely related to the study medication — one non-fatal heroin 
overdose and one non-fatal car crash in a polydrug (heroin and cocaine)-using 
patient. One death was reported in each group (A, B and C). In the SIH group, the 
patient’s death had occurred several hours after discharge from hospitalisation for 
an epileptic seizure treated with the opioid antagonist naloxone.
In the Spanish trial, 14 SAEs were reported in 14 patients, equally distributed 
between the two study groups (March et al., 2006). In the SIH group, none of the 
seven SAEs were definitely related to trial medication, two were not related to it and 
five were probably related to heroin (two occurring in one patient). One death, due 
to speedball overdose, was registered in the control group, which was confirmed by 
a forensic analysis and report.
Over the 12-month follow-up period of the German SIH RCT, a total of 315 SAEs 
were reported. Of these, 177 were among 124 patients in SIH and 138 among 
88 patients in oral MMT (Haasen et al., 2007). In 58 instances in the SIH group, the 
adverse event was possibly, probably or definitely related to the study medication 
(of which 41 occurred within minutes after injection, and the majority (n = 31) were 
related to respiratory depression and a lesser number (n = 10) to an epileptic 
seizure). In the oral methadone group, SAEs that were classed as possibly, probably 
or definitely related to the study medication were just under four times less (n = 15) 
than those in the SIH group.
In the SIH group, SAEs that were possibly, probably or definitely related to the study 
medication were reported to occur 2.5 times more often than in the methadone 
group (every 2 572 vs. 6 501 treatment days in the SIH and methadone groups, 
respectively).
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From a total of 12 deaths over the 12-month study period, five were registered in 
the SIH and seven in the methadone group. Of these, five were reported to have 
occurred while the participant was using study medication and none was reported 
to be possibly, probably or definitely related to the trial medication (three in the SIH 
group: one spleen rupture after falling, one intoxication with illicit methadone and 
one due to pneumonia and myocarditis; two in the methadone group: one ruptured 
aneurysm and one unknown reason but no methadone implicated) (Haasen et al., 
2007).
Oviedo-Joekes and colleagues (2009) reported a total of 79 SAEs in 54 patients: 
51 in the SIH group, 18 in the methadone group and 10 in the hydromorphone 
group. One death — unrelated to the study drug (methadone) — was reported for 
the NAOMI study period. Commonly related to injectable heroin were overdoses 
and seizures, with 7 out of 10 patients who had required naloxone subsequently 
reporting use of other drugs, such as benzodiazepines or cocaine, prior to the 
overdose.
Strang et al. (2010) reported seven SAEs in the injectable heroin group and nine in 
the oral methadone group. Of three events judged to be related to trial treatments, 
two had occurred in injectable heroin patients (and one of injectable methadone) 
— one at 17 days into treatment after the patient’s regular dose of 200 mg of 
intramuscular heroin, and the other at 42 days into treatment after the patient’s 
regular dose of 200 mg of intravenous heroin. The rate of SAEs was reported as one 
in every 6 613 injections for injectable heroin. For oral methadone, none of the SAEs 
had been judged to be related to the treatment received.
Conclusion
More SAEs have been reported to occur in patients receiving SIH than in those 
receiving oral methadone. This suggests that SIH may be less safe and therefore 
requires more resources and clinical attention in order to manage greater safety 
issues.
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Cochrane systematic review of SIH treatment trials
The authors are grateful to colleagues from the Cochrane Drugs and Alcohol Group 
who prepared and produced the following summary (pp. 55–66) of the results from 
a systematic review of SIH treatment trials, and thus complementing the material 
reported in the previous section and providing additional detail.
Who produces the Cochrane systematic reviews on drugs and alcohol?
The Cochrane Drugs and Alcohol Group
The Cochrane Drugs and Alcohol Group (CDAG) is part of the Cochrane 
Collaboration and produces, updates and disseminates systematic reviews of trials 
on the prevention, treatment and rehabilitation of problematic drug and alcohol use. 
It was founded in 1998 in Rome, which is home to the editorial base office. Since 
then, around 200 authors have published with the CDAG: the majority come from 
the European Union, but many are also from Australia, Asia, North America, South 
America, South Africa and the Middle East.
The systematic reviews published by CDAG are based mainly on randomised 
controlled trials (RCTs) and controlled clinical trials, testing active interventions 
aimed at reducing the potential for harm or the actual harm directly related to the 
use of different dependence-producing substances, but other study designs also are 
included, in limited circumstances.
The publication of Cochrane reviews follows an editorial peer-reviewed process from 
the protocol stage onwards, with regular updates every two years or when new study 
results become available, according to the criteria of the Cochrane Collaboration 
(Higgins and Green, 2008).
As of January 2010, CDAG published 52 reviews covering pharmacological and 
psychosocial treatments of opioid (20 reviews), alcohol (10 reviews), cocaine 
and other psychostimulant (11 reviews), polydrug (four reviews), and cannabis, 
benzodiazepine and methaqualone (one review each) abuse or dependence. The 
effectiveness of preventive interventions across different substances was considered 
in four reviews.
For more information about CDAG activities, it is possible to consult the relevant 
website (http://www.cdag.cochrane.org); more general information about the 
Cochrane Collaboration can be found at http://www.cochrane.org/
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The contribution from systematic reviews of randomised controlled studies to the 
evidence of effectiveness
Systematic reviews are aimed at collating all available evidence that fits pre-specified 
inclusion criteria in order to address a specific question (Higgins and Green, 
2008). In practice, to develop a systematic review, all the studies (published and 
unpublished) that meet a set of pre-specified inclusion criteria should be identified, 
appraised and synthesised in an accessible format (Mulrow, 1994).
What are the meta-analyses?
Many systematic reviews include meta-analyses to summarise the results of 
independent studies (Glass, 1976). Meta-analyses can provide more precise estimates 
of the effects of healthcare and can facilitate investigations of the consistency of 
evidence across different studies. However, it should be noted that meta-analysis 
refers to the statistical technique of pooling the results of single studies, which can be 
carried out only in the absence of relevant heterogeneity (either statistical or clinical) 
across studies.
In the review of effectiveness, the suggested measure of effect for dichotomous 
outcomes is the risk ratio (based on the comparison among the proportion of 
events in the experimental groups and the control groups) and the 95 % confidence 
interval (CI), which is calculated for each individual study and then, when possible, 
pooled in a meta-analysis. The width of the CI for an individual study depends, to a 
large extent, on the sample size. Larger studies tend to give more precise estimates of 
effects (and hence have narrower CIs) than smaller studies.
To contribute to a pooled result, each study is weighted according to the number 
of participants and number of events (larger studies, which have smaller standard 
errors, are given more weight than smaller studies, which have larger standard 
errors). Eventually, a 95 % CI is also reported for the pooled results.
Why are study inclusion criteria pre-specified?
Cochrane systematic reviews are the result of a complex process that includes 
formulating a proper question, comprehensively searching studies, objectively 
selecting and extracting data, critically evaluating primary studies, and synthesising 
and updating results. In the last few years, grading the quality of the evidence has 
been added to this process. Several studies have evaluated the quality of systematic 
reviews and consistently found a better quality for Cochrane versus non-Cochrane 
57
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
reviews (Jadad et al., 2000; Olsen et al., 2001; Moja et al., 2005; Delaney et al., 
2007; Moher et al., 2007; Tricco et al., 2009).
The main feature of Cochrane reviews is the publication of a protocol of the review 
beforehand; peer review of protocols is carried out before the results of the studies 
that are to be included are analysed, and this avoids biases. Prior knowledge of the 
results of a potentially eligible study, for example, might influence the definition of a 
review question, the subsequent criteria for eligibility and the choice of intervention 
comparisons to analyse or the outcomes to be reported in the review.
On the other hand, systematic reviews are often (but not always) retrospective, and 
for this reason it is important that the methods used are established and documented 
in advance (Light and Pillemer, 1984).
The protocol of a review should specify the inclusion criteria of studies to answer 
the review question, and in particular the types of population (participants), types of 
interventions (and comparisons) and the types of outcomes that are of interest. The 
outcomes, in particular, should be pre-specified and not listed only on the basis of 
their presence in the studies considered.
The subsequent review should adhere to the pre-published protocol, although 
changes may sometimes be introduced if necessary. Nonetheless, every effort should 
be made to adhere to the pre-determined protocol without undue changes.
Post hoc decisions made when the impact on the results of the research is known, 
such as excluding selected studies from a systematic review, are highly susceptible to 
bias and should be avoided (Higgins and Green, 2008).
How to read and interpret a ‘funnel plot’?
Funnel plots are the typical graph representing the meta-analysis results. They are 
useful as they allow a visual interpretation of the many elements that contribute to the 
final results.
Taking as an example the funnel plot in Figure 1, we illustrate the main components 
below:
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Figure 1: An example funnel plot and its components
A. A title indicates what interventions are compared to obtain what outcome.
B. Each study has a reference with the date of publication (if published).
C.  The number of patients with the event (related to the outcome) and the total number of patients 
randomised to each arm is indicated for each study.
D.  The relative weight attributed to each study is indicated. As explained earlier, the weight is 
attributed taking into account the number of participants and events (larger studies, with smaller 
standard errors, are given more weight than smaller studies with larger standard errors).
E.  A label indicates the measure of effect that has been calculated for each study.
F.  Each risk ratio is represented graphically by a square and a horizontal line whose extension 
indicates the confidence interval (CI) (the estimate of variation due to chance). The last diamond 
represents the pooled analysis which, in this example, favours the experimental intervention.
G.  A horizontal line indicates the position of the measures of effect in relation to the null hypothesis. 
The null hypothesis is the number 1 (the perfect symmetry of proportions of events between the 
interventions and the comparisons arms).
  Two labels (‘favours experimental’ and ‘favours control’) indicate which parts of the line represent 
the experimental superiority and which part the control superiority.
  When the representation of a risk ratio or its confidence intervals crosses the vertical line, this 
indicates that the results of the individual study are not statistically significant.
  In the specific case, the experimental intervention gave better results and the risk ratio of 1.44 
means that people in the heroin groups have 44 % more probability of being retained in treatment at 
the end of the study period.
H.  The test for heterogeneity describes the percentage of variability in effect estimates that is due to 
heterogeneity rather than chance. Statistical heterogeneity is considered when confidence intervals 
for the results of individual studies have a poor overlap. In the case of the above-represented meta-
analysis, the result of I 2 = 67 % may be interpreted as moderate to substantial heterogeneity.
Study or Subgroup
Total (95 % CI)
Heterogeneity: Tau  = 0.02; Chi  = 9.05, df = 3 (P = 0.03); I  = 67 %
Test for overall effect: Z = 3.74 (P = 0.0002)
Events Total Events Total Weight
Total events 484
704
295
684 100.0 % 1.44 [1.19, 1.75]
 Year
RIOTT, 2010 38 43 29 42 25.0 % 1.28 [1.02, 1.61] 2008
Haasen et al., 2007 346 515 200 500 33.5 % 1.68 [1.48, 1.90] 2004
NAOMI, 2009 77 115 45 111 22.8 % 1.65 [1.27, 2.14] 2004
PEPSA, 2006 23 31 21 31 18.7 % 1.10 [0.80, 1.51] 2003
Heroin + methadone Methadone Risk Ratio
IV, Random, 95 % CI
0.05 0.2 1 5 20
Favours control Favours experimental
A
G
B
C
D
E
F
Risk Ratio
IV, Random, 95 % CI
Supervised injected heroin plus flexible dosages of oral methadone versus oral
methadone to retain people in treatment
²²²
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The Cochrane systematic review on heroin-assisted treatment
Main results
Published as a protocol in 2001, the Cochrane systematic review on heroin maintenance 
for chronic heroin-dependent individuals (2010) was initiated to include prospectively 
the results from the existing, ongoing or planned randomised controlled studies about 
maintenance treatment with pharmaceutical heroin versus any other treatments.
At the time of first publication (2003), the review included four randomised controlled 
studies (with 577 participants) by Hartnoll et al. (1980), Perneger et al. (1998) and the two 
Dutch studies (Central Committee for the Treatment of Heroin Addicts CCBH (A) and CCBH 
(B)) by van den Brink et al. (2003). The studies conducted in Switzerland by Uchtenhagen 
(1999) were not included because they were not randomised controlled studies.
The studies included in the review were not comparable in terms of interventions 
and outcomes, and even though the heroin arms gave better end point measures, no 
overall conclusive results were possible.
When the results from a large new study by Haasen (2007) (of 1 032 patients) 
and the Spanish experimental drug prescription programme in Andalusia (PEPSA) 
(March et al., 2006; Perea-Milla et al., 2009), as well as from Canadian (Oviedo-
Joekes et al., 2009) and, most recently, British (Strang et al., 2010) studies became 
available, the review was updated and the conclusions revised accordingly.
The updated version of the review encompassed eight studies and 2 007 patients, 
analysed in two steps. The first step compared the differences between SIH as the 
experimental intervention and oral methadone as the control intervention and 
included four recent studies (March et al., 2006; Haasen et al., 2007; Oviedo-Joekes 
et al., 2009; Strang et al., 2010). The study by Perneger et al. (1998) was not 
included in this comparison because the control intervention was on a waiting list 
for treatment as usual, and it was therefore included in a second step comparison. 
This second step compared the differences between heroin provision (all route of 
administrations) plus flexible doses of methadone versus any other interventions, 
and it included the valid data from all eight studies.
The pooled results of four of the most recent studies comparing SIH plus flexible 
dosages of methadone treatment with oral methadone showed that heroin helps 
patients to remain in treatment (valid data from four studies, n = 1388; risk ratio 1.44 
(95 % CI 1.19–1.75) heterogeneity; P = 0.03) (see Figure 2).
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Figure 2: Supervised injectable heroin plus flexible dosages of oral methadone versus oral 
methadone to retain people in treatment 
The results from the Dutch studies (van den Brink et al., 2003) could not be included 
in the meta-analysis for this outcome as the authors declared the non-comparability 
of the groups owing to differences in the discharge rules.
The results for the meta-analysis including all the studies, which consider 
unsupervised provision of heroin and/or compared SIH with waiting list or standard 
treatment, remain in favour of heroin provision (see Figure 3).
Figure 3: Heroin plus flexible dosages of oral methadone versus other interventions to retain 
people in treatment
Study or Subgroup
RIOTT, 2010
Haasen et al., 2007
NAOMI, 2009
PEPSA, 2006
Total (95 % CI)
Total events
Heterogeneity: Tau  = 0.02; Chi  = 9.05, df = 3 (P = 0.03); I  = 67 %
Test for overall effect: Z = 3.74 (P = 0.0002)
Events
38
346
77
23
484
Total
43
515
115
31
704
Events
29
200
45
21
295
Total
42
500
111
31
684
Weight
25.0 %
33.5 %
22.8 %
18.7 %
100.0 %
IV, Random, 95 % CI
1.28 [1.02, 1.61]
1.68 [1.48, 1.90]
1.65 [1.27, 2.14]
1.10 [0.80, 1.51]
1.44 [1.19, 1.75]
Year
2008
2004
2004
2003
Heroin + methadone Methadone Risk Ratio Risk Ratio
IV, Random, 95 % CI
0.05 0.2 1 5 20
Favours control Favours experimental
²²²
Study or Subgroup
Total events
Heterogeneity: Tau  = 0.06; Chi  = 31.18, df = 5 (P < 0.00001); I  = 84 %
Test for overall effect: Z = 3.26 (P = 0.001)
Events
543
Total Events
332
Total Weight IV, Random, 95 % CI
Total (95 % CI) 775 760 100.0 % 1.44 [1.16, 1.79]
Year
Hartnoll et al., 1980 32 44 15 52 11.0 % 2.52 [1.59, 4.01] 1975
Perneger et al., 1998 27 27 22 24 19.9 % 1.09 [0.95, 1.26] 1996
PEPSA, 2006 23 31 21 31 14.8 % 1.10 [0.80, 1.51] 2003
Haasen et al., 2007 346 515 200 500 20.3 % 1.68 [1.48, 1.90] 2004
NAOMI, 2009 77 115 45 111 16.6 % 1.65 [1.27, 2.14] 2004
RIOTT, 2010 38 43 29 42 17.5 % 1.28 [1.02, 1.61] 2008
Experimental Control Risk Ratio Risk Ratio
IV, Random, 95 % CI
0.01 0.1 1 10 100
Favours control Favours experimental
² ²²
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Heroin provision appears also to have a protective effect on mortality even though 
it is known that randomised controlled studies, owing to their short period of 
observation, are not appropriate for measuring this outcome (Figures 4 and 5).
Figure 4: Supervised injectable heroin plus methadone versus oral methadone —   
Outcome: mortality
For the mortality outcome among the patients provided with SIH or oral methadone, 
it can be noted that the British trial was not included in the meta-analysis because the 
original trial protocol did not declare that it would measure this outcome. Personal 
communication with the principal investigator (John Strang) informed us that no 
lethal events occurred in the two study arms during the trial phase, confirming that 
the study should not be added to the meta-analysis. In fact, if studies with zero 
events in both comparison arms are pooled in the meta-analysis, the pooled total 
become less precise in terms of statistical significance, and they do not contribute to 
cumulative knowledge (Higgins and Green, 2008).
Study or Subgroup
Total (95 % CI)
Total events
Heterogeneity: Tau  = 0.00; Chi  = 0.61, df = 3 (P = 0.89); I  = 0 %
Test for overall effect: Z = 0.88 (P = 0.038)
Events Total Events Total Weight IV, Random, 95 % CI Year
Heroin + methadone Methadone Risk Ratio Risk Ratio
IV, Random, 95 % CI
CCBH (A), 2002
PEPSA, 2006
Haasen et al., 2007
NAOMI, 2009
1
0
5
0
6
76
31
515
115
737
1
1
7
1
10
98
31
500
111
740
12.0 %
9.1 %
70.0 %
8.9 %
100.0 %
1.29 [0.08, 20.28]
0.33 [0.01, 7.88]
0.69 [0.22, 2.17]
0.32 [0.01, 7.82]
0.65 [0.25, 1.69]
2001
2003
2004
2004
0.01 0.1 1 10 100
Favours experimental Favours control
²²²
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Figure 5: Heroin provision (various modalities and routes of administration) versus 
methadone in different modalities — Outcome: mortality
Only five studies were eligible for inclusion in the meta-analysis of the mortality 
outcome among the patients provided with heroin (any modality and route of 
administration) versus methadone in different modalities. The studies by Perneger et 
al. (1998) and Strang et al. (2010) did not measure the outcome, and there were no 
deaths in any of the compared groups in the Dutch study on inhaled heroin (van den 
Brink et al., 2003).
The studies also show a protective effect for criminal activities and the risk of being 
incarcerated; while the positive effect on social functioning is not different between 
the study groups, an equal achievement confirms the beneficial effect of being in 
treatment.
On the negative side of heroin provision, there is a higher risk of adverse events that, 
despite being rare, are more frequent among heroin-treated patients in all the studies 
reporting it. The Cochrane reviewers, in agreement with the conclusions of the trials 
(Haasen et al., 2007; Oviedo-Joekes et al., 2009; Strang et al., 2010), recommend 
that the treatment should be provided in settings where emergencies can be readily 
treated (see Figure 6).
Study or Subgroup
Total events
Heterogeneity: Tau  = 0.00; Chi  = 1.58, df = 4 (P < 0.81); I  = 0 %
Test for overall effect: Z = 0.55 (P = 0.58)
Events Total Events Total Weight IV, Random, 95 % CI
Total (95 % CI)
Year
Experimental Control Risk Ratio Risk Ratio
IV, Random, 95 % CI
0.01 0.1 1 10 100
Favours experimental Favours control
Hartnoll et al., 1980
CCBH (A), 2002
PEPSA, 2006
NAOMI, 2009
Haasen et al., 2007 (¹)
2
1
0
0
5
8
44
76
31
115
515
781
1
1
1
1
7
11
52
98
31
111
500
792
14.0 %
10.3 %
7.8 %
7.7 %
60.2 %
100.0 %
2.36 [0.22, 25.20]
1.29 [0.08, 20.28]
0.33 [0.01, 7.88]
0.32 [0.01, 7.82]
0.69 [0.22, 2.17]
0.78 [0.32, 1.89]
1975
2001
2003
2004
2004
(¹) None of the deaths were probably, possibly or definitely related to study medication.
²²²
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Figure 6: Supervised injectable heroin plus methadone versus oral methadone —  
Outcome: adverse events related to intervention medications
Heroin prescription is shown to help to reduce illicit drug use, a domain that is 
considered as a primary outcome in each study (see Table 3).
Table 3: Definition of responders at study level, measures of effect and number of 
patients that is needed to treat (NNT) in order to have one patient responding to 
treatment
Study  
name
Definition  
of ‘responder’
Measure of effect as 
published and ARR (1)
Number needed  
to treat (2) 
Strang  
et al., 2010
Reduction of regular  
use of ‘street’ heroin ≤50 % 
negative urinalysis  
specimens during  
weeks 14–26
Injectable heroin:  
(72 % [n=31]) 
Oral methadone  
(27 % [n=11], 
OR (3) = 7.42, (95 %  
CI 2.69–20.46), P<0.0001
ARR=0.46  
(95 % CI 0.27–0.65)
NNT=2.17  
(95 % CI 1.60–3.97)
(1)  Absolute risk reduction (ARR) = difference between the proportion of events in the experimental arm 
and the control arm.
(2)  Number needed to treat (NNT) = 1/ARR or the number of patients that are needed to be treated in 
order to obtain one success. The ‘ideal’ NNT is one.
(3)  Odds ratio (OR) = ratio of the odds of an event occurring in the experimental group to the odds of it 
occurring in the comparison group.
Study or Subgroup
Total (95 % CI)
Total events
Heterogeneity: Tau  = 0.00; Chi  = 1.29, df = 2 (P = 0.52); I  = 0 %
Test for overall effect: Z = 3.06 (P = 0.008)
Events Total Events Total Weight IV, Random, 95 % CI Year
Heroin + methadone Methadone Risk Ratio Risk Ratio
IV, Random, 95 % CI
0.01 0.1 1 10 100
Favours experimental Favours control
PEPSA, 2006 (¹)
NAOMI, 2009
RIOTT, 2010
4
24
2
30
31
115
43
189
0
0
0
0
31
111
42
184
33.5 %
35.8 %
30.7 %
100.0 %
9.00 [0.51, 160.39]
47.31 [2.91, 768.63]
4.89 [0.24, 98.85]
13.50 [2.55, 71.53]
2003
2004
2008
(¹) Five events probably related to Diacetylmorphine occurred to four patients.
²² ²
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Table 3 (continued)
Oviedo-
Joekes et al., 
2009
Retention in addiction 
treatment at 12 months 
(defined as receipt of the 
study medication on at least 
10 of the 14 days before 
the 12-month assessment, or 
confirmation of retention in 
any other treatment program 
or abstinence from opioids 
during this interval).
Improvement of at least 
20 % from the baseline 
score (measured by the 
European ASI) (4) for illicit-
drug use or legal status (or 
both). In addition, to rule 
out deterioration in other 
variables, a patient with 
a response could have a 
decrease of 10 % or more on 
at most one of the remaining 
composite scores.
Retention in treatment: 87.8 % 
in the diacetylmorphine group, 
54.1 % in the methadone group 
(rate ratio=1.62; 95 %  
CI 1.35–1.95; P<0.001).
ARR=0.34 (95 % CI 0.23–0.45)
Reduction in illicit-drug use  
or other illegal activities: 67.0 % 
diacetylmorphine group 47.7 % 
methadone group (rate ratio= 
1.40; 95 % CI 1.11–1.77; 
P=0.004)
ARR=0.19  
(95 % CI 0.07–0.32)
NNT=2.9  
(95 % CI 2.22–4.35)
NNT=5.3  
(95 % CI 3.1–14.3)
Haasen  
et al., 2007
Health: at least a 20 % 
improvement and at least 
4 points on the OTI (5) Health 
Scale (physical health) and/or 
at least a 20 % improvement 
in the GSI (6) (mental health), 
without a deterioration of 
more than 20 % in the other 
area of health.
Reduction in Illicit drug use: 
reduction in the use of ‘street’ 
heroin with at least 3 of 
5 urine samples negative for 
the drug in the month prior 
to the 12-month assessment 
and no increase in cocaine 
use (hair analysis). If less than 
3 urine samples or no hair 
was available at 12 months, 
data from urine or hair 
testing at 6 months were 
used.
Health Improvement  
(adjusted OR=1.54, 95 %  
CI 1.02–2.34, P=0.042).
ARR=0.06  
(95 % CI 0.01–0.11)
‘Illicit drug use’ (adjusted 
OR=1.91, 95 % CI 1.30–2.79, 
P=0.001).
ARR=0.14 (95 % CI 0.08–0.20)
NNT=16.7  
(95 % CI 9.09–100)
NNT=7.1  
(95 % CI 5–12.5)
(4) ASI: Addiction Severity Index.
(5) OTI: Opiate Treatment Index. 
(6) GSI: Global Severity Index.
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Table 3 (continued)
March  
et al., 2006
At least 20 % improvement at 
9 months, compared with the 
baseline values, in general 
health or psychological or 
family adjustment, without a 
deterioration superior to 20 % 
in any of these dimensions 
evaluated with the respective 
ASI composite scores.
MDO (7) index 70.4 % 
experimental group;  
60.9 % control group,  
difference not  
statistically significant.
ARR=0.10 
NNT=10 (8) 
Van den Brink 
et al., 2003 
(CCBH A)
Responders: at least 40 % 
improvement in at least one 
of the 3 domains of inclusion 
(physical, mental, social) 
at the end of the treatment 
compared with baseline; if 
this improvement was not 
at the expense of a serious 
(≥ 40 %) deterioration in 
functioning in any of the 
other outcome domains; and 
if the improvement was not 
accompanied by a substantial 
(≥ 20 %) increase in use of 
cocaine or amphetamines.
risk difference=24.3 %,  
(95 % CI 9.6–39)
NNT=4.1  
(95 % CI 2.6–10.4)
Van den Brink 
et al., 2003 
(CCBH B)
see above risk difference 22.3 %, 
(95 % CI 11.0–34.6)
NNT=4.4  
(95 % CI 2.9–9.1)
(7) MDO: Dichotomous Multidimension Outcome Index.
(8)  Not statistically significant.
Number needed to treat
The number needed to treat (NNT) has been calculated for each study (Table 3) and 
it indicates the number of patients that needs to be treated to obtain one respondent 
patient. Numerically, the NNT is the reciprocal of the difference between the proportion 
of events in the experimental and the comparison group (absolute risk reduction).
It is important to highlight that the NNT cannot be compared across the included 
studies as the criteria for being ‘responders’ were different. Nonetheless, the results 
show that providing heroin can be quite effective in obtaining pre-specified effects 
on patients. Taking into consideration that the ideal NNT would be one (the unreal 
situation in which every single patient succeeded), it is easily understood that an 
NNT close to three or four would be very good results, especially considering the 
nature of the patients studied. These patients are, by definition, long-term treatment 
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refractory and dependent on heroin, and therefore are very likely to fail to respond 
to treatment.
Long-term trajectories
The findings of extended (2- to 6-year) follow-up studies are an important addition to 
the shorter (6- to 12-month) data available about treating this most difficult group of 
heroin users.
Switzerland, 2001, 2003
Rehm and colleagues (2001) demonstrated the safety and long-term benefits of SIH 
in different outcome categories based on a cohort of 237 patients seen between 
January 1994 and December 2000 in 21 outpatient treatment centres in Switzerland.
A total of 1 693 (86 %) patients have remained in the heroin treatment programmes 
across the country for at least 3 months, 1 378 (70 %) for at least a year, 985 (50 %) 
for at least 2.5 years and 669 (34 %) for 5 years or longer. Among those who 
have dropped out, a clear relationship has been established between length of stay 
and reasons for discharge (P < 0.001), with discharges related to lack of patient 
cooperation occurring early on (< 4 months) rather than later on (> 3 years) in SIH 
(30 % vs. 4 %, respectively). On the other hand, transfer onto abstinence-based 
treatment or treatments other than methadone tended to be more common late in 
treatment, and while only 9 % of the discharges during the first four months switched 
to abstinence treatment, this proportion accumulated to 29 % for patients discharged 
after three years of treatment.
A sharp reduction was reported in illicit ‘addictive behaviour’. For example, daily 
use of ‘street’ heroin declined from 82 % (baseline) to 6 % (18 months) and similar 
reductions were observed with cocaine and benzodiazepine use, which decreased 
from 29 % to 5 % and from 19 % to 9 %, respectively. These considerable reductions 
in drug use occurred in tandem with significant improvements in all measures of 
health and social behaviour. The health of those with severe somatic (baseline: 22 % 
vs. 18 months: 13 %; P = 0.001) or mental (baseline: 37 % vs. 18 months: 19 %; 
P < 0.0001) problems at the start of treatment improved, and those with a low BMI 
were observed to put on weight (baseline: 35 % vs. 18 months: 24 %; P < 0.0001). 
Also, long-term improvement was evident in reduced proportions of patients with 
an unstable housing situation (baseline: 43 % vs. 18 months: 21 %; P < 0.0001), 
homelessness (baseline: 18 % vs. 18 months: 1 %; P < 0.0001), unemployment 
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(baseline: 73 % vs. 18 months: 45 %; P < 0.0001) and those receiving welfare 
payments (baseline: 63 % vs. 18 months: 54 %; P = 0.035).
Increased proportions of patients reported no debts (baseline: 26 % vs. 18 months: 
33 %; P = 0.026) and no visits to illegal drug scenes in the last month (baseline: 
14 % vs. 18 months: 59 %; P < 0.0001). Finally, a smaller proportion of patients 
reported illegal income (baseline: 69 % vs. 18 months: 11 %; P < 0.0001) and 
these reductions in criminality were corroborated by objective judicial data in an 
independent investigation (Kilias and Rabasa, 1998).
A subsequent six-year follow-up study (Güttinger et al., 2003) focused on two groups 
of SIH patients in Switzerland: (i) those who have continuously been in SIH treatment 
since entry into the initial Swiss SIH treatment study or those who have re-entered this 
treatment and (ii) ex-patients who have discontinued SIH at the time of the follow-up. 
The study found that of all patients examined (n = 366), 332 (88.3 %) were alive at 
the six-year follow-up point, and of these patients, 40 % were still in SIH. Compared 
with baseline status, in relation to use of illicit drugs, illegal income and other social 
functioning variables, the results at follow-up showed significant improvements, which 
were evident in patients remaining in SIH for a minimum average period of 2.4 years. 
Of those still in treatment at the six-year mark, a significantly smaller proportion (4 %) 
were still using illicit heroin daily or almost daily compared with 19 % in the group of 
SIH-terminators (χ = 14.3; P < 0.001). A less positive result indicated that both patient 
groups — those still in SIH treatment as well as those who had terminated treatment 
— were showing an increase in unemployment and reliance on social benefits.
Seven-year mortality data from the Swiss studies (Rehm et al., 2005) showed a 1 % 
death rate per year of patients in SIH treatment, which was lower than the 2.5–3 % 
mortality rate of Swiss heroin users in 1990s (Rehm, 1995), and lower compared with 
the mortality rates of opioid users in other maintenance treatments in other countries.
Germany, 2008
All patients of the SIH group were included in the long-term follow-up study, plus a 
random sample of patients whose initial randomised treatment was oral methadone, 
but who, after the initial 12-month period, were offered to take vacated SIH places.
In 2008, Verthein and colleagues (Verthein et al., 2008) published the findings of a 
prospective cohort study of 515 heroin patients initially recruited into the German 
SIH RCT. At two years, 55 % were still in SIH, with an average treatment duration 
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of 527 (± 276) days. Most drop-outs (n = 225) had switched to another addiction 
treatment, predominantly MMT (27 %), or were imprisoned in the meantime (16 %).
With respect to illicit drug use, the reduction of ‘street’ heroin use achieved during 
the first six months of the RCT (less than one day of use within the last month) 
(Haasen et al., 2007) has been sustained throughout the two-year follow-up. Earlier 
gains of reduced cocaine use were also present at the two-year point when patients 
were using cocaine on an average of three days (compared with a mean of nine 
days at baseline). Similarly, the greatest changes in the symptoms related to both 
physical and mental health had occurred during the first six months after treatment 
initiation (Haasen et al., 2007) and were thereafter stabilised at satisfactory levels.
In the social domain, marked improvements were observed during the two-year 
treatment period, with a significantly higher proportion of patients in stable housing 
at 24 months compared with 12 months and baseline (24 months: 91 % vs. 12 
months: 82 % vs. baseline: 76 %; P < 0.001) and a significant increase in the drug-
free social contacts, for example leisure activities in the company of people without 
drug or alcohol problems (24 months: 30 % vs. 12 months: 22 % vs. baseline: 15 %; 
P < 0.001), and involvement in leisure behaviour (24 months: 74 % vs. 12 months: 
71 % vs. baseline: 59 %; P < 0.001). The rate of employment among SIH patients had 
increased in the first year of treatment, but no further gains were reported in that 
domain (24 months: 26 % vs. 12 months: 26 % vs. baseline: 15 %; P < 0.001).
Similarly, last month, prior to assessment, illegal activities, according to EuropASI 
(Kokkevi and Hartgers, 1995) had decreased in the first year of treatment, although 
this was not followed by substantial further decline during the second year (24 
months: 25 % vs. 12 months: 23 % vs. baseline: 70 %; P < 0.001).
On safety, the study reported that the main SAEs associated with SIH — respiratory 
depression and epileptic seizures, both occurring within minutes after injection — 
occurred in 6 % (respiratory depression) and 8 % (epileptic seizures) of the two-year 
sample. Within the study period, eight patients treated initially with diacetylmorphine 
had died: five while in treatment and three after discontinuation of SIH. No death 
was reported to be causally related to the study medication (Verthein et al., 2008).
Spain, 2010
The Andalusian research group reported that 44.4 % of the original SIH treatment 
patients were still in receipt of SIH treatment at two-year follow-up, and, while all 
69
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
study participants were reported to have achieved significant reductions in ‘street’ 
heroin use (measured as self-reported mean number of days used in last month) from 
baseline to two years post trial, those continuously engaging in SIH treatment were 
the only group that had, at two years, sustained the health-related improvements 
made over the nine-month trial period (Oviedo-Joekes et al., 2010).
The Netherlands, 2010
Completers of SIH (both injectable and inhalable) in the Dutch trials and those 
who were eligible to be brought back into supervised heroin treatment (i.e. were 
showing positive response to SIH or had deteriorated seriously after the planned 
discontinuation of SIH treatment) were followed in an observational cohort study for 
3 years (Blanken et al., 2010). Assessment was carried out at the end of the second, 
third and fourth years of SIH treatment.
The study used two dichotomous outcome indicators of recovery: (i) ‘health recovery’, 
defined as the absence of problems in physical and mental health, social functioning 
and involvement in illegal activity and (ii) ‘complete recovery’, defined as the absence 
of any problems in tandem with lack of any non-prescribed drug and excessive 
alcohol use.
Four-year retention was 56 % (95 % CI: 47.6–63.8 %), with the main reasons for 
terminating SIH being violation of house rules (23 %) and unsatisfactory treatment 
response (21 %). Of the 66 patients who were not in SIH treatment at the end 
follow-up point, the majority (85 %) were in substitution treatment; although seven 
patients had progressed to abstinence-based treatment, nine were no longer in 
treatment and one had died, 7 months after leaving SIH treatment.
Patients in receipt of SIH treatment at the 4-year follow-up point showed significantly 
higher response rates than those who had terminated SIH (90 % vs. 21 %; 69 % 
difference; OR 48 %; 95 % CI: 17.6–159.1; P < 0.0001). Continued SIH treatment was 
also associated with an increasing proportion of patients without health problems 
who had stopped illicit drug use and excessive alcohol use (that is complete 
recoverers) — from 12 % after the first year to 25 % after 4 years of SIH (OR 1.24; 
95 % CI 1.04–1.48; P = 0.02).
Four-year data on the safety of SIH treatment reported by the Dutch group included 
11 SAEs, two of which probably related to the prescribed heroin (inpatient drug 
detoxification and pneumonia). No deaths had occurred in the study group, and 
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the SAEs among the patients who had discontinued SIH before the final follow-up 
assessment were not related to the termination of treatment.
Conclusion
Retention in SIH treatment is still high at 2- (44 %; Oviedo-Joekes et al., 2010), 
2.5- (50 %; Rehm et al., 2001), 4- (56 %; Blanken et al., 2010) and 6-year (40 %; 
Güttinger et al., 2003) follow-up. There is consistency in the finding of sustained and 
additional benefit in terms of reduced drug use and improved health status and social 
functioning. Different studies, however, have used different outcome measures, making 
direct comparisons difficult and presenting challenges for sought-after firm conclusions 
about the long-term benefit of SIH treatment. It is imperative that the collection of 
comparable data is continued as we begin to develop an evidence base, capturing 
any remission to illicit drug use, elimination of related problems and, more importantly, 
enhanced quality of life and social functioning of patients in long-term SIH treatment.
Patients’ perspectives
A qualitative study (Romo et al., 2009) involving 21 patients receiving SIH treatment 
was conducted in the final phase of the RCT of injectable treatment in Spain. The 
findings of this study recognised that SIH treatment not only offered patients ‘legal 
medicine’, that is pharmaceutical-grade heroin, but also fundamentally changed the 
situation in which heroin was acquired and administered by patients. In addition, the 
contextual change was associated with improvements in a range of areas of patients’ 
lives, such as physical and mental health, family relationships and work. Blanken et 
al. (2010b), based on the qualitative accounts of 24 patients receiving heroin in the 
Dutch trials, provided further evidence for the consistency in patients’ appreciation of 
the quality of prescribed heroin and the positive experience of the structure provided 
by the injectable maintenance clinics, as well as the availability of a secure supply of 
pharmaceutical heroin.
Conclusion
There is a dearth of research into the treatment expectations and satisfaction of 
patients in SIH treatment, reflecting the lack of research in general in these topics 
in relation to addiction treatment. Future studies will need to address these areas, 
together with research examining families’ perceptions of treatment, including the 
impact it has on family relationships.
71
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
Impact of supervised injectable heroin clinics and service provision 
on local communities
A critical issue that SIH clinics, akin to other substance misuse services, are facing 
is the resistance that the local community may have towards a supervised injectable 
maintenance clinic and the patients it is looking after.
Driven by the need to evaluate whether the establishment and operation of SIH clinics 
generates an impact (e.g. changes in street public nuisance, amount of criminal 
offences) for those residing and working in surrounding areas, two community impact 
studies have been conducted, and their findings are outlined below.
Lasnier et al. (2010) looked at the impact of SIH clinics on public safety, assessing 
changes in the amount of criminal offences (violent crimes, property crimes and 
drug-related crimes) and acts of public disorder in the Vancouver and Montreal sites 
before and during the Canadian trial (2002–06). A primary hypothesis that was 
tested by the research group related to the general concern that SIH clinics may 
induce a ‘honeypot’ effect, leading to increases in crime and/or disorder problems 
in the clinic locality. A competing suggestion that was also tested in this study was 
around a possible reduction, rather than an increase, in the occurrence of crime in 
the local communities. Data on crime (assault, robbery, theft, breaking and entering, 
vehicle theft, illegal possession of property, possession of a prohibited substance 
and trafficking in a prohibited substance) and disorder (disorderly conduct, public 
nuisance, misbehaviour, drifting and panhandling) were collected from the Montreal 
and Vancouver police departments. The study found that most indicators remained 
stable during the pre- and post-implementation phase of the Canadian trial at 
both sites. For example, no impact was detected of either the introduction of the 
SIH clinics or the increase in the number of attending patients on the number of 
violent or property crimes committed in the clinic vicinity (Montreal and Vancouver 
downtown eastside). In fact, the SIH clinic’s presence in Montreal appeared to be 
correlated with a significant (although negligibly small) reduction in the number of 
property offences (t-ratio = –2.041; P < 0.05). Similarly, no relationship was detected 
between acts of disorder inside the two areas under study and the operational status 
of the SIH clinics and the monthly increase of the number of SIH clinic attendees. It 
was concluded that the SIH clinics operating at both localities had had no clearly 
observable impact on crime and disorder in the local communities. However, as 
the number of participants enrolled at each site of the Canadian trial was too small 
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(Vancouver: n = 158; Montreal: n = 52), the study might have been underpowered to 
detect significant effects had they existed.
Another study that took a similar focus was carried out in London, United Kingdom. 
Miller et al. (2010; 2011) evaluated the impact on the local community of the 
supervised injectable clinic that was set up to provide SIH within the RIOTT, London, 
and documented the expectations, fears and experiences of the local community 
members.
Based on 21 key informants who were interviewed before the trial, the study 
reported concern and, in some instances, clear opposition, stemming from a fear 
over an increase in the street drug user population (n = 11), crime (n = 6) and drug 
dealing (n = 1). After two years, during which time 35 individuals had participated 
in the trial and had attended the local supervised injecting clinic, 40 community 
members, including everybody who had taken part in the initial wave of interviews, 
were approached and asked about their current perception of the trial and any 
current concerns. Although some key concerns were expressed, relating to street 
drinking and antisocial behaviour, alcohol licensing, and young people and violence, 
there were no particular major issues about the trial specifically. In fact, a third of the 
key informants had not previously been aware of the trial. None of the participants 
reported a perceived change in the level of crimes committed locally, nor in drug use 
and dealing, street drinking, public intoxication, street cleanliness or local trade since 
the start of the trial.
Corroboration with Metropolitan Police figures carried out by the same research 
team revealed no significant changes in monthly or average annual crime levels in 
the local area (Boroughs of Southwark and Lambeth) over the two-year trial period. 
Similarly, antisocial street behaviour data collected from the Camberwell Street 
Population Forum (CSPF) (3) between 12 November 2004 and 8 September 2006 
showed that all study individuals (n = 7) identified on this register had dropped off 
the CSPF list while undergoing injectables treatment, and no injectables treatment 
participants were subsequently noted in this record. Furthermore, the study found 
that, on average, trial participants were spending 20 weeks less on the CSPF register 
than the general street population. The study concluded that the trial has had limited 
(3) The CSPF is the operations forum, with enforcement and police surveillance powers, of 
the Camberwell Street Drinking Initiative (CSDI), established to facilitate discussion of 
possible solutions for street users with local agencies and local groups.
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impact, either positive or negative, on the local community. It identified a sensitive 
instrument (CSPF) for measuring local impact to illuminate treatment effect for 
patients who were originally identified as violators of local community order.
Conclusion
While a definite conclusion is difficult, owing to the small study samples and the fact 
that many extrinsic factors may be involved in shaping the process around observed 
local crime and disorder trends, available data consistently suggest no positive or 
negative effects of SIH clinics on public safety. Future research attention will also 
need to address the perceived public nuisance, security and potential for diversion 
where SIH unfolds outside of the research context.
References
Ali, R., Auriacombe, M., Casas, M., et al. (1999), Report of the external panel on the 
evaluation of the Swiss scientific studies of medically prescribed narcotics to drug 
addicts, World Health Organization, Geneva.
Altman, D. G. (1998), ‘Confidence intervals for the number needed to treat’, British 
Medical Journal 317, pp. 1309–1312.
Amato, L., Davoli, M., Vecchi, S., et al. (2011), ‘Cochrane systematic reviews 
in the field of addiction: What’s there and what should be’, Drug and Alcohol 
Dependence 113, pp. 96–103.
Ashcroft, R. E. Chadwick, D. W., Clark, S. R. L., et al. (1997), ‘Implications of socio-
cultural contexts for the ethics of clinical trials’, Health Technology Assessment 9. 
Online at: http://www.hta.ac.uk/project/htapubs
Blanken, P., van den Brink, W., Hendriks, V.M., et al. (2010b), ‘Heroin-assisted 
treatment in the Netherlands: History, findings, and international context’, European 
Neuropsychopharmacology 20, pp. 105–158.
Blanken, P., Hendriks, V., van Ree, J. and van den Brink, W. (2010), ‘Outcome of 
long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin 
addicts in the Netherlands’, Addiction 105, pp. 300–308.
van den Brink, W., Hendriks, V. M. and van Ree, J. M. (1999), ‘Medical 
co-prescription of heroin to chronic, treatment-resistant methadone patients in the 
Netherlands’, Journal of Drug Issues 29, pp. 587–608.
74
New heroin-assisted treatment
van den Brink, W., Hendricks, V. M., Blanken, P., et al. (2003), ‘Medical prescription 
of heroin to treatment resistant heroin addicts: two randomised trials’, British Medical 
Journal 327, pp. 310–316.
Darke, S., Ward, J., Hall, W., Heather, N. and Wodak, A. (1991), The Opiate Treatment 
Index (OTI) researcher’s manual, National Drug and Alcohol Research Centre Technical 
Report Number 11, National Drug and Alcohol Research Centre, Sydney.
Darke, S., Hall, W., Wodak, A., Heather, N. and Ward, J. (1992), ‘Development and 
validation of a multidimensional instrument for assessing outcome of treatment among 
opiate users: the Opiate Treatment Index’, British Journal of Addiction 87, pp. 733–742.
Derogatis, L. R. and Cleary, P. A. (1997), SCL-90 administration, scoring and 
procedure manual for the revised version, Johns Hopkins University School of 
Medicine, Baltimore (MD).
Dijkgraaf, G. W., Van der Zanden, B. P., De Borgie, A. J. M., et al. (2005), ‘Cost 
utility analysis of co-prescribed heroin compared with methadone maintenance 
treatment in heroin addicts in two randomised trials’, British Medical Journal 330, 
pp. 7503–7506.
Delaney, A., Bagshaw, S. M., Ferland, A., et al. (2007), ‘The quality of reports of 
critical care meta-analyses in the Cochrane Database of Systematic Reviews: an 
independent appraisal’, Critical Care Medicine 35, pp. 589–594.
Ferri, M., Davoli, M., and Perucci, C. (2011), ‘Heroin maintenance for chronic heroin 
dependents’, Cochrane Database of Systematic Reviews, Issue 3: http://summaries.
cochrane.org/CD003410/pharmaceutical-heroin-for-heroin-maintenance-in-chronic-
heroin-dependents
Fischer, B., Rehm, J., Kirst, M., et al. (2002), ‘Heroin-assisted treatment as a response 
to the public health problem of opiate dependence’, European Journal of Public 
Health 2, pp. 228–234.
Gacond, A. (2004), ‘Analyse der Todesfälle von Juli 1996 bis Dezember 2000 
während und nach der heroingestützten Behandlung’, cited in Rehm, J., et al. (2005).
Gandek, B., Ware, J. E., Aaronson, N. K., et al. (1998), ‘Cross-validation of item 
selection and scoring for the SF-12 health survey in nine countries: Results from 
the IQOLA project. International Quality of Life Assessment’, Journal of Clinical 
Epidemiology 51, pp. 1171–1178.
75
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
Glass, G., V. (1976), ‘Primary, secondary and meta-analysis of research’, Educational 
Researcher 5, pp. 3–8.
Glasziou, P., Chalmers, I., Rawlins, M. and McCulloch, P. (2007), ‘When are 
randomised trials unnecessary? Picking signal from noise’, British Medical Journal 
334, pp. 349–351.
Güttinger, F., Gschwend, P., Schulte, B., Rehm, J. and Uchtenhagen, A. (2003), 
‘Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year 
follow-up’, European Addiction Research 9, pp. 73–79.
Haasen, C., Verthein, U., Degkwitz, P., et al. (2007), ‘Heroin-assisted treatment for 
opioid dependence: randomised controlled trial’, British Journal of Psychiatry 191, 
pp. 55–62.
Hartnoll, R. L., Mitcheson, M. C., Battersby, A., et al. (1980), ‘Evaluation of heroin 
maintenance in controlled trial’, Archives of General Psychiatry 37, pp. 877–884.
Higgins, J. P. T. and Green, S. (2008), Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.0.1. (updated September 2009), The Cochrane Collaboration.
Jadad, A. R., Moher, M., Browman, G. P., et al. (2000), ‘Systematic reviews 
and meta-analyses on treatment of asthma: critical evaluation’, British Medical 
Journal 320, pp. 537–540.
Jones, S. H., Thornicroft, G., Coffey, M. and Dunn, G. (1995), ‘A brief mental health 
outcome scale — reliability and validity of the Global Assessment of Functioning 
(GAF)’, British Journal of Psychiatry 166, pp. 654–659.
Kilias, M. and Rabasa, J. (1998), ‘Does heroin prescription reduce crime? Results 
from the evaluation of the Swiss heroin prescription projects’, Studies on Crime and 
Crime Prevention 7, pp. 127–133.
Klous, M.G., Nuijen, B., van den Brink, W., Van Ree, J.M. and Beijnen, J.H. (2004a), 
‘Pharmaceutical development of an intravenous dosage form of diacetylmorphine 
hydrochloride’, Journal of Pharmaceutical Science and Technology 58, pp. 287–295.
Klous, M.G., Nuijen, B., van den Brink, W., Van Ree, J.M. and Beijnen, J.H. (2004b), 
‘Development and manufacture of diacetylmorphine/caffeine sachets for inhalation 
via ‘chasing the dragon’ by heroin addicts’, Drug Development and International 
Pharmacy 30, pp. 775–784.
76
New heroin-assisted treatment
Klous, M.G., Nuijen, B., van den Brink, W., Van Ree, J.M. and Beijnen, J.H. (2004c), 
‘Process characterisation, optimisation, and validation of production of 
diacetylmorphine/caffeine sachets: a design of experiments approach’, International 
Journal of Pharmaceutics 285, pp. 65–75.
Kokkevi, A. and Hartgers, C. (1995), ‘EuropASI: European adaptation of a 
multidimensional assessment instrument for drug and alcohol dependence’, European 
Addiction Research 1, pp. 208–210.
Lasnier, B., Brochu, S., Boyd, N. and Fischer, B. (2010), ‘A heroin prescription trial: 
Case studies from Montreal and Vancouver on crime and disorder in the surrounding 
neighbourhoods’, International Journal of Drug Policy 21, pp. 28–35.
Light, R. J. and Pillemer, D. B. (1984), Summing up: the science of reviewing research, 
Harvard University Press, Cambridge (MA).
Lintzeris, N., Strang, J., Metrebian, N., et al. (2006), ‘Methodology for the 
Randomised Injecting Opiate Treatment Trial (RIOTT): evaluating injectable 
methadone and injectable heroin treatment versus optimised oral methadone 
treatment in the UK’, Harm Reduction Journal 3, pp. 28–33.
Löbmann, R. and Verthein, U. (2009), ‘Explaining the effectiveness of heroin-assisted 
treatment on crime reductions’, Law and Human Behaviour 33, pp. 83–95.
March, J. C., Oviedo-Joekes, E., Perea-Milla, E., Carrasco, F. and the PEPSA Team 
(2006), ‘Controlled trial of prescribed heroin in the treatment of opioid addiction’, 
Journal of Substance Abuse Treatment 31(2), pp. 203–211.
McLellan, T., Kushner, H., Metzger, D., et al. (1992), ‘The fifth edition of the Addiction 
Severity Index’, Journal of Substance Abuse Treatment 9, pp.199–213.
Miller, P., McKenzie, S., Lintzeris, N., Martin, A. and Strang, J. (2010), ‘The 
community impact of RIOTT, a medically supervised injectable maintenance clinic in 
south London’, Mental Health and Substance Use: Dual Diagnosis 3, pp. 248–259.
Miller, P., McKenzie, S., Walker, J., Lintzeris, N. and Strang, J. (2011), ‘Investigating 
the effect on public behaviour of patients of a medical supervised injectable 
maintenance clinic’, Drugs and Alcohol Today, 11, pp. 204–209.
Moher, D., Tetzlaff, J., Tricco, A. C., Sampson, M. and Altman, D. G. (2007), 
‘Epidemiology and reporting characteristics of systematic reviews’, PLoS Medicine 4, 
e78.
77
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
Moja, P. L., Castelli, B., McCauley, L., Grilli, R. and Auxilia, F. (2005), ‘Cochrane 
EPOC group: closing the gap between quality assurance and organization of care 
research and front line professionals’, Annali di Igiene 17, pp. 585–590.
Mulrow, C. D. (1994), ‘Rationale for systematic reviews’, British Medical Journal 309, 
pp. 597–599.
National Treatment Agency for Substance Misuse (2003), ‘Injectable Heroin (and 
Injectable Methadone). Potential Roles in Drug Treatment. Full Guidance Report ’, 
National Treatment Agency, London.
Nationale Drug Monitor (NDM) (2001), Jaarbericht NDM. Bureau NDM. Utrecht: 
Cited in van den Brink, W., et al. (2003).
Olsen, O., Middleton, P., Ezzo, J., et al. (2001), ‘Quality of Cochrane reviews: 
assessment of sample from 1998’, British Medical Journal 323, pp. 829–832.
Oviedo-Joekes, E., Nosyk, B., Brissette S., et al. (2008), ‘The North American Opiate 
Medication Initiative (NAOMI): profile of participants in North America’s first trial of 
heroin-assisted treatment’, Journal of Urban Health 85, pp. 812–825.
Oviedo-Joekes, E., Brissette, S., Marsh, D., et al. (2009), ‘Diacetylmorphine versus 
methadone for the treatment of opioid addiction’, The New England Journal of 
Medicine 361, pp. 777–786.
Oviedo-Joekes, E., March, J.C., Romero, M., and Perea-Milla, E. (2010), ‘The 
Andalusian trial on heroin-assisted treatment: A two year follow-up’, Drug and 
Alcohol Review 29, pp. 75–80.
Perea-Milla, E., Aycaguer, L. C., Cerda, J. C., et al. (2009), ‘Efficacy of prescribed 
injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders 
and non-responders according to a multi-domain outcome index’, Trials 10, p. 70.
Perneger, T. V., Giner, F., del Rio, M. and Mino, A. (1998), ‘Randomised trial of 
heroin maintenance programme for addicts who fail in conventional drug treatments’, 
British Medical Journal 317, pp. 13–18.
Prescription of injectable diacetylmorphine (heroin) in case of opioid dependence; 
Rules of guidance No 9240, 11 May 2009. Online at: http://www.emcdda.europa.
eu/best-practice/standards/treatment
Pukrop, P., Möller, H. J., Sass, H., et al. (1999), ‘Quality of life. Construct validation 
and the development of a modular system’, Nervenarzt 70, pp. 41–53 (in German).
78
New heroin-assisted treatment
Rehm, J. (1995), ‘Situation sociale des consommateurs de drogues’, in Fahrenkrug, H., 
Rehm, J., Muller, R., Klingemann, H., and Linder, R. (eds.), Drogues illegales en Suisse 
1990–1993. La situation dans les cantons et en Suisse, Seismo, Zürich, pp. 35–54.
Rehm, J., Gschwend, P., Steffen, T., et al. (2001), ‘Feasibility, safety, and efficacy of 
injectable heroin prescription for refractory opioid addicts: a follow-up study’, The 
Lancet 358, pp. 1417–1420.
Rehm, J., Frick, U., Hartwig, C., et al. (2005), ‘Mortality in heroin-assisted treatment 
in Switzerland 1994–2000’, Drug and Alcohol Dependence 79, pp. 137–143.
Reimer, J., Verthein, U., Karow, A., Schäfer, I., Naber, D. and Haasen, C. (2011), 
‘Physical and mental health in severe opioid-dependent patients within a randomised 
controlled maintenance treatment trial’, Addiction 106, pp. 1647–1655.
Romo, N., Poo, M., Ballesta, R. and the PEPSA Team (2009), ‘From illegal poison to 
legal medicine: A qualitative research in a heroin-prescription trial in Spain’, Drug 
and Alcohol Review 28, pp. 186–195.
Ryser, H. (1999), ‘Analyse der Todesfälle in den Versuchen für eine arztliche 
Verschreibung von Betäubungsmitteln’. Dissertation, University of Zürich. Cited in 
Rehm et al. (2005).
Schechter, M. T. (2002), ‘NAOMI — her time has come. North American Opiate 
Medication Initiative’, Journal of Urban Health 79, pp. 164–165.
Schechter, M., et al. (2006), ‘North American Opiate Medication Initiative (NAOMI): 
Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-
Refractory Injection Opiate Users’, Canadian Institutes of Health Research, Canada 
(unpublished).
Strang, J., Metrebian, N., Lintzeris, N., et al. (2010), ‘Supervised injectable heroin 
or injectable methadone versus optimised oral methadone as treatment for chronic 
heroin addicts in England after persistent failure in orthodox treatment (RIOTT): 
a randomised trial’, Lancet 375, pp.1885–1895.
Tricco, A. C., Tetzlaff, J., Pham, B., Brehaut, J. and Moher, D. (2009), ‘Non-Cochrane 
vs. Cochrane reviews were twice as likely to have positive conclusion statements: 
cross-sectional study’, Journal of Clinical Epidemiology 62, pp. 380–386.
79
Chapter 3: Scientific evidence base for supervised injectable heroin treatment
Uchtenhagen, A., Dobler-Mikola, A., and Gutzwiller., F. (1996), ‘Medically controlled 
prescription of narcotics: a Swiss national project’, International Journal of Drug 
Policy 7, pp. 31–36.
Uchtenhagen, A., Gutzwiller, F., Dobler-Mikola, A., et al. (1997), ‘Programme 
for medical prescription of narcotics: a synthesis of results’, European Addiction 
Research 3, pp. 160–163.
Uchtenhagen, A., Dobler-Mikola, A., Steffen, T., Gutzwiller, F. R. and Pfeifer, S. 
(1999), Prescription of narcotics for heroin addicts, Basel, Karger.
Verthein, U., Bonorden-Kleij, K., Degkwitz, P., et al. (2008), ‘Long-term effects of 
heroin-assisted treatment in Germany’, Addiction 103, pp. 960–966.

81
Chapter 4: Economic evaluation of supervised 
injectable heroin treatment
The Swiss experiment 82
The Dutch trial 85
The German trial 88
References 91
82
Chapter 4: Economic evaluation of supervised 
injectable heroin treatment
This chapter covers the evidence detailed in the published papers and project reports 
from the German, Dutch and Swiss studies examining heroin-prescribing treatment, 
both in a public domain and on a confidential basis, to identify reports of any 
existing findings of previous economic evaluation of heroin-prescribing treatment.
Two publications and unpublished economic analysis from Germany were identified, 
and their findings are summarised here. The three countries that have evaluated 
the costs and outcomes of heroin treatment have chosen different approaches to 
economic evaluation (see Glossary). The selection of one or another approach for 
economic analysis, that is cost–benefit (in the Swiss experiment) or cost–utility (within 
the German and Dutch trials), determines which cost categories are included in the 
analyses. Therefore, inclusion or not of different cost categories is likely to differ 
between the different studies. More importantly, however, the aim and outcome 
measures of the evaluation differ between the types of evaluation, and thus prevents 
comparison between the findings of the different research groups.
To allow for more direct comparison between the unit costs, these have been 
recalculated and adjusted for 2009 using country-specific consumer price indices 
(CPIs) (OECD, 2010). Original unit cost figures, along with original price years, are 
kept and reported in brackets following adjusted figures.
The Swiss experiment
A study by Gutzwiller and Steffen (2000) aimed to (i) determine the costs for various 
services and the therapeutic results of six pilot injectable heroin maintenance treatment 
projects and a total of 452 participants and (ii) compare the results according to 
project size of large-scale (> 98 patients), medium-scale (60 patients) and small-scale 
(19–40 patients) heroin maintenance treatment projects (price year 1995).
Description of clinic
The six supervised injectable maintenance clinics in Switzerland are stand-alone 
clinics that are purpose built with varied capacity — large-scale (Basel, Project Janus, 
n = 134; Berne, Project KODA-1, n = 98), medium-scale (Zürich, Project Lifeline, 
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n = 60; Zürich, Project ZOKL-2, n = 90) and small-scale clinics (Olten, Project HEROL, 
n = 30; Thun, Project H, n = 40).
In all six clinics, heroin is dispensed during set opening hours in the morning, 
afternoon and evening (8–10 a.m., 1–3 p.m., 6–9 p.m.) 7 days a week. The staff–
client ratio is one staff member for every 10–15 patients, with at least two staff 
members present at all times.
Multi-dose 10-g diacetylmorphine ampoules (Diaphin®) manufactured by DiaMo 
Narcotics GmbH, Switzerland, are used. The multi-dose Diaphin ampoules are 
reconstituted in accordance with the manufacturer’s recommendation — on a 
cleaned surface within the clinic conforming to Swiss ‘aseptic conditions’. Multiple 
syringes are drawn up from the reconstituted solution for multiple patients’ use and 
could be stored for up to 72 hours.
Direct costs of the projects
The costs of the six projects were measured, using a purpose-designed timesheet, 
over a period of one month. For a range of reasons (holidays, work overload, etc.), 
the time expenditure data could not be collected during the same period in all 
projects; the four-week periods were thus extended and the survey was carried out 
between September and December 1995.
The following types of costs were assessed:
• direct costs — including the opiates dispensed (heroin, methadone, morphine, 
substitution drugs), medical material and external medical services;
• fees for third-party services — fees paid for services not regulated by an 
employment contract and for which no social benefits accrue;
• labour costs — wages and extra allowances of the entire workforce involved in 
the project, including social services, further costs for personnel and services 
provided free of charge by the canton, commune or other institutions. These 
costs were broken down for each project per person per day according to 
the following tasks: research; social insurance; medical attendance; opiate 
dispensing; and project management/administration; and
• other operating costs — rent, interests, maintenance, depreciation, material 
insurances, energy and heating and administrative costs.
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All costs in this study were calculated for large-, medium- and small-scale projects. 
The total costs per participant and day classified according to cost category and 
capacity of the projects are grouped in Table 4.
Table 4: Costs (EUR; mean values) classified according to cost category  
and clinic capacity
Projects Number of 
participants 
Direct  
costs 
Personnel 
costs
Other 
operational costs 
Total costs per 
patient/day 
Total costs per 
patient/year 
Large scale 232 6.0 (5.3) 24.8 (21.7) 3.3 (3.0) 34.8 (31.0) 12 702 (11 315)
Medium scale 150 9.3 (8.6) 26.1 (23.1) 4.0 (3.4) 39.4 (35.1) 14 381 (12 812)
Small scale 70 5.6 (4.9) 29.8 (26.8) 4.3 (3.6) 39.7 (35.3) 14 491 (12 885)
All projects 452 7.0 (6.3) 26.9 (23.9) 3.9 (3.3) 38.0 (33.8) 13 870 (12 337)
Note: Unit cost figures are recalculated and adjusted for 2009 (with original cost figures from price 
year 1995 reported in brackets).
The costs for personnel in this study were further divided into a number of sectors, 
including care, medical assistance, dispensing of drugs, and administrative work and 
research. Of the EUR 26.9 spent on the average for personnel expenditures, 4.8 % 
were for research expenses, 21.3 % for social assistance, 7.5 % for medical care, 
28.8 % for drug dispensation and 40.2 % for general administration.
Without the costs for research, the average total costs per participant and day incurred 
by the study were reduced from EUR 38.0 to EUR 36.5 when all projects were considered.
Overall benefit per participant per day
This evaluation focused on and covered four key domains of benefit (listed below), 
which were valuated, based on procedures and rates applicable for Switzerland and 
expressed also in terms of benefits per participant and per day. The partial benefits 
in the four domains were then added and directly compared with the costs.
These were as follows:
1. Housing — reduced housing costs and costs for services such as accompanied 
forms of housing, treatment and care (in institutional forms of housing such as 
night shelters, treatment centres, psychiatric wards).
2. Work and professional status (productivity) — increased productivity defined as 
the amount which salaried and self-employed persons contribute per year to the 
GDP, including housework.
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3. Legal behaviour — reduced costs to victims; police investigations and 
prosecution; pre-trial detention; legal proceedings (trial); and imprisonment.
4. Health — reduced frequency of diseases associated with drug abuse, exposure 
and neglect; a decrease in medical expenditure for ambulatory and inpatient 
treatment.
The benefits calculated per participant and day in the different sectors were EUR 1.3 
(EUR 1.17, price year 1995) for housing, EUR 2.0 (EUR 1.8, price year 1995) for work, 
and EUR 59.0 (EUR 52.5, price year 1995) and EUR 14.0 (EUR 12.5, price year 1995) 
for legal behaviour and health, respectively. The overall benefit was obtained by 
adding the partial benefits as ascertained in this study, and this amounted to EUR 
78.2 (EUR 69.6, price year 1995) per participant per day. The highest benefit was 
obtained in the sector of ‘legal behaviour’, which accounted for 75 % of the total 
benefit. The improvement in the domain of ‘health’ was also substantial, accounting 
for almost 18 % of the total benefit, whereas the benefit in the domains of ‘housing’ 
and ‘work’ were less important from an economic point of view.
Costs and benefits
The cost–benefit analysis of this study determined the economic relationship between 
the costs of the treatment intervention to its socio-economic benefits. This analysis 
was based on the fundamental assumption that illicit drug opiate use and addiction 
results in a wide variety of direct and indirect costs, and cost was determined from 
a societal perspective. The perceived socio-economic benefits of injectable heroin 
maintenance treatment in the four domains outlined above were compared with 
the individual economic costs. Results showed that the costs of treatment were 
compensated by the overall revenue achieved — EUR 26 470 (EUR 23 563, price 
year 1995) per year, leading to an annual socio-economic benefit of EUR 13 096 
(EUR 11 658, price year 1995).
The Dutch trial
Dijkgraaf et al. (2005) have determined the cost utility of medically supervised 
injectable heroin (SIH) compared with methadone maintenance treatment for chronic 
treatment-resistant heroin addicts. The economic analysis was performed with pooled 
data from 430 patients enrolled in inhalable or injectable heroin treatment within the 
two Dutch heroin trials (price year 2001).
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Description of clinic
Eight outpatient treatment units in six cities in the Netherlands (Amsterdam, the 
Hague, Groningen, Heerlen, Rotterdam, Utrecht) were established. Heroin was 
dispensed up to three times a day during the opening hours of these treatment 
units — in the morning, at noon and in the evening, seven days a week. Heroin was 
prescribed in the Dutch clinics in an injectable and an inhalable form.
The main outcome measures included one year costs estimated from a societal 
perspective and quality-adjusted life years (QALYs) based on responses to the 
EuroQol questionnaire (EQ-5D, EuroQol Group, 1990; 2005) at baseline and at 6, 
10 and 12 months during SIH treatment.
In this study, the following cost data were collected:
1. Direct medical care within the programme — healthcare staff; security personnel; 
materials, overheads and depreciations over 30 years of initial rebuilding costs of 
the heroin dispensation clinic.
2. Use of external healthcare resources — out-of-institution consultations; 
institutional outpatient consultations; institutional inpatient stays/week.
3. Travel related to the programme.
4. Illegal activities — law enforcement (police investigations, prosecution, 
adjudication, imprisonment, resettlement) and damage to victims.
Production loss due to sick leave or lowered efficiency at work was not measured 
because unemployment or disability rates were expected to be high in the target 
population. Neither were financial consequences of changes in patients’ housing 
arrangements in the community or changes in the public’s perception of safety.
Use of resources, programme-related travel and crime data were collected using 
clinical report forms and the European version of the Addiction Severity Index 
(EuropASI). The EuropASI was completed at the same intervals as the EQ-5D.
Direct cost of heroin treatment and oral methadone maintenance treatment
The costs, averaged per person and grouped by type (as described above), were as 
follows: for the heroin and methadone maintenance treatment group: EUR 20 410 
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(EUR 17 634, price year 2001); for the methadone-only group, the average annual 
costs per participant amounted to EUR 1 634 (EUR 1 412, price year 2001).
Heroin:
• other healthcare costs — EUR 1 343 (EUR 1 160, price year 2001);
• health-related travel — EUR 695 (EUR 600, price year 2001);
• damage to victims — EUR 11 131 (EUR 9 617, price year 2001); and
• law enforcement costs — EUR 10 135 (EUR 8 756, price year 2001).
With cost of clinic, these amounted to a total of EUR 43 713 (EUR 37 767, price 
year 2001) per heroin patient per year.
Oral methadone:
• other healthcare costs — EUR 1 303 (EUR 1 126, price year 2001);
• health-related travel — EUR 169 (EUR 146, price year 2001);
• damage to victims — EUR 40 500 (EUR 34 991, price year 2001); and
• law enforcement costs — EUR 14 914 (EUR 12 885, price year 2001).
The total annual costs, including cost of clinic averaged per person in the methadone 
group, thus reached EUR 58 520 (EUR 50 560, price year 2001).
Cost utility
Significant mean cost differences between the two groups was observed where 
the heroin treatment group had significantly higher treatment costs compared with 
the oral methadone group. The costs of law enforcement and of damage to victims 
from criminal activities were, however, higher for the oral methadone group than 
in the heroin treatment group, resulting in mean total net savings to society from 
the provision of heroin treatment of EUR 14 807 (95 % confidence interval (CI) EUR 
1 254–29 201; EUR 12 793 (95 % CI EUR 1 083–25 229), price year 2001), higher 
than that from the provision of oral methadone maintenance treatment. Heroin 
treatment was also associated with higher QALYs than oral methadone — 0.058 
more QALYs per patient per year (95 % CI 0.016–0.099).
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The German trial
The abridged economic evaluation report (Haasen, 2009) of SIH and methadone 
maintenance treatment in Germany was performed on 1 015 trial participants (price 
year 2006).
Description of clinic
In the German trial, heroin was dispensed up to three times a day during the 
opening hours of outpatient units hosting the supervised injecting clinics — in the 
morning, at noon and in the evening, seven days a week.
Costs
In the context of the German model project, the average annual costs amounted 
to EUR 19 020 (EUR 18 060, price year 2006) per study participant in the SIH 
treatment and to EUR 3 490 (EUR 3 314, price year 2006) per participant in the 
methadone treatment group. The methadone treatment plus psychosocial support 
had additional average annual costs of EUR 2 031 (EUR 1 928, price year 2006) 
per study participant per annum. The main part of the expenditures was personnel 
related. The higher expenditures of SIH treatment in comparison with methadone 
treatment were mainly a result of the longer operating clinic times and higher safety 
measures, such as injecting under medical supervision.
Savings from improved health
Compared with the previous year, there were no significant changes in the use of 
other prescribed medication for both groups. However, there were changes in the use 
of health services (acute/inpatient and community psychiatric care units). Reduction 
in mental health service use, in relation to the previous year, resulted in savings 
to the health system of EUR 3 978 (EUR 3 777, price year 2006) over a 12-month 
period for the heroin group. For the methadone group, the health/treatment cost 
reduction reached approximately EUR 1 194 (EUR 1 134, price year 2006) for the 
same period of time.
Savings from reduced offending and regained productivity
Reductions in offending behaviour, court appearance and regained productivity 
were greater in the heroin group in comparison with the methadone group. When 
valuated for the heroin group, the harm due to risk and offending had decreased by 
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EUR –3 424 (EUR 3 251, price year 2006) over the first 12 months in treatment. For 
the same period, the damage related to criminal behaviour and risk taking had risen 
by EUR 792 (EUR 752, price year 2006) in the methadone treatment group. Similarly, 
the savings related to custody and prison stays were significantly greater for the 
SIH group than for the methadone group (SIH: EUR –1 273 (EUR –1 209, price 
year 2006); MMT: EUR –870 (EUR –826, price year 2006)).
Also, during the study, a small increase in gainful employment was observed. This 
amounted, in the SIH treatment group, to EUR 172 (EUR 163, price year 2006) and 
in the methadone group to EUR 197 (EUR 187, price year 2006) per study participant 
per year.
In summary, SIH generated savings of about EUR 6 301 (EUR 5 985, price 
year 2006) per patient per year from improved health, reduced offending and 
regained productivity, while the costs of methadone treatment remained greater 
than its calculated savings (EUR –2 179 (EUR –2 069, price year 2006)).
Cost utility
This analysis showed that with additional medical costs, SIH could achieve a 
higher level of quality of life than that achieved with methadone treatment. It 
was less expensive to reach a QALY by SIH than it was by methadone treatment 
(SIH: EUR 163 140 (EUR 154 907, price year 2006) for each QALY; methadone: 
EUR 179 934 (EUR 170 853, price year 2006) for each QALY).
Only when consideration is made to the numbers of participants completing and 
terminating treatment and the additional costs associated with increased retention 
is methadone treatment clearly superior over heroin treatment. However, an 
examination of the costs generated by participants following their drop-out from 
treatment suggests that methadone treatment is less favourable in economic terms for 
this group of patients.
Conclusion
The reported cost per patient per year in an SIH maintenance programme was 
between EUR 12 700 and EUR 20 400. The lowest cost was reported by Switzerland 
at between EUR 12 700 and EUR 14 500, depending on the capacity of the 
outpatient treatment programme; EUR 19 000 was reported for Germany and 
EUR 20 400 for the Netherlands. SIH cost was substantially higher than the cost of 
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oral methadone maintenance treatment provision at EUR 1 600 (the Netherlands) 
and at EUR 3 500 (Germany). This was largely because of higher staffing 
requirements for SIH provision — at least two staff members must be present at all 
times and it is necessary to supervise all injecting of heroin medication at the clinic. 
Therefore, clinics had to be open daily, and for extended hours. In addition, all 
programmes had employed therapists, social workers and other staff members to 
help clients deal with drug-related health and social problems.
Studies consistently demonstrated a considerable economic benefit of SIH, 
particularly from the reduction in the cost of criminal procedures and imprisonment. 
Based on the results of the studies from Germany and the Netherlands, which directly 
compared the cost and cost utility of heroin and oral methadone maintenance 
treatment, methadone maintenance appeared to be the less costly programme to 
provide. However, when costs of crime are included, heroin maintenance appeared 
to be more cost-effective.
The Swiss study reported an annual socio-economic benefit of EUR 13 000 for each 
patient in heroin treatment, which was comparable to the finding of the Dutch group 
for a societal saving of EUR 15 000 per year for every patient maintained on heroin 
treatment. In the German cohort, SIH treatment generated savings of about EUR 
6 000 per year from improved health, reduced offending and regained productivity. 
The German and Dutch studies reported a significant improvement in the quality of 
life in the heroin-maintained patients.
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This chapter describes the different commercial pharmaceutical diacetylmorphine 
products that are currently available, as well as listing key features of each 
product, including the amount per ampoule or vial, whether it was with or without 
a reusable membrane and whether it was licensed or safety-tested for multi-dose 
use (see Table 5). It was felt that such a review of the products was necessary for 
unveiling differences in national approaches as well as differences in the degree of 
availability and access to pharmaceutical heroin.
Presently, three countries produce pharmaceutical heroin that is available to the 
supervised heroin maintenance clinics. The greatest availability of products is in the 
United Kingdom, where several medicinal diacetylmorphine products are licensed for 
pain relief and also used for the treatment of addiction:
(i) Auralis diamorphine hydrochloride BP, available in five strengths (5 mg, 10 mg, 
30 mg, 100 mg, 500 mg), with two of them typically used in addiction treatment: 
100 mg and 500 mg of lyophilisate (powder for solution for injection). 
The existing product is not licensed for addiction treatment. However, the company 
plans to submit a licence application with the UK Medicines and Healthcare 
Products Regulatory Agency (MHRA) in early 2012 for the 100-mg and 500-mg 
variants of diacetylmorphine hydrochloride injection BP. This product is expected 
to be branded with the trade name ‘Addimorph’, and the proposed indication is 
for addiction use. Auralis has also developed a 3-g multi-dose presentation in a 
vial that will be submitted to the MHRA for licensure in 2012. 
The shelf life of the product is 36 months. 
The final pack design for all strengths of Addimorph is being developed. However, 
the current container for both the 100-mg and 500-mg diacetylmorphine packs 
are 5-ml clear Ph. Eur. Class I glass ampoules containing either 100 mg or 
500 mg of diacetylmorphine hydrochloride BP lyophilisate each. 
The 100-mg and 500-mg variants (4) and the 3-g product has been tested and 
shown to meet the requirements for multi-dose use. 
The price of the products is dependent upon the current drug tariff price, and so it 
is subject to change.
(4) The licenses for Auralis diamorphine (100-mg and 500-mg variants) do not restrict the 
product to single use. If the product is not used immediately, it can be stored for up to 
24 hours, or longer if it has been reconstituted under aseptic conditions. This would 
allow for both multi-use and multi-dose handling.
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(ii) TEVA diacetylmorphine hydrochloride powder solution for injection is 
available in 2-ml clear glass vials (5 mg, 10 mg and 30 mg strengths) and 
5-ml clear glass vials (100 mg and 500 mg strengths). 
At present, the product is indicated for the relief of severe pain and holds no 
licence approval for addiction treatment. Tests of the sterility and chemical 
stability of the product indicate and recommend its use for up to 24 hours 
from opening after dilution and storage between 20 ºC and 25 ºC.
(iii) Wockhardt UK Ltd diacetylmorphine (5 mg, 10 mg, 30 mg, 100 mg and 
500 mg) — ampoules with freeze-dried diacetylmorphine for reconstitution 
and injection. The products are usually supplied in National Health Service 
(NHS) tenders, and therefore the price is highly variable.
The Netherlands and Switzerland also have their own medicinal diacetylmorphine 
products:
(iv) Diacetylmorphine hydrochloride monohydrate 10-g vials (Diaphin®), 
manufactured by DiaMo Narcotics GmbH, Switzerland (DiaMo), licensed 
and safety-tested for multi-dose use with approval in Denmark, Germany 
and Switzerland. The price differs between the countries because of different 
levels of distribution and other infrastructure and safety requirements set by 
different governments, as well as the variable extent of the level of service. 
In addition, DiaMo is also producing Diaphin tablets — Diaphin IR 200® 
immediate release (fast onset) and Diaphin SR 200® slow release, both 
containing 200 mg of diacetylmorphine hydrochloride — with marketing 
authorisation in Switzerland since December 2010.
(v) In the Netherlands, two products have been developed — diacetylmorphine 
hydrochloride for injection and diacetylmorphine base for inhalation. 
A private company (Diacetyl-M BV) holds the pharmaceutical market licences 
for both products, while being under strict contractual terms with the Ministry 
of Health in the Netherlands regarding production, distribution and price 
settings. 
There are no ampoules available owing to the low flexibility in dosing. 
Diacetylmorphine hydrochloride is available as a multi-dose vial containing 
3 g of lyophilised diacetylmorphine hydrochloride. The chemical stability and 
antimicrobial properties of the solution for injection allow a vial prepared 
for use in the morning (dissolving the lyophilised powder in water) to be 
used for 12 hours (Klous et al., 2004a; Blanken et al., 2010). Vials for heroin 
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hydrochloride have a membrane that can be repeatedly used within 12 hours 
from opening and after first use. In practice, local nurses use a spike (with a 
lid), enabling multiple doses to be extracted without continuously inserting a 
needle through the membrane. 
Diacetylmorphine base is available as a powder, containing a 3:1 mixture 
of diacetylmorphine base and caffeine anhydrate developed in four 
dosages: 75-, 100-, 150- and 200-mg sachets (Klous et al., 2004b; Blanken 
et al., 2010). 
There is no publicly available price for either of the Diacetyl-M BV products.
Table 5: Summary of currently available commercial pharmaceutical 
diacetylmorphine products used in addiction treatment
Company  
and country  
of origin 
Product Amount per  
ampoule/vial
Re-usable 
membrane
Licensed or  
safety-tested  
for multi-dose use
Auralis, UK Diamorphine 
hydrochloride powder 
for solution for injection
100 mg and 
500 mg
N/A Yes 
TEVA, UK Diamorphine 
hydrochloride  
(for injection)
2 ml clear glass 
vial (5 mg, 10 
mg  
and 30 mg 
strengths) 
5 ml clear glass 
vial (100 mg 
and 500 mg 
strengths)
Yes Yes
Wockhardt  
UK Ltd, UK
Diamorphine 
hydrochloride powder 
for solution for injection
30 mg, 100 mg, 
500 mg 
ampoules BP
N/A (single-use) No 
DiaMo, 
Switzerland
Diamorphine 
hydrochloride 
monohydrate (Diaphin®)
10 g vial Yes Yes
Diacetyl-M BV, 
Netherlands
Diamorphine 
hydrochloride  
solution for injection
Diamorphine base  
(for inhalation)
3 g multi-dose 
vial 
75 mg, 100 mg, 
150 mg, 200 
mg sachets
Yes
N/A
Yes
N/A
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In this chapter, we describe the implementation and delivery of supervised injectable 
heroin (SIH) treatment, based on initial analysis and synthesis with a key national 
stakeholder and other expert sources, and the operational policies and other relevant 
documentation and data sources.
At this phase, the research team switched from collation and analysis of original data 
source materials to national key informants (lead clinicians and/or researchers who have 
pioneered SIH trials and practice or others with a strategic overview of SIH treatment) and 
alternative data sources. The aims were: (i) to test the implementation, operational delivery 
and clinical practice of SIH as practised within European countries (Belgium, Denmark, 
Germany, Spain, the Netherlands, the United Kingdom and Switzerland) and Canada; and 
(ii) to identify aspects of implementation, organisational delivery and clinical practice which 
helped or presented challenges to delivering SIH. These other key sources included:
• recently published national/local SIH clinical guidance reports (e.g. injectable 
heroin (and injectable methadone), National Treatment Agency (NTA), 
2003; prescription of injectable diacetylmorphine (heroin) in case of opioid 
dependence, 2009);
• ‘grey literature’ sources; and
• the identification of wider sources by national key informants.
National key informants were accessed and asked to contribute to the report using 
the following format and guiding list of topics:
(a) Historical background:
i. National policy/drug strategy/legal framework for substitution treatment/
existing service provision.
ii. Drug and related health/social problems and rationale for SIH treatment.
(b) Description of implementation:
i. National policy/legislation concerning SIH treatment.
ii. Supply of diacetylmorphine.
iii. Government/local direction/involvement.
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(c) Description of operational delivery:
i. Types of clinic models, setting and capacity.
ii. Accessibility.
iii. Service provision and logistics.
iv. Cost.
v. Supply, storage, preparation and administration of diacetylmorphine.
vi. Laboratory methods to differentiate between pharmaceutical and ‘street’ 
heroin use.
(d) Description of clinical practice and operational issues:
i. Use of clinical guidelines.
ii. Inter-agency partnerships between SIH clinics and other health and social 
services.
iii. Social reintegration intervention.
iv. Admission and discharge criteria (particularly for disciplinary discharge).
v. Clients’ experience/perspective.
(e) What worked and challenges for the implementation of this treatment.
Switzerland
Historical background
National policy/drug strategy/legal framework for substitution treatment/existing 
service provision
Drug-free therapeutic communities were set up in 1970 in all regions of the country, 
mostly run by not-for-profit non-governmental organisations, some as commercial 
institutions and, only exceptionally, as public institutions. After the revision of 
National Narcotic Law in 1975, methadone maintenance treatment (MMT) was 
systematically introduced under the control of Cantonal Health Authorities (BetMG, 
1975, Article 15a). Consequently, an extended and diversified treatment system 
for heroin addicts was available in all cities where SIH started, with outpatient 
and inpatient detoxification services, long-term residential rehabilitation centres 
(therapeutic communities) and outpatient clinics providing psychosocial treatment 
and/or agonist maintenance treatment (mainly methadone, but also buprenorphine) 
(BAG, 1991). Maintenance treatment was also provided in private practice through 
family doctors (60 % of all methadone maintenance; Hosek, 2006). By 1994, when 
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the first SIH clinics were opened, the treatment system included 12 000 treatment 
slots for methadone maintenance and 1 250 places in residential rehabilitation.
The Federal Law on Narcotics in its revised version of 1975 allowed the use of 
narcotic drugs for scientific research and for limited medical use, with a special 
authorisation by the Federal Office of Public Health (BetMG, 1975, Article 8). The 
national cohort study with medical prescription of heroin, 1994–96, was based on a 
Federal Decree of 1991. After the positive evaluation of the study (Uchtenhagen et 
al., 1999), endorsed by a World Health Organization (WHO) international expert 
committee (Ali et al., 1999) and a randomised substudy (Perneger et al., 1998), 
federal decrees allowed the continuation of this practice (Bundesrat, 1999). Follow-up 
studies confirmed its feasibility and safety (Rehm et al., 2001) so that it could be 
adopted as regular treatment and prolonged by national parliament in 2003.
The introduction of SIH was made in accordance with United Nations (UN) 
conventions. The Single Convention of 1961 allowed the use of scheduled substances 
for scientific research, including clinical trials, if in line with national legislation, 
and the 1971 Convention on Psychotropic Drugs allowed the use of schedule I 
drugs for ‘scientific and very limited medical purposes’ (Article 7). The ratification 
of this convention in 1996 reserved the option to set up research on the medical 
prescription of diacetylmorphine in the treatment of heroin dependence. This was not 
changed when ratifying the 1988 Convention, by 1998.
Drug and related health/social problems and rationale for SIH treatment
The decision to set up a research project with the medical prescribing of heroin was 
part of a new national drug policy issued in 1991 by the Swiss federal government 
(Bundesrat, 1991) and included in the revised Federal Law on Narcotics by 2009 
(BetMG, 2010). This policy is based on prevention, treatment, harm reduction and 
law enforcement, and innovative approaches were encouraged in all four pillars. 
All innovations had to be documented and evaluated. Supervised heroin prescribing 
was one of the innovations in treatment.
The main reasons for this new policy were:
 — high and increasing prevalence rates of human immunodeficiency virus (HIV) 
among drug injectors (the highest rates in Europe);
 — high and increasing prevalence rates of heroin users (over fourfold increase 
within 10 years);
 — high and increasing rates of overdose mortality (fourfold increase within 10 years);
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 — open drug scenes in major cities, with intolerable consequences for the safety 
and public order;
 — incapacity of city administrations and cantonal authorities to cope with the 
problems; and
 — non-governmental organisation initiatives with harm-reduction approaches 
proved to be useful.
The specific rationale for SIH treatment was the growing number of patients in MMT 
who continued to inject illegal drugs, as well as the large number of injectors in the 
open drug scenes who were out of treatment. The public health aim was to reach out 
to these individuals, to cover as many injectors as possible and engage them in the 
treatment system (Uchtenhagen et al., 1999, 2010).
Description of implementation
National policy/legislation concerning SIH treatment
A revision of the Federal Narcotic Law was necessary to provide a definite legal 
basis for SIH provision. The revision passed parliament in 2008 and obtained an 
overall approving vote at a national referendum held a year later (BetMG, 2010, 
Chapter 1a). This allowed for SIH treatment to become a regular treatment option 
provided in authorised clinics only and with the permission of the Federal Office of 
Public Health (BetMG, 2010).
Procurement, supply and distribution of diacetylmorphine
The various preparations (ampoules and slow-release and immediate-release 
tablets) are produced in a specialised commercial production site in Switzerland 
under the auspices of the Federal Office of Public Health (DiaMo Narcotics GmbH, 
Switzerland). This site was part of the federal administration during the cohort study, 
and was then outsourced when SIH became a regular treatment modality.
Government/local direction/involvement
The national government has set out detailed regulations for the local implementation 
of clinics, especially for the safety of patients and for preventing medication diversion. 
Thus, federal decrees have provided the regulations for SIH treatment and these 
regulations are laid out in a comprehensive handbook on SIH treatment (BAG, 2000).
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Description of operational delivery
Types of clinic models, setting and capacity
There are 23 heroin clinics, two of which are in prisons.
Only four clinics are exclusively providing SIH treatment, and the rest are providing 
all forms of agonist maintenance treatment or a comprehensive programme for 
substance misuse treatment (Infodrog, 2010).
The overall capacity of the injectable heroin maintenance clinics is 1 454 treatment 
slots. This number is authorised by the Federal Office of Public Health. The capacity 
of the individual clinics varies between 15 slots and 210 slots (Infodrog, 2010).
If needed, patients from the injectable maintenance clinics can receive oral 
diacetylmorphine while in residential care during crisis situations, or in somatic 
hospitals while being hospitalised (with special authorisation, and under the 
responsibility of the prescribing doctor at the SIH clinic where the patient is enrolled 
(Infodrog, 2010).
Geographical coverage/accessibility
All but one of the supervised injectable maintenance clinics are located in the 
German-speaking region of the country. There is one clinic in the French-speaking 
region (Geneva) and none in the Italian-speaking region. No SIH clinic can be 
opened against the will of the competent cantonal authorities.
Clinic opening hours and number of clinics per day
The typical opening hours of the supervised injecting clinics guarantee adequate 
accessibility. All clinics have two or three blocks of opening hours, one in the 
morning, one in the afternoon and/or one in the early evening. The number of hours 
per block depends on the number of patients and varies from 2 to 4 hours. All clinics 
are opened on Saturdays and Sundays, some with reduced opening hours. In a few 
clinics, the daily consultations are made on appointment (Infodrog, 2010).
The capacity of the injectable maintenance clinics (n = 1 454) is greater than the 
number of patients involved (n = 1 356 by July 2011) and there are no waiting lists at 
any of the clinics. This is a strong indicator for a good coverage of those in need for 
this treatment approach.
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The overall coverage of the estimated number of heroin-dependent individuals with 
agonist maintenance therapies is 67 %; SIH alone provides 8 % of the maintenance 
therapies (Hosek, 2006). 
Service provision and logistics
The SIH maintenance clinics respect full safety conditions, particularly ones relating 
to the visually controlled intake of injectables and the logistical controls, in order to 
prevent any leakage of pharmaceutical heroin into the illicit market. These conditions 
are part of a comprehensive handbook on SIH, which can be consulted at all times 
by any staff member (especially junior/new staff), and which serves as a reference 
tool in the staff supervision process (BAG, 2000).
Visually supervised self-administration of the medication does not include the oral 
preparations that can be taken out for home consumption for a few days, under 
certain conditions, such as stabilised daily dosage, no polydrug use, and a stabilised 
social and health situation. A recent cohort study found this application to be safe 
and effective (Frick et al., 2006a, 2010).
Logistic controls include book-keeping of incoming amounts of pharmaceutical 
heroin, stored and daily dispensed individual dosages. Compliance with these 
regulations is ensured by Swissmedic staff via regular inspections. During the last 
years, no infraction of rules could be found during the control visits (BAG, 2009).
Storage, preparation and administration of diacetylmorphine
The procedures are centrally regulated by the Federal Office of Public Health and the 
Federal Office for Pharmaceutics Swissmedic.
Heroin clinics inform the production company on the quantities needed, which 
are sent by safety transport to the clinic and stored in special safes. Book-keeping 
records include delivered and stored amounts of heroin and the individual daily 
doses used.
Daily doses are individually determined by the doctor and prepared for 
administration. All doses are self-administered under supervision by a medic or a 
nurse (BAG, 2000). A missed dose leads to a reduction of the next dose in order to 
avoid over-sedation. The average daily dose per patient has varied in the last five 
years (533–467 mg) (BAG, 2009).
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The average time spent for supervising injecting is five minutes per patient. In 
addition, 20 more minutes are spent per patient per day. Psychosocial interventions 
are available to all patients, and sessions to provide these are scheduled individually.
Laboratory methods to differentiate between pharmaceutical and ‘street’ heroin use
In a few clinics, urines are analysed for 6-mono-acetylmorphine, which is considered 
to be a likely indicator of ‘street’ heroin use; in the majority of clinics, the funds for 
this analysis are not available.
Description of clinical practice and related issues
Use of clinical guidelines
The detailed guidelines are set up in the handbook for SIH treatment; it contains all 
regulations, recommendations and necessary additional information to guarantee 
good practice. The handbook was produced by experts under the guidance and 
responsibility of the Federal Office for Public Health (BAG, 2000).
The main responsibility for supervising daily practice is with the clinical directors. In 
addition, the Federal Office of Public Health and Swissmedic make regular controls 
of the practice, including site visits. A checklist is in use for these controls.
At entry, a comprehensive assessment of the health, social condition and needs of 
the individual is made by the respective professionals. The prescribing physician 
determines the dosages and the regime and all changes of those. Social support needs 
are dealt with by social workers, and individual and family counselling is provided by 
psychotherapists. Preparation and supervision of injections is the task of nurses.
Staff and staffing structure
Staffing structure and staff/patient ratios differ between the stand-alone supervised 
injectable maintenance clinics and integrated specialised substance abuse services, 
depending on the various target groups served and the range of services provided.
The stand-alone clinics typically have multi-disciplinary teams, including medical 
doctors, nurses, psychologists and social workers. A minimum of 0.7 % of a 
physician’s post and 0.7 % of a psychosocial professional’s post per patient is 
conditional for an SIH clinic. By the end of 2008, a total of 363 staff worked in the 
23 heroin clinics (BAG, 2009).
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The stand-alone clinics have organised themselves for continued training according 
to needs, for discussing upcoming problems and for administrative matters. There is 
an e-mail network of doctors working in the clinics, and an administrator responsible 
for all the clinics. Whenever needed, a regional or national workshop is organised 
for exchanging good practice and experience and for additional training.
In integrated services, training and support for SIH treatment-specific issues is part 
of an overall training and support scheme, mainly directed at staff working with 
maintenance patients.
The clinical teams have been stable over the years; the average staff turnover is 
about 17 % per year (BAG, 2009). This is about the same as for other medical staff 
at the front line.
Inter-agency partnerships between SIH treatment clinics and other health and 
social services
In line with the diverse functions and structural models, the supervised injectable 
maintenance clinics have also diversified links and partnerships with other services. 
The guiding principle is to respond to the wider needs of patients, including their 
health and social needs. The degree of providing, for example, somatic, psychiatric 
or social assistance varies considerably within the different clinics and is contingent 
upon the extent of partnerships with external services. The costs of some of the 
external services are covered by patients’ health insurance; others are free of charge.
Social reintegration intervention
All clinics have social workers with the aim of improving patients’ living conditions 
and, to the extent possible, resocialisation of patients. Networking with other 
services for housing, job opportunities, sheltered living and so on are part of their 
responsibility.
Operational costs
A survey carried out in 1995 on the costs of heroin clinics (stand-alone and 
integrated) per patient/day reported costs of between CHF 47 and 54 in larger and 
smaller clinics, respectively (Gutzwiller and Steffen, 2000). In 2008, the average 
costs per patient/day were CHF 57. The total cost for 1 300 SIH patients amounts to 
CHF 27 million per year; of which 80 % is paid by health insurance and the rest is 
covered by welfare (psychosocial care) and patients themselves (BAG, 2009).
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Admission and discharge criteria (particularly for disciplinary discharge)
The entry criteria to the supervised injectable maintenance clinics are a minimum age 
of 18 years, a minimum of two years of opiate dependence, a minimum of two past 
failed treatment episodes, deposition of driver licence while engaging in SIH and 
informed consent with regulations and rules (BAG, 2000).
Reasons for disciplinary discharge involve severe violence, carrying weapons, 
repeatedly bringing illegal drugs into the premises, taking injectables out from the 
premises and breaking into the premises. Exclusion is the most severe sanction; 
other sanctions are loss of privileged regimes, cautioning and temporarily replacing 
heroin with methadone. The competence for exclusion is with the chief physician. All 
patients and staff members are aware of the house rules and the consequences from 
non-compliance with those (BAG, 2000).
An overview of exits in the years 2005–09 showed 40–55 % transfers back to MMT, 
9–20 % transfers back to drug-free treatment, 5–15 % deaths, 2–10 % arrests and 
3–7 % involuntary discharges. Smaller proportions of patients were reported as 
hospitalised, moved away or exited for an unknown reason (Hiltebrand et al., 2010).
The criteria for moving to another treatment are mainly the patients’ preference; 
staff have the task of discussing with the patient the possible consequences of such 
a change and, if a decision is made, to help find the appropriate institution where 
treatment can be continued. HIV seropositivity and delinquency are found to increase 
the risk for dropping out of SIH treatment (Frick et al., 2008).
Approximately 50 % of patients stay in treatment for at least two years and around 
20 % for 15 years or longer. The average stay is three years. Only a small minority 
drops out without changing to another treatment (BAG, 2008).
Description of patient characteristics
The typical patient’s characteristics mirror the entry criteria, which are strictly followed 
and controlled centrally. In the course of years, the average age of patients has 
increased and is approximately 40 years (range 20–71 years). The average age at 
entry increased from 31 years in 1994 to 41 years in 2009 (Hiltebrand et al., 2010).
On average, 77 % of patients are male and 23 % are female. Over 80 % of new 
entries come on their own initiative, and approximately 8.5 % have a court order 
(Hiltebrand et al., 2010).
109
Chapter 6: Implementation and clinical practice of supervised injectable heroin treatment in Europe and beyond
The rate of HIV seropositivity at entry has shown a decline over the last five years, 
from 20 % to 11 %; the rate of hepatitis C seropositivity has fallen, from 77 % to 
63 %. The risk of seroconversion was also reduced during enrolment in the SIH 
treatment programme (Steffen et al., 1999).
During 2005–10, approximately 14–21 % of new entries had full-time or part-time 
employment, but only 11–15 % could live from their working income, while 24–27 % lived 
on disability or unemployment payments and over 50 % on welfare. Only a small minority 
lives on income from illegal activities (0–0.9 %) or prostitution (0–0.6 %) (BAC, 2011). After 
one year or longer in treatment, 42 % are integrated into the labour market (BAC, 2009).
Approximately 76 % of new entries have a stable living situation and 41.2 % are 
living alone (Hiltebrand et al., 2010); after a year in treatment, the respective rates 
are 96 % and 58 % (BAG, 2009).
Over 90 % had previously been in maintenance treatment, over 70 % had tried to 
detoxify and live drug-free and about half had tried outpatient care and residential 
treatment. On average, the duration of previous treatments was 73 months for 
agonist maintenance, 19 months for residential rehabilitation and 7 months for 
detoxification and aftercare (Hiltebrand et al., 2010).
More than half of SIH patients were dually diagnosed; the most frequent psychiatric 
conditions were personality disorders, behavioural disorders and/or affective 
disorders (Frei and Rehm, 2002). The rate of dual diagnosis has been relatively 
stable over the last years.
What works and what are the challenges for the implementation of SIH treatment 
in Switzerland?
SIH treatment is well accepted and has received a majority of votes in a number of 
local and national referenda. Only one of the major political parties is against SIH 
prescribing. Practical problems have mostly been resolved, the implementation no 
longer presents difficulties, and within the treatment system and the target population 
it is an accepted therapeutic modality.
Conclusion
All requirements to continue SIH treatment as a regular treatment under special 
conditions are in place: a definite legal basis, funding by health insurance and 
additional local sources, a well-established clinical practice and a monitoring system.
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The policy is to continue this therapeutic approach as one element in a 
comprehensive treatment system. Ten years after the introduction of SIH, the 
treatment system had developed from 11 000 to 18 000 treatment slots in MMT, 
and 1 300 in therapeutic communities. SIH had completed the system, increasing to 
the present capacity of 1 454, but it has not replaced any of the other therapeutic 
approaches. This continues to be the main strategy (Uchtenhagen, 2010).
A monitoring system and a quality assurance system document procedures 
any unintended events and effects, such as overdoses and seizures. The 
comprehensive handbook on heroin-assisted treatment, which provides all the 
rules, recommendations and basic information for a professional working style in 
the clinics, will be revised in the light of accumulated experience and of changes 
in the characteristics of heroin users. A working group is mandated to adapt the 
regulations and recommendations accordingly.
The safety conditions will not be changed; preventing a leakage into an illicit market 
is still a political priority. So far, according to police information, such leakage has 
not been detected. Also, SIH treatment will remain restricted for authorised outpatient 
clinics and prisons; it will not be allowed in private practice, in contrast to other 
agonist maintenance treatments.
The Netherlands
Historical background
National policy/drug strategy/legal framework for substitution treatment/existing 
service provision
Notable illicit heroin use began in the Netherlands in the autumn of 1972. At first, 
heroin use was largely limited to the native Dutch population and the route of 
administration was mainly through intravenous injection. A rapid upsurge in the 
number of heroin users was recorded around 1975 when Surinam, a former colony 
of the Netherlands, became independent. Young Surinamese men started to play a 
major role in the street trade of heroin, and many of them became users themselves. 
They adhered to their own way of administering the drug; that is, not injecting but 
inhaling. Since then, the estimated number of heroin users increased from 10 000 
in 1977 to 20 000 in 1979 and 30 000 between 1988 and 1996. The general 
picture was one of a relatively stable population of problematic heroin users with 
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a low incidence of new cases and a low mortality rate. However, the percentage 
of injectors among heroin users dropped from 60 % in the 1980s to 10–15 % in 
the late 1990s. Currently, the vast majority is using heroin mainly or exclusively by 
inhalation (‘chasing the dragon’).
Methadone maintenance treatment was introduced in 1968 in the Netherlands for 
the treatment of morphine-dependent patients. Following the introduction of heroin 
in the Netherlands in 1972, treatments with methadone were primarily directed 
towards achieving abstinence from heroin dependence. Generally, these methadone 
reduction programmes suffered from high drop-out rates, and there was a serious 
threat that they would lose contact with many of the addicts. As a response to the 
rapid increase in the number of problematic heroin users during the late 1970s, 
and the introduction of HIV/acquired immune deficiency syndrome (AIDS) in the 
mid-1980s, the aim of oral methadone prescription in the Netherlands shifted 
from achieving abstinence towards achieving stabilisation and reducing harm. At 
the time that the heroin trials started, most of the methadone programmes in the 
Netherlands were so called ‘low-threshold’ maintenance programmes, characterised 
by the absence of mandatory counselling, the absence of sanctions in case of drug 
positive urines and relatively low doses of methadone. According to the treatment 
staff at the MMT centres in 1990, 36 % of methadone patients were functioning 
well, 40 % were frequently using illegal drugs and were not socially integrated and 
24 % were extremely problematic, with daily use of various illegal substances and 
committing frequent criminal acts (Driessen FMHM, 1990). Taken together, these 
findings suggest that in 1995 (just before the start of the Dutch heroin trials), MMT 
was widely available in the Netherlands. At least 50 % of all problematic heroin 
users were enrolled in one of these programmes and, of these, about 40 % did very 
well. However, a substantial number of the patients failed to benefit from MMT (using 
illegal substances and often involved in criminal acts) and supervised injectable (and 
inhalable) heroin maintenance was thought to be a suitable and promising additional 
treatment option for these treatment-refractory patients.
By the late 1980s in the Netherlands, the stable and ageing population of problematic 
heroin users was served by a comprehensive treatment and healthcare system that 
provided services free of charge, including various kinds of abstinence-orientated 
treatment facilities (e.g. inpatient and outpatient detoxification, methadone reduction, 
residential treatment, therapeutic communities) and a wide range of facilities directed 
at stabilisation and harm reduction (e.g. methadone maintenance, needle and syringe 
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exchange, sheltered housing, user rooms). Depending on the local circumstances, 
65–85 % of problematic heroin users were in contact with the formal treatment 
system: 50–60 % in MMT and 15–25 % in abstinence-orientated treatment. All 
methadone maintenance programmes in the Netherlands had at least some medical, 
psychotherapeutic and psychosocial treatment offered to their patients, but the nature, 
intensity and structure of this treatment offer varied considerably. Medical prescription 
of heroin was seen as a final treatment option intended only for chronic heroin-
dependent patients who had repeatedly failed in other available treatments, including 
a state-of-the-art methadone maintenance programme (van den Brink et al., 1999).
Drug and related health/social problems and rationale for SIH treatment
In 1995, approximately 70 % of the heroin addicts in the Netherlands were in contact 
with the treatment system, including 15–20 % in drug-free treatment settings and 
50–60 % in one of the methadone maintenance programmes. Around 40 % of the 
patients in MMT did very well, but a substantial number of patients failed to benefit 
from this treatment (using illegal substances and often involved in criminal acts). In 
order to improve the situation of these patients, a number of small non-controlled 
experiments were conducted between 1983 and 1995, including experiments with 
intravenous morphine in 1983 (n = 37), intravenous methadone (n = 30) in 1990 
and oral dextromoramide (n = 53) in 1995. In 1994, the Swiss had started the 
medical prescription of SIH to treatment-resistant heroin-dependent patients. The 
first positive results from the Swiss heroin experiment (Uchtenhagen et al., 1996) led 
the Netherlands Minister of Health in 1996 to ask the Netherlands Health Council 
to formulate conditions for the prescription of heroin in the Netherlands. The Health 
Council advised the minister to conduct two randomised controlled trials (RCTs), 
one for treatment-refractory heroin-dependent patients injecting heroin and one for 
similar patients inhaling heroin. Both trials were in full agreement with the Dutch 
narcotic law, which at the time (1998) allowed the use of diacetylmorphine (heroin) 
for scientific purposes, but not for routine clinical practice.
Description of implementation
National policy/legislation concerning SIH treatment
The national drug policy of the Netherlands is an integrated mix of prevention, 
treatment, harm reduction and law enforcement. Within the treatment domain, both 
drug-free and harm-reduction approaches are actively supported at the national, 
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regional and local level. MMT is the core treatment for heroin addiction and is freely 
available for an indefinite period for all treatment-seeking heroin addicts. Since the 
registration of diacetylmorphine (heroin) as a medicinal product (Medicines Evaluation 
Board, 2006) and the change of the national narcotic law (Staatsblad, 2009), SIH is 
available free of charge for all treatment-resistant heroin-dependent patients.
After the positive evolution of the Dutch heroin trials in February 2002 (van den 
Brink et al., 2003) and the registration of diacetylmorphine as a medicinal product 
for the treatment of treatment-resistant heroin-dependent patients by the Netherlands 
Medicines Evaluation Board in December 2006, the national narcotic law was 
changed in July 2009 to allow the use of diacetylmorphine for both scientific research 
and regular medical treatments in specially authorised clinics (Blanken et al., 2010a).
Procurement, supply and distribution of diacetylmorphine
The different preparations (diacetylmorphine hydrochloride for injection and 
diacetylmorphine base/caffeine for inhalation) were developed in the Netherlands 
(Klous, 2004c; Rook, 2004; Blanken et al., 2010a). Both products are currently 
produced by a special firm that has a long-term agreement with the Netherlands 
Ministry of Health to supply pharmaceutical-grade heroin to all authorised SIH clinics 
in the Netherlands. The medication is delivered by armoured cars at the SIH clinics, 
where it is stored in a special safe from where it is distributed to individual patients 
during their visits to the clinic. Special drug accountability procedures and monthly 
controls by a pharmacist are required in order to prevent diversion. It should be noted 
that SIH in the Netherlands means the co-prescription of methadone plus heroin; a 
situation referred to by others as a heroin-augmented methadone treatment.
Government/local direction/involvement
The national government has an exclusive agreement with the producers of 
pharmaceutical-grade diacetylmorphine and has the exclusive right to appoint 
heroin clinics. According to the adapted narcotic law, heroin can be prescribed 
only in these specially appointed and authorised clinics. Moreover, these clinics 
have to comply with a series of minimum requirements in terms of staffing, training, 
architectural layout and the maximum number of patients that is allowed to be 
treated in that clinic. In addition, these clinics have to comply with the special 
direction of the National Health Inspectorate and with annual external audits. Finally, 
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all clinics have to submit an annual progress report on all individual patients to the 
National Health Inspectorate.
Description of operational delivery
Nature of the clinics, settings and capacity
Currently (July 2011), there are 17 heroin clinics in 15 cities in the Netherlands, 
treating a total of about 650 patients on any given day. Amsterdam and Rotterdam 
each host two clinics. The maximum number of treatment slots is set by the national 
government. The capacity of the individual clinics varies between 20 and 75 slots.
All clinics are part of addiction treatment services that provide a comprehensive 
programme for substance-use disorder treatment, including crisis intervention, 
abstinence-orientated interventions (residential and outpatient treatment) and harm-
reduction treatments (methadone, buprenorphine, needle exchange, user rooms, 
social services). In many instances, the heroin clinic is located at the same location or 
is very close to the other addiction and mental health services of the city.
Geographical coverage/accessibility
At least one clinic is present in all big cities (with a population of more 
than 300 000) and in most of the larger cities (with a population of more than 
100 000–300 000). Smaller cities are not yet served and it is not very likely that 
such clinics will be opened in the near future. No clinic can be opened against the 
will of the local authorities. SIH treatment is freely available for an indefinite time for 
all patients who meet the entry criteria and are willing to comply with the house rules 
of the treatment centre. In all centres, heroin can be either injected or inhaled, and 
heroin is generally prescribed in combination with a daily dose of oral methadone.
All clinics have three blocks of opening hours: one in the morning, one in the 
afternoon and one in the early evening. The number of hours per block depends on 
the number of patients and varies from 2 to 4 hours. All clinics are open 7 days a 
week, including all Saturdays and all Sundays. Currently, the capacity of the heroin 
clinics (n = 745) is slightly greater than the number of patients treated (n = 650 in 
July 2011). There are no waiting lists at any of the clinics. This is a strong indicator 
for a good coverage of those in need of this treatment approach. Currently, SIH 
serves approximately 5 % of all heroin-dependent patients in substitution treatment in 
the Netherlands.
115
Chapter 6: Implementation and clinical practice of supervised injectable heroin treatment in Europe and beyond
Service provision and logistics
Treatment conditions are described in detail in a comprehensive manual, which 
can be consulted by all staff at any time and serves as a reference tool for staff 
supervision. In addition, the clinics have to respect detailed safety conditions, 
especially the visually supervised intake of inhalable and injectable heroin, and 
the logistical controls in order to prevent any diversion to the illicit market. Logistic 
controls include detailed drug accountability, including book-keeping of incoming 
amounts and storage amounts and registration of daily dispensed dosages per 
patient. An annual progress report, including a standardised assessment of the 
physical and mental condition and social function of patients, has to be sent to 
and approved by the Netherlands Health Inspectorate in order to continue heroin 
treatment.
Storage, preparation and administration of diacetylmorphine
Almost all procedures relating to the production, distribution and storage of 
diacetylmorphine are centrally regulated by the Netherlands Health Inspectorate. SIH 
clinics inform the production company on the quantities needed, which are then sent by 
armoured cars to the clinic and stored in special safes. Book-keeping includes arrivals, 
stores and daily dosage for each patient. A pharmacist performs a monthly edit on the 
quality of the execution of the procedures and the actual amount of diacetylmorphine 
in stock. Compliance with the regulations is controlled by the Netherlands Health 
Inspectorate.
Daily doses are individually determined by the doctor and prepared for 
administration on site. Staff assist injecting patients if needed. Inhaling patients 
generally do not need assistance. Missed doses lead to a reduction of the next 
dose in order to avoid overdosing. There are no take-home doses and the use of 
alcohol, cannabis or other illicit drugs in the treatment unit is strictly forbidden.
The average time spent for supervised injecting is 5–10 minutes per patient. For 
safety reasons, injecting patients are required to stay in the treatment unit at 
least 15 minutes after they have taken the prescribed heroin. Additional special 
psychosocial interventions are scheduled individually. The average time spent for 
supervised inhaling is about 20–30 minutes and these patients are not required to 
stay in the treatment unit after they have taken their prescribed heroin.
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Laboratory methods to differentiate pharmaceutical from ‘street’ heroin
No attempts are made to verify self-reported use of ‘street’ heroin because it is 
assumed that patients in SIH can generally use as much diacetylmorphine as they 
wish (average dose about 500 mg/day with a maximum dose of 1 000 mg/day) 
and because urines positive for ‘street heroin’ would not be sanctioned and would 
not automatically result in expulsion from the treatment programme.
Description of clinical practice and related issues
Use of clinical guidelines
Detailed guidelines are available in the Manual for Heroin Treatment. This manual 
contains all regulations, recommendations and necessary additional information to 
guarantee good clinical practice. The handbook was produced by experts under the 
guidance and responsibility of the Central Committee for the Treatment of Heroin 
Addicts (CCBH, 2002). The main responsibility for supervising daily practice is with the 
clinic coordinator. In addition, the CCBH makes monthly visits to check the quality of the 
execution of the treatment and compliance to the guidelines. If needed, the Netherlands 
Health Inspectorate can do an official inspection. Finally, an annual external audit is 
performed by a contract research organisation following a fixed list of checks.
At entry, a comprehensive assessment of the treatment history, health, social 
condition and needs is made by the physician and nurse. The prescribing physician 
determines the doses and the regime and all changes of those. Counselling and 
social support needs are dealt with by the social worker. Preparation and supervision 
of injections are the tasks of nurses.
Staff and staffing structure
Staffing structure is similar in all SIH clinics, but staff/patient ratios differ depending on 
the size of the centre, that is the number of patients in treatment at the centre. All clinics 
have a multi-disciplinary team, including a physician, nurses and a social worker. In 
addition, all centres have their own security staff and a supervising pharmacist. Teams 
are quite stable, with an average staff turnover of 10–20 % per year.
Interagency partnerships between heroin clinics and other health and social services
All SIH clinics are part of an addiction treatment service with a comprehensive 
treatment offer for substance-use disorders and generally also for other mental 
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health and social problems. The guiding principle is to cover as much as possible all 
the health and social needs of the patients within the SIH clinic. However, if needed, 
patients can be referred within the addiction treatment service or to some external 
healthcare organisation or social services provider. Generally, these external services 
are covered by the health insurance of the patient or by the local government in 
cases of non-insured patients.
Social reintegration intervention
All SIH clinics have their own social worker who aims to improve the living conditions 
and, to the extent possible, the resocialisation of patients. Networking with other services 
for housing, job finding, sheltered living and so on are part of their responsibility.
Operational costs
Costs per patient per year are dependent on the size of the treatment unit, the 
housing costs in a specific city and the percentage of inhalers within the treatment 
group, as inhaling takes approximately 20–30 minutes whereas injecting heroin 
generally takes no more than 10 minutes.
The main costs were those of personnel, including a project coordinator (0.5 full-time 
equivalent (fte) for 25 patients, 0.75 fte for 50 patients and 1.0 fte for 75 patients), a 
physician (0.4 fte for 25 patients, 0.6 fte for 50 patients and 0.8 fte for 75 patients 
unit), nurses (7 fte for 25 patients, 9 fte for 50 patients and 10.5 fte for 75 patients), 
security personnel during opening hours (1.0 fte for 25 patients, 1.2 fte for 50 patients 
and 1.4 fte for 75 patients) and a pharmacist (0.1 fte independent of the size of the 
clinic). The second highest costs were general material expenses, including adaptations 
to existing buildings, depreciations, rent, cleaning, energy and maintenance (all 
dependent on the size of the treatment centre). Patient-related material costs were 
relatively modest and included the costs for pharmaceutical-grade heroin and other 
medical supplies. Depending on the number of patients per treatment unit, the costs for 
SIH treatment range between EUR 15 000 and EUR 27 000 per patient per year.
Admission and discharge criteria (particularly for disciplinary discharge)
The entry criteria are a minimum age of 25 years, a minimum duration of five years 
of opiate dependence, failure to benefit from adequately dosed MMT as indicated 
by (nearly) daily use of illicit heroin, and serious impairments in physical or mental 
health or social function (including lack of contacts outside the drug scene and 
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criminal involvement). In addition, participants have to agree with regulations and 
rules. Reasons for disciplinary discharge can be severe violence, carrying weapons, 
bringing illegal drugs into the premises repeatedly, stealing heroin from the premises 
and breaking into the premises. Permanent exclusion is the most severe sanction; 
other sanctions are tightening the regimen and temporary exclusion (replacing heroin 
with methadone). The competence for exclusion is a team decision, except when 
medical reasons prevail, in which case the physician decides. All patients and all 
staff know the house rules and the consequences of non-compliance.
Naturalistic long-term follow-up studies indicate that for most patients, SIH treatment 
is just a phase in their illness and treatment career, and with time many patients leave 
SIH treatment, as shown by the following retention rates: 1 year, 70 %; 2 years, 60 %; 
3 years, 46 %; 4 years, 39 %; and 6 years, 25 %. Most of the patients who leave SIH 
treatment within this period return to MMT, generally with a higher dose of methadone 
and in a much better condition (60–80 %), and relatively small proportions move to 
abstinence treatment (5–10 %), drop out of treatment altogether (10 %) or die (10 %) 
(Blanken et al., 2010b). The criteria for moving to another treatment are mainly patient 
preference or expulsion owing to repeated rule violation. Staff have the responsibility 
to inform the patient, to discuss the possible consequences of the various changes and 
— if a decision is made — to help find the appropriate service to continue treatment.
Description of patient characteristics
In a naturalistic study (2003–05; n = 345) examining the effectiveness of SIH treatment 
under routine clinical circumstances, the effects and the patient characteristics 
were very similar to those in the RCTs (Blanken et al., 2010a): 86 % male, mean 
age 41.6 years, 75 % with low education, 13 % homeless, 91 % unemployed, 8 % 
HIV positive, 34 % with a lifetime suicide attempt, duration of regular heroin use of 
19.8 years, duration of cocaine use of 13.0 years, and 26 days of heroin use and 
15 days of cocaine use in last month before heroin treatment. Of all patients in routine 
SIH, 22 % were injecting and 78 % were inhaling diacetylmorphine.
What works and what are the challenges for the implementation of SIH treatment 
in the Netherlands?
Although MMT has been an undisputed treatment for opioid addiction since 1968 in 
the Netherlands and harm-reduction programmes such as needle exchanges were 
implemented without much opposition, heroin treatment has been a highly debated 
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issue with highly polarised positions taken by the various national political parties. 
On the other hand, heroin treatment has been received with little political opposition 
at the local level, although neighbourhood representatives were rather sceptical at 
the beginning of the trials. Currently, there seems to be a national consensus that 
heroin treatment is a useful addition to the existing treatments for heroin addicts, 
and the programme is fully financed by the Ministry of Health together with the 
municipalities with one or more heroin clinics. The presence of an independent 
research organisation (CCBH), the ongoing care about possible public nuisance due 
to the presence of a heroin clinic in a certain neighbourhood, the publications of the 
results in prestigious scientific journals (e.g. BMJ, Addiction), the results of the cost-
effectiveness study and the approval of diacetylmorphine as a regular medicinal 
product for the treatment of chronic, treatment-resistant heroin addicts by the 
Netherlands Medicines Evaluation Board (MEB) have been instrumental in the current 
acceptance of SIH by almost all political parties, cities and neighbourhoods. With 
the exception of some practical problems, the implementation of heroin treatment 
no longer presents difficulties within or outside the treatment system. Currently, the 
most important issue is to preserve the high quality of heroin provision as a routine 
intervention. Regular internal and external audits are needed to check and — if 
needed — restore the formal requirements in terms of staff ratio and quality and in 
terms of adherence to the treatment guidelines.
Conclusion
All requirements to continue SIH as a routine medical treatment under special 
conditions are in place: a registered medication, a definite legal basis, funding by 
health insurance and additional local sources, a well-established clinical practice, 
and a monitoring and audit system. The plan is to continue this therapeutic approach 
as one useful element in a comprehensive treatment system. After 12 years of 
experience with SIH, MMT is still the main treatment modality for heroin-dependent 
patients, and abstinence-orientated treatments are still available for those patients 
choosing this treatment option (including some newly started Minnesota clinics). In 
general, the high-quality services of the SIH centres have resulted in new quality 
requirements and quality improvements in existing methadone and abstinence-
orientated treatment programmes. Twelve years after the introduction of SIH, it is 
recognised that SIH is not the final answer for all patients. Therefore, new treatments 
have to be developed for those who do not benefit from the currently available 
treatments. Consequently, an RCT with contingency management added to SIH has 
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been initiated in order to further reduce cocaine use in heroin-dependent patients in 
SIH and to improve their prognosis. In addition, a study has been initiated to treat 
SIH-refractory patients with a new type of neuromodulation: deep brain stimulation 
(e.g. Mantione et al., 2010). Other approaches being explored for those who do 
not seem to benefit from SIH include the support and improvement of existing social 
support systems and of user rooms.
Finally, explicit clinical guidelines for supervised injectable and inhalable heroin 
treatment, along with an ongoing interest in the needs of the patients, are mandatory 
in a treatment system that seeks to be of optimal service to the patients, their family 
and society as a whole.
Spain
Historical background
National policy/drug strategy/legal framework for substitution treatment/existing 
service provision/rationale for SIH treatment
The basic structure and organisation of addiction services in Spain is guided by the 
National Drug Strategy and the National Drug Plan. However, each autonomous 
community also develops its own drug plan. Addiction services are structured around 
different treatment phases, sequential and parallel — from harm reduction to social 
integration, including detoxification, oral substitution therapy and abstinence-orientated 
interventions, services and programmes. These services are provided by public and 
private (contracted) centres, and are free at the level of the individual patient.
Despite the broad array of services provided and the wide availability of MMT 
programmes, there was still an important subgroup of heroin users not reached 
by the healthcare system and, therefore, not benefiting from those services. In 
addition, as a consequence of the HIV epidemic in the 1980s, there was a high 
prevalence/incidence of HIV among opioid-using injecting drug users, despite the 
wide implementation of MMT and harm-reduction strategies (Rinken and Romero, 
2002). The success of the Swiss experience in the 1990s in the provision of medically 
prescribed injectable heroin under supervision showed that SIH treatment was a 
safe and feasible treatment alternative (Uchtenhagen et al., 1999). The critical HIV 
situation and the lack of alternatives for those not being reached by the addiction 
treatment system were the main factors that drove the introduction of SIH in Spain.
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Spain approves and ratifies the UN Single Conventions, and therefore heroin is 
considered a Schedule I drug. Following extensive negotiations with the federal 
authorities, an RCT was approved in 2002 that aimed to test the feasibility of the 
introduction of SIH prescribing in Spain, as well as its efficacy in the treatment of 
long-term opioid-dependent users (March et al., 2006). While it was intended that 
several provinces and autonomous communities would be recruited as trial sites, and 
would offer SIH under trial conditions, it was only possible to carry out the study at 
one clinic in Granada, Andalusia. At present, the use of heroin remains limited to 
research (clinical or other), and in restricted quantities upon authorisation from the 
Spanish Agency of Drugs and Health Products. Within this frame, supervised heroin 
prescription is allowed only as an investigational product and is not available as 
part of routine treatment. Currently, patients at the supervised injectable maintenance 
clinic in Granada are receiving SIH under compassionate use (5) (6).
Description of implementation
National policy/legislation concerning SIH treatment
Since 2009, the supervised injectable maintenance clinic in Granada prescribes 
heroin under a compassionate-use law. The involvement of the national government 
entails the provision of the necessary authorisations for the importation, storage 
and delivery of pharmaceutical heroin to the individual user in the clinic through 
the Spanish Agency of Drugs and Health Products. The Andalusian government is 
responsible for the ongoing management and the funding of the clinic through the 
Foundation for Social Integration and Assistance, which carries out the courses of 
action commissioned by the Equality and Social Welfare Ministry.
Procurement, supply and distribution of diacetylmorphine
The clinic uses pharmaceutical heroin imported from Macfarlane Smith (Edinburgh) 
as raw powder, with the vials prepared by a hospital pharmacy unit.
(5) Clinical trials are regulated by Article 23.1 Real Decreto 561/1993, revised by 
Capítulo V del Real Decreto 223/2004.
(6)  Compassionate use is intended to facilitate the availability to patients of new treatment 
options under development, which are not available or authorised in the country. See 
EMEA (2007), Evaluation of medicines for human use, European Medicines Agency, 
London. Online at: http://www.ema.europa.eu/docs/en_GB/document_library/
Regulatory_and_procedural_guideline/2009/10/WC500004075.pdf
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Description of operational delivery
Types of clinic models, setting and capacity
The SIH clinic in Granada City is situated in one of the biggest hospitals in the city 
and it is part of the addiction treatment services. The clinic targets long-term socially 
excluded opioid-dependent individuals with severe drug-related co-morbidities who 
are not benefiting from available addiction treatments.
Geographical coverage/accessibility
A total of 56 patients can be treated in this clinic (PEPSA, 2010); however, only 
17 are currently (July 2011) receiving SIH treatment. Following the end of the trial, 
the future of the clinic was uncertain and this posed a significant burden on both 
the staff and the patients, possibly accounting for the small number of individuals 
currently engaging in SIH. More importantly, however, the primary reason for the 
small number of patients receiving treatment is the declining number of injectors in 
the geographical coverage area. In 2008, a total of 1 646 patients were receiving 
MMT in the province of Granada, and at treatment entry, less than 5 % reported 
injecting heroin (alone or in combination with other drugs) as the most frequent route 
of administration in the prior month (data for all Andalusia) (Consejería para la 
Igualdad y Bienestar Social, 2008, 2009).
Clinic opening hours and number of clinics per day
Patients attend the clinic to receive their medication or other concomitant treatment 
prescribed, to follow-up on treatment with antiretrovirals, for nursing and medical 
doctor appointments, for support and consultation with other specialists, and for use 
of the treatment centres’ computers and recreational facilities, among others. Patients 
can visit the clinic for SIH consumption on weekdays (Monday–Friday) up to twice per 
day (morning session: 08.15–10.45; afternoon session: 15.15–17.15). At each visit, a 
minimum of 20 minutes is allocated for pre- and post-assessment for safety reasons.
Storage, preparation and administration of diacetylmorphine
The heroin is directly shipped to the hospital pharmacy, which shares premises 
with the SIH clinic. A pharmacist prepares the vials. The nurses from the SIH clinic 
then prepare patients’ individual syringes. All doses are self-administered under 
supervision. Pre-dose assessment determines whether the patient is fit to receive 
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the medication. Following injection, patients’ responses are assessed and they are 
discharged if no adverse reactions are present (Plaza et al., 2007).
Laboratory methods to differentiate between pharmaceutical and ‘street’ heroin use
During the study period, acetylcodeine was chosen as a marker for ‘street’ heroin 
use. However, this method returned too many false negatives and this practice was 
discontinued. Currently, no laboratory methods are used to detect ‘street’ heroin use.
Description of clinical practice and related issues
Use of clinical guidelines
Treatment is provided in accordance with a revised version of the clinical protocol 
developed for the purposes of the clinical trial. Monitoring of the clinical practice 
continues internally, including data collection on adverse events and other 
clinical outcomes and indicators. Guidance for good clinical practice is followed 
and practices are reviewed through conventional mechanisms, such as annual 
evaluations, regular visits to the clinics and routine reports.
Staff and staffing structure
The daily staffing in the supervised injectable maintenance clinic is as follows: three 
nurses, one physician, an administrative assistant and a security guard. Nurses 
are in charge of pre-dose assessment (e.g. whether the patient is fit to receive their 
injectable medication), support the compliance with and preparation of concomitant 
medications (e.g. antiretrovirals), injecting supervision and post-dose assessment 
(e.g. sedation). They provide primary care and health education on a variety of 
topics in consultation with the patient. Physicians, besides following the patients’ 
treatment regarding the prescription of the medication, provide integral healthcare 
in consultation with another specialist, if required. Physicians and nurses coordinate 
with other agencies to reach individuals who might be eligible for SIH treatment, 
organise activities to engage patients’ families and act as liaison with other addiction 
services. Nurses and physicians are trained in the prevention and treatment of drug 
dependency and drug-related problems. They participate in continued education 
and relevant workshops for specialist addictions professionals.
Following the end of the clinical trial, most of the healthcare workers were let go. 
However, since the compassionate-use programme began operating, the team has 
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been very stable. The programme has a total of six experienced nurses and two 
physicians, who have been working at the injectable clinic for a range of between 
4–7 and 2–5 years, respectively.
Admission and discharge criteria
The majority of the patients in treatment at the injectable maintenance clinic are 
former participants of the 2003 trial. The trial inclusion criteria were as follows: 
opioid dependence for two years or more, age of 18 years or older, resident in 
Granada in the previous year, currently injecting, two previous MMT attempts and 
presenting at least two of the following conditions — infectious diseases related 
to injecting drug use (e.g. HIV), mental health problems (e.g. depression) and 
psychosocial problems (e.g. illegal activities). In 2009, three new patients who were 
not part of the 2003 trial were admitted to the SIH clinic. The admission criteria are 
similar to the trial eligibility criteria; however, the previous MMT treatment criterion 
has been replaced by two previous addiction treatments.
The reasons for patients’ discontinuation of SIH treatment varied over time. Until the end 
of 2007, patient discontinuation guidelines followed the 2003 trial research protocol 
where those who failed to attend the clinic for five consecutive days (or 40 non-
consecutive days) were discharged from treatment and could not be re-admitted. Other 
discontinuations involved disciplinary discharge, following which most of the patients 
were re-admitted into MMT. The most recent regulations state that patients can be 
transferred back onto MMT at any time and return to the clinic in the event of a relapse.
What are the debates and challenges for the implementation of SIH treatment in Spain?
In 2005, 59.9 % of the Spanish population indicated that the supervised medical 
administration of heroin to solve the drug problem was ‘a very important measure’ 
(Reitox, 2006). Since 1997, three Spanish autonomous communities have made 
proposals to provide SIH treatment — Andalusia (March et al., 2006), Catalonia 
(Colom, 2005) and the Basque Country (Iraurgi et al., 2005) — but these have not 
been approved, and it appears that approval is being considered only in the frame 
of an RCT.
Conclusion
Of the three autonomous communities, Andalusia was the only one that could 
actually carry out an RCT and that is still providing SIH treatment to a small number 
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of patients. In this case, the drastic decline in the use of injection as a primary route 
of administration of illicit heroin played a significant role in the non-expansion  
of SIH treatment in that community, even before the RCT started, when three sites 
were reduced to one. After a long-lasting political debate between the central and 
autonomic government to gain approval for the RCT, the study could not recruit the 
initial planned sample as the number of ‘street’ heroin injectors was already declining. 
With a group of heroin-dependent individuals not benefiting from oral methadone, 
Andalusia is still in need of pharmacological alternatives for the treatment of  
opioid dependency. In response to this situation, the Andalusian research team 
developed a proposal to test two oral formulations: diacetylmorphine and morphine 
in comparison with oral methadone (March et al., 2007). The study is still obtaining 
all the regulatory approvals needed to provide a non-licensed medication. A key 
aspect of this proposal is to test the feasibility of providing oral heroin formulations 
following procedures similar to those established in oral methadone service provision 
(i.e. mostly through the primary healthcare system). In time, if oral SIH is proven 
effective and the delivery through the primary healthcare system is likely to be 
feasible, its incorporation into the addiction treatment system may be a possible 
alternative for opioid-dependent individuals currently not injecting and not benefiting 
sufficiently from other treatment approaches.
Germany
Historical background
National policy/drug strategy/legal framework for substitution treatment/existing 
service provision
The discussion on the introduction of SIH treatment as an alternative to maintenance 
treatment for opioid-dependent patients with other substances was initiated 
in 1992, when the federal state of Hamburg introduced a respective bill to change 
the Narcotics Act (Betäubungsmittelgesetz) in order to allow the prescription of 
medical diacetylmorphine. In 1993, the city of Frankfurt applied for permission at 
the Ministry of Health to carry out a controlled medical trial on the prescription 
of diacetylmorphine. Both initiatives did not have sufficient political backing, but 
intensified the discussion on the topic. In 1999, the results of diacetylmorphine 
prescription in Switzerland then led to a joint initiative between cities and federal 
states together with the Ministry of Health to start a clinical controlled trial on 
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diacetylmorphine prescription. The trial was initiated in 2001 and carried out in 
seven cities, and the results, which showed that diacetylmorphine prescription was 
more effective than methadone maintenance in the treatment of severely dependent 
opioid addicts, were presented in 2006.
In November 2007, the Bundesrat (upper house of the German federal parliament) 
tabled a bill on SIH treatment in the Bundestag (lower house of the German federal 
parliament) (BT Drucksache 16/7249) and another one on the same subject in March 
2009 (BT Drucksache 16/11515). The aim of both bills was to transfer SIH treatment 
into regular care. On 28 May 2009, the German Bundestag passed the ‘Act on 
Diacetylmorphine-assisted Substitution Therapy’, creating the legal preconditions for 
a transfer of the diacetylmorphine-assisted treatment into regular care by changing 
the Narcotics Act, the Medical Products Act and the Regulation on the Prescription 
of Narcotic Drugs. The act stipulates among others that diacetylmorphine 
(pharmaceutically produced heroin) becomes eligible to prescription — on very 
narrow criteria — as a narcotic drug used for severely dependent opioid addicts. 
The act was then presented to the Bundesrat and finally endorsed in a plenary 
session on 10 June 2009. The Act on Diacetylmorphine-assisted Treatment entered 
into force on 21 June 2009.
Drug and related health/social problems and rationale for SIH treatment
The decision to set up a clinical trial for the prescription of diacetylmorphine was 
based on a revised drug policy strategy by the German government in 1998, which 
introduced new harm-reduction measures. The rationale of the introduction of SIH 
treatment was based on epidemiological data showing that of the estimated 180 000 
opioid-dependent persons in Germany, 50 % at most can be found in some type 
of maintenance treatment, yet of these, approximately 10–20 % do not achieve 
remission from illicit drug use, and therefore can be considered non-responders. 
Furthermore, mortality statistics had shown a renewed increase in drug-related 
deaths in the late 1990s, reaching almost the same level as the peak in 1991 despite 
an increase in treatment slots for maintenance treatment, which had been introduced 
in Germany in 1991 to try to reduce drug-related mortality. The specific rationale 
for SIH treatment was the growing number of patients in maintenance treatment 
that continued to inject illegal drugs and the large number of injectors in open drug 
scenes that were not presently in treatment.
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Description of implementation
National policy/legislation concerning SIH treatment
In order to allow the prescription of diacetylmorphine within the framework of a 
clinical trial, an exceptional permission under the Narcotics Act was made. This 
permission allowed prescription within the clinical trial and continued treatment 
for patients who had completed the trial. A revision of the Narcotics Act became 
necessary in order for the treatment to be continued after the end of the trial. A bill 
for this revision passed the upper and lower houses of parliament in 2009, so that 
diacetylmorphine treatment is now regulated by the Narcotics Act.
Procurement, supply and distribution of diacetylmorphine
Diacetylmorphine is supplied in ampoules by the Swiss manufacturer DiaMo 
Narcotics GmbH, through a German subsidiary of the company.
Government/local direction/involvement
The authorities are not involved in the direct treatment, as all treating clinics are 
run by institutions involved in healthcare. However, local and some state authorities 
are involved in funding the treatment until other funding solutions are found. 
Furthermore, federal authorities have set up regulations for the implementation of 
treatment.
Description of operational delivery
Types of clinic models, setting and capacity
Presently, there are seven outpatient clinics in Germany where patients can receive 
diacetylmorphine treatment. They are the same seven clinics that were also involved 
in the trial. All clinics are outpatient, with either separate entrances only for 
patients receiving diacetylmorphine treatment or at least separate hours to avoid 
mingling of patients receiving diacetylmorphine maintenance with those receiving 
methadone maintenance. All clinics have both patients in diacetylmorphine and MMT 
(or buprenorphine treatment).
Clinic capacity varies from 12 to approximately 70 and depends mainly on financial 
resources controlled by the authorities. Presently (July 2011), there are around 
300 patients in diacetylmorphine treatment.
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Geographical coverage/accessibility
All seven clinics are located in a central part of their respective town and are easily 
accessible. Opening hours differ from one clinic to the next, but run from morning to 
evening, allowing for at least two injections daily, but in most clinics three. All clinics 
are open seven days a week.
Service provision and logistics
All clinics provide an injection room that is supervised by nursing staff, as stated 
by the respective regulations. Logistic controls include book-keeping of incoming 
amounts, storage amounts and daily dispensed doses per patient.
Storage, preparation and administration of diacetylmorphine
After delivery by the pharmaceutical company DiaMo Narcotics GmbH, 
diacetylmorphine is stored in a safe in the respective clinic. Diacetylmorphine 
ampoules contain diacetylmorphine in a powdered form. The ampoule is prepared 
with distilled water and the respective dose for a patient is then withdrawn from 
the ampoule. Ampoules are used not just for one patient, but for all consecutively 
treated patients in a clinic until the ampoule is empty. The syringe is then handed 
to the patient after identification and alcohol breathalyser test. The intravenous 
administration of diacetylmorphine is undertaken by the patient him- or herself.
Laboratory methods to differentiate between pharmaceutical and ‘street’ heroin use
As in the German heroin trial, urines are analysed for papaverine and acetylcodeine, 
which are considered to be probable indicators of ‘street’ heroin use. However, owing 
to limited financial resources, these urinalyses are not carried out on a regular basis.
Description of clinical practice and operational issues
Use of clinical guidelines
Presently, a treatment handbook, similar to the respective Swiss handbook, is being 
developed. Until completion of this handbook, physicians abide by the detailed 
regulations set out by the Narcotics Act, the guidelines set up by the Federal 
Physicians Board and, in some clinics, additional guidelines set up by the clinic.
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Inter-agency partnerships between SIH treatment clinics and other health and 
social services
Most clinics have diversified links and partnerships to other services. The guiding 
principle is to cover as much as possible of all the health and social needs of 
patients. The degree of assistance provision varies considerably. Partnerships with 
external services are conditional for all needs which cannot be covered internally. 
Some of these external services are covered by health insurance, others are free 
of charge.
Social reintegration intervention
All clinics have social workers caring for an improvement of living conditions and, 
to the extent possible, vocational reintegration. Networking with other services for 
housing, jobs and other services are part of their responsibility.
Operational costs
Presently, the costs of diacetylmorphine treatment have to be carried by local 
authorities, as discussions on including diacetylmorphine treatment as a provision by 
insurance companies are still under way. Quality insurance is financed by the federal 
government through an evaluation carried out by the Zentrum für Interdisziplinäre 
Suchtforschung (ZIS) in Hamburg.
Admission and discharge criteria (particularly for disciplinary discharge)
Admission criteria are stated in the Narcotics Act and are based on criteria used in 
the clinical trial. Patients have to be at least 23 years old, have been dependent on 
opioids for at least five years and be using illicit drugs mainly intravenously, have 
considerable somatic and mental problems, and have had at least two unsuccessful 
treatment attempts.
Discharge criteria are set up by each clinic and mainly cover the aspects of criminal 
activity within the premises of the clinic, and especially (attempted) diversion 
of diacetylmorphine from the clinic. The leading physician takes the decision of 
discharge. Patients can also terminate their diacetylmorphine treatment and move on 
to other treatment options.
130
New heroin-assisted treatment
What works and what are the challenges for the implementation of SIH treatment 
in Germany?
The positive results of the clinical trial were so unambiguous that the political 
support developed sufficient momentum to convince a federal government that 
was originally sceptical of this type of treatment. The main challenge for the future 
of diacetylmorphine treatment in Germany lies in the negotiations concerning the 
financial aspects covered by the insurance companies. Should the negotiations lead to 
a positive result and insurance companies are asked to cover most of the costs, then 
SIH treatment will have a future in Germany and will most probably be extended to 
other cities. Should the negotiations lead to a result where insurance companies cover 
only a proportion of its cost, then SIH treatment will remain a marginal treatment 
option or even possibly wither away as public spending will not be available. 
Therefore, negotiations on SIH treatment are presently in a key situation. 
Canada
Historical background
The idea of heroin treatment for opioid dependence is not new to Canada. Almost 
four decades ago, in 1972, the Canadian Government Commission of Inquiry 
into the Non-medical Use of Drugs chaired by Gerald Le Dain recommended in 
its report the ‘implementation of a heroin prescription trial for addicts who could 
not be attracted into conventional forms of opioid addiction treatment’ (Canadian 
Government, 1972).
Regrettably, no action was taken on this recommendation for several decades despite 
the fact that opioid dependence has remained a critical public health problem with 
an estimated 80 000 opioid users across Canada in 2006. Oral MMT remains to 
this day the most common and accepted treatment for opioid dependence, with 
approximately 26 % of the estimated opioid-user population in Canada enrolled in 
MMT in 2003 (Popova et al., 2006). While there has been a tenfold expansion of 
MMT in the last 15 years (College of Physicians and Surgeons in British Columbia, 
2005; Popova et al., 2006), a recent study of all MMT treatment episodes in 
British Columbia over roughly the same period showed only a 42 % retention rate 
at 12 months (Popova et al., 2006). Among the significant predictors of time to 
discontinuation of treatment were age, medical co-morbidities, physician-patient 
load, neighbourhood-level socio-economic status indicators, compliance and daily 
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dose. There continue to exist many barriers to both attracting and retaining patients 
in MMT programmes.
Given that oral substitution treatment was not benefitting a significant subpopulation 
of opioid users in the United States, and given the positive reports from Switzerland 
about heroin prescription in supervised clinics, a group of scientists and treatment 
experts from across the United States and Canada came together in 1998 to 
examine the potential for SIH treatment in the North American context. This group 
formed the North American Opiate Medication Initiative (NAOMI) and met regularly 
over the next 24 months to produce and refine a clinical trial protocol while 
exploring the legal, regulatory, financial and logistical implications of such a trial in 
the two host countries. During this period, it became increasingly apparent that no 
United States site would be able to participate, but the Canadian members continued 
to work on implementing a trial in Canada.
The context for the SIH treatment trial in Canada
One of the most significant challenges to conducting the NAOMI trial in Canada 
was that, unlike Europe, governments were not proponents of the trial in Canada; 
rather, the proposal was put forward by a group of independent scientists and 
treatment experts who, on their own, had to obtain all the necessary approvals 
from government agencies that may not necessarily have been supportive of such a 
controversial study.
The NAOMI trial was successful at obtaining a EUR 5.9 million (CAD 8.1 million) 
research grant from the Canadian Institutes of Health Research (CIHR), a non-
political peer-review research agency. Another EUR 1.8 million (CAD 2.5 million) 
was raised from other sources for expenses such as drug costs and renovations. The 
trial obtained ethics approvals from three host institutions. It also received approval 
from the Therapeutic Products Directorate of Health Canada, which regulates 
investigational treatments.
In Canada, heroin is controlled under Schedule I of the Controlled Drugs and 
Substances Act (1996), and is not a licensed medication. In order to provide SIH 
treatment, an exemption for importing, storing, prescribing, handling and receiving 
heroin is needed from the Office of Controlled Substances of Health Canada. This 
so-called ‘Section 56 exemption’ is granted ‘[…] if, in the opinion of the Minister, 
the exemption is necessary for a medical or scientific purpose or is otherwise in 
the public interest’ (Controlled Drugs and Substances Act, 1996). To obtain such an 
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exemption, the NAOMI team was required to make significant renovations to the 
study clinics, mostly pertaining to security equipment and procedures, in order to 
ensure that study heroin would not be diverted into the black market.
Prior to initiation, it became apparent that the clinic in Toronto would not be able to 
begin the trial for more than six months after the other two sites, and also there were 
concerns about recruitment at the Toronto site. For these reasons, it was decided to 
concentrate the trial in Vancouver and Montreal. 
The NAOMI trial
The NAOMI trail was a parallel, open-label, phase III RCT carried out in Vancouver 
and Montreal involving 251 participants, and was conducted between March 
2005 and July 2008. A total of 251 participants were randomised to receive oral 
methadone (n = 111) or injectable heroin (diacetylmorphine hydrochloride; DiaMo 
Narcotics GmbH, Switzerland) (n = 115). In addition, a small group of participants 
(n = 25) was randomised to receive injectable hydromorphone instead of heroin 
for the purpose of validation of self-reported illicit heroin use by urine testing. 
Administration of MMT versus injectable drugs was not blinded, but heroin and 
hydromorphone were administered in a double-blind fashion.
The injectable medications were self-administered under supervision in the treatment 
clinics (one in each city) up to three times daily with a maximum daily dose of 
1 000 mg for heroin and 333 mg for hydromorphone. Patients receiving injectable 
medications could at any time switch partially or totally to oral methadone if deemed 
appropriate. Methadone dosages and delivery were based on best practices and 
current clinical practice guidelines. All patients were offered a comprehensive range 
of psychosocial and primary care services, in keeping with Health Canada best 
practices. Study treatments were provided for 12 months followed by a three-month 
period during which participants still being treated with injectable drugs were 
transitioned to conventional therapies such as methadone. Heroin was not available 
to participants after this 15-month period.
The results of the NAOMI trial were very positive with respect to SIH treatment 
(Oviedo-Joekes et al., 2010a). The results regarding the small group of 25 people 
who received hydromorphone were surprising. At the end of the study, none of the 
participants in the hydromorphone group thought they were definitely receiving this 
drug. Retention rates with heroin and hydromorphone were virtually identical. So, 
too, were declines in the use of ‘street’ heroin. There were no differences in the safety 
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profile of the medications. The investigators concluded that hydromorphone may be 
as safe and effective as heroin and opioid-agonist substitution treatments, but larger 
studies are required to confirm this. This could have a significant impact in many 
settings where political considerations and stigma might deter the use of medically 
prescribed heroin.
Lack of SIH after the trial
In the latter half of the NAOMI trial, the investigators applied to Health Canada 
for ‘compassionate access’ to heroin beyond trial completion, but such access was 
denied. So was access to funding for the provision of hydromorphone at the clinics. 
Thus, from July 2008 to the present (July 2011), the two specially constructed clinics 
in Vancouver and Montreal have provided neither heroin nor hydromorphone-
assisted therapy to any clients.
What are the challenges for the implementation of SIH treatment in Canada?
Challenges to implementing SIH in Canada exist at both the federal and provincial 
levels. The federal government is responsible for both regulating drugs and 
for the criminal law. Any physician who wishes to prescribe heroin will require 
a Section 56 exemption to the Controlled Drugs and Substances Act from the 
Federal Minister of Health. Without this, a prescribing physician would be subject 
to criminal prosecution. While the federal ministry may be willing to exempt a 
scientific study that is limited both in numbers of participants and in duration, it is 
unlikely to approve SIH treatment as ongoing regular healthcare practice at present. 
The stigma associated with heroin probably plays a key role in making injectable 
hydromorphone an attractive alternative.
Within the Canadian health system, the political problem is both stigma and cost, 
with immense pressure to curb health spending. However, the recent evidence from 
trials, as summarised in this Insights publication, points clearly to heroin treatment 
being incrementally more cost-effective than the treatments that are currently being 
funded, at least for the severe populations studied. This paradox can be partly 
explained by the fact that government departments tend to operate in silos and the 
savings that occur with heroin treatment in criminal justice, policing, jail and court 
costs are not actually savings seen within the healthcare system, which is shouldering 
the additional costs. It is thus difficult for health ministers to take the wider societal 
perspective that is critical in cost-effectiveness evaluation and policy.
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United Kingdom
Historical background
National policy/drug strategy/legal framework for substitution treatment/existing 
service provision
It is estimated that there are around 300 000 problematic drug users (using heroin 
and cocaine) in England (Hay et al., 2010). Just over half (167 256) 
are opiate users in contact with drug treatment services in any one year (National 
Treatment Agency for Substance Misuse, 2010). The majority of those in treatment 
report opiate drugs (primarily heroin) as their main problem drug.
There are a wide range of services in the United Kingdom aimed at treating heroin 
use and related problems. Services in the United Kingdom are shaped by the 
government’s national drug strategy. However, service provision is uneven within the 
United Kingdom and the type of service or intervention offered reflects local funding 
and local philosophies. Drug services are provided by a wide range of providers 
including National Health Service (NHS) providers — general practitioners, specialist 
NHS drug services, hospital inpatient detoxification units and, increasingly, the 
voluntary and private sector such as street-based agencies, residential rehabilitation 
units, crisis intervention units and self-help groups, and private doctors.
Interventions include those providing substitute maintenance prescribing and those 
providing abstinence-based treatment such as residential treatment units and day 
centres providing structured psychosocial services. Efforts to reduce the problems 
associated with heroin use have largely centred on drug substitution treatment, most 
commonly the prescription of oral methadone and, more recently, buprenorphine. 
There has been a major expansion of opiate substitution treatment and there has 
been a fourfold increase in the number of patients in substitution treatment over the 
last 15 years. Methadone accounts for around 80 % of NHS opiate prescriptions 
for heroin dependence in England and Wales and buprenorphine accounting for 
around 16 % (Strang et al., 2007). Any doctor in the United Kingdom may prescribe 
methadone or buprenorphine for the purposes of treating addiction and there is no 
limitation on this treatment.
Uniquely in the United Kingdom, methadone ampoules can also be prescribed. 
Historically, they have at times been a substantial part of opiate substitution treatment 
in the United Kingdom (e.g. around 30 % in the 1970s and approximately 10 % in 
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the early 1990s), but they now account for approximately 2 % of all methadone 
prescriptions in England and Wales (Strang et al., 2007). Injectable heroin can 
also be prescribed in the United Kingdom to heroin addicts as an opiate treatment 
and has been a treatment option for over 80 years, and this has historically been 
important. However, over the last 30 years, this practice has become progressively 
rarer and now comprises less than 1 % of all opiate substitution treatment 
in the United Kingdom. The established method of heroin prescription in the 
United Kingdom has been as a ‘take-away’ supply, which is then injected in an 
unsupervised context. In practice, few doctors have prescribed it and few patients 
have received it (Metrebian et al., 2002).
The practice of prescribing injectable opiate substitution treatment for heroin 
dependence has been steadily diminishing in the United Kingdom, while the 
proportion of opiate prescriptions for methadone and buprenorphine have remained 
fairly stable. Prescriptions for methadone ampoules have significantly reduced 
from 9.3 % of all methadone prescriptions in England and Wales in 1995 (Strang 
et al., 1996) to 1.85 % of all methadone prescriptions in 2005 (Strang et al., 
2007). Moreover, prescriptions for heroin have gone down from 1.6 % of opiate 
prescriptions in 1995 (Strang et al., 1996) to 0.3 % in 2005 (Strang et al., 2007). 
The prescription of injectable opiates and particularly heroin has steadily decreased, 
firstly owing to an increase in the international confidence in the benefits of oral 
MMT (and more recently oral buprenorphine maintenance treatment), with an 
accompanying substantial scientific evidence base for these oral treatments (NICE 
Technology Appraisal TA 114, 2006; Mattick et al., 2008, 2009); secondly, there 
has been more awareness of the marked potential for abuse of prescribed injectable 
drugs and the potential for their diversion on to the illicit market (with increased 
risk of spread of abuse and addiction and the danger of overdose); thirdly, the 
lack of evidence for its effectiveness; and fourthly, more recently there has been 
more awareness of the greater cost of these injectable medications compared with 
oral formulations (Metrebian et al., 2002, 2007). Heroin is prescribed in England 
and Wales, with huge regional variations, with some regions prescribing to over 
100 patients whereas others prescribe to only one or two patients (Stimson and 
Metrebian, 2003).
In 2002, the United Kingdom government recognised the potential of heroin 
prescribing (the recent trials undertaken in Switzerland and the Netherlands had 
reported promising results) and in its Updated Drugs Strategy (Home Office, 2002) 
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called for heroin prescribing to be expanded and delivered under medical 
supervision to all those with a clinical need for it. In response, the NTA published 
a guidance report (National Treatment Agency for Substance Misuse, 2003) on 
the potential role of injectable heroin and methadone within treatment services. 
This guidance signified a considerable shift from the existing approaches to 
delivering injectable heroin and methadone maintenance in the United Kingdom 
by recommending that it should be a second-line treatment and that it should be 
considered only for those patients not responding to oral substitution treatment 
delivered under optimal conditions. Moreover, the guidance recommended that 
patients entering injectable maintenance programmes should have fully supervised 
dosing of their injectable opioids through the establishment of new clinics with the 
capacity for supervised injecting. Such supervision would allow the use of higher 
maintenance doses with safety and security.
In 2002, the House of Commons Home Affairs Select Committee recommended that 
there should be a thorough evaluation of heroin-prescribing treatment (House of 
Commons Home Affairs Committee, 2002). As a result, funds were made available 
for the establishment of new pilot supervised injecting clinics providing both 
injectable heroin and injectable methadone treatment under strict daily supervision.
Drug and related health/social problems and rationale for SIH treatment
Oral MMT is the most common drug treatment for opiate dependence and there 
is strong evidence for its effectiveness for most heroin users entering treatment 
(Mattick et al., 2009). Buprenorphine is the second most commonly prescribed opiate 
substitution treatment, comprising approximately 15 % of all opiate substitution 
treatment prescriptions in England, although less in Scotland and more in Northern 
Ireland (Strang et al., 2007). However, there is a significant minority of heroin 
addicts who appear unable to make much progress with oral methadone treatment 
and continue to inject ‘street’ heroin despite receiving conventional treatment. For 
these most severe and entrenched heroin addicts, it has been argued that treatment 
with pharmaceutical heroin (diacetylmorphine) may be a better solution. Heroin 
treatment has been a feature of the British response to illicit opiate use over the past 
80 years. However, unlike recent European developments, where treatment centres 
have been established to deliver supervised injectable opioid treatment (IOT), the 
British approach has provided heroin for unsupervised injections at home and had a 
limited capacity for the supervised dosing of injectables. There have been concerns 
regarding this practice, including concerns regarding the cost of heroin treatment, 
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the potential for the diversion of medications and the prolongation of drug use and 
injecting ‘careers’ of patients (Zador, 2001). In the light of the small number of British 
studies of heroin prescribing and the promising results from studies in other European 
countries examining heroin treatment delivered within supervised injecting clinics, 
the English randomised trial was established to specifically answer the research 
question of whether efforts should be made to optimise conventional treatment for 
such patients (e.g. encouraging high oral doses, supervised dosing, psychosocial 
interventions and regular attendance) in order to reduce regular illicit heroin use, or 
whether such patients should be treated with injected methadone or injected heroin 
in newly developed supervised injecting clinics.
Description of implementation
National policy/legislation concerning SIH treatment
The medical use of pharmaceutical heroin (diacetylmorphine) for palliative care and 
for the treatment of addiction has always been legal in the United Kingdom. In 1926, 
the Rolleston Report (Ministry of Health, 1926) established the right of doctors to treat 
heroin dependence by long-term or maintenance prescribing of opiates (including 
heroin). Later, in the late 1960s, the Dangerous Drug Act of 1967 restricted the 
prescribing of heroin in the treatment of addiction to those doctors licensed by the 
Home Office to do so. The doctors who obtained licences were mostly psychiatrists 
in charge of addiction treatment centres or clinics set up by the NHS. Doctors still 
require a special licence to prescribe heroin for addiction, but prescribing heroin for 
the treatment of other medical conditions has been unaffected.
Heroin prescribing for the treatment of addiction continues to be a legal option for 
the treatment of heroin problems. Some doctors continue to prescribe heroin for 
unsupervised consumption at home, but this is becoming progressively rarer.
The three supervised injecting RIOTT clinics continue to provide supervised injectable 
heroin (and injectable methadone) treatment as a second-line treatment to chronic 
opiate-dependent treatment-refractory patients outside of the trial.
Supply of diacetylmorphine
Up until mid-2008, specially imported supplies of pharmaceutical heroin from the 
Swiss pharmaceutical manufacturer DiaMo Narcotics GmbH were used in the clinics. 
The pharmaceutical heroin was presented as 10-g multi-dose vials (in comparison 
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with British diacetylmorphine in single-use ampoules), which were considered to 
be more appropriate for use in the supervised clinics and less expensive than the 
diacetylmorphine available from British pharmaceutical companies. In addition, 
the supply from DiaMo Narcotics GmbH was considered to be more reliable than 
the uncertain supply of British diacetylmorphine in 2005, following problems with 
pharmaceutical production.
However, following British concern about the potential for bacterial contamination 
of reconstituted diacetylmorphine when reconstituting diacetylmorphine under non-
aseptic conditions (although following manufacturers’ guidelines), and the desire to 
remove expensive import duty costs, the supply of diacetylmorphine was reviewed. 
The clinics now use the recently approved British Auralis diacetylmorphine single-
dose ampoules (available as 100 mg and 500 mg, freeze-dried).
Government/local direction/involvement
The clinics are funded centrally by the Department of Health. In the 2008 United 
Kingdom government’s drug strategy ‘Drugs: Protecting Families and Communities’ 
(HM Government, 2008), the government committed itself to supporting the 
treatments that were found to be most effective, including injectable heroin.
Description of operational delivery
Types of clinic models, setting and capacity
At present, there are three supervised injecting clinics in operation in the United 
Kingdom, with a total capacity of up to 100 (capacity for individual clinics: 24, 
30 and 40). The clinics were established within existing large NHS community 
drug services providing oral substitute maintenance treatment. Two of the clinics 
are physically located within existing drug service buildings and the smaller clinic 
(capacity 24) is situated a short distance from it, in its own building (shared with a 
community counselling service).
Accessibility
The three supervised injectable maintenance clinics were established in south London, 
Darlington and Brighton. The clinics are situated within larger specialist drug clinics 
providing treatment to between 320 and 800 patients. The clinic in south London is 
located in an inner-city area, with very high levels of deprivation, substance misuse 
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and mental health needs. It has a catchment area with a population of 747 400. The 
clinic in Darlington is located in a residential area in a historic market town with a 
population of 97 838. The clinic situated in the seaside city of Brighton and Hove has 
a population of 250 000 and is in an area with very high numbers of drug problems 
and fatal overdoses. The clinic is housed in a central residential area with a mix of 
privately owned homes, council housing and rented accommodation.
Each clinic is a dedicated service, open seven days per week; patients are able to 
attend the clinic for injections in the morning and/or afternoon. The clinics are open 
for two hours each morning and afternoon session — usually between 9–11 a.m. 
and 3–5 p.m. (Monday to Friday) and 9–11 a.m. and 2–4 p.m. (Saturday, Sunday 
and public holidays).
Description of clinical practice and related issues
Detailed guidelines drawn from those for the Dutch and Swiss clinics and originally 
developed for the RIOTT trial are used in the clinics in England. These guidelines 
also draw upon work previously published by the National Treatment Agency for 
Substance Misuse (2003). The NTA convened an expert advisory group to develop 
guidelines on the role of prescribing injectable heroin and injectable methadone, 
which were published in 2003 (National Treatment Agency for Substance Misuse, 
2003). The guidance identified this treatment as a second-line treatment to be 
considered for those patients not responding to oral substitution treatment delivered 
under optimal conditions.
The guidelines include eligibility criteria, screening assessment, dose titration and 
conversion from oral methadone to diacetylmorphine, procedures for supervising 
injecting, observation and monitoring pre- and post-injection, emergency procedures 
in case of overdose or anaphylactic shock, and pharmacy procedures including the 
storage, reconstitution and dispensing of heroin ampoules.
The clinics offer both injectable heroin and injectable methadone for self-injection 
under medical supervision. There are no take-home injections. Patients are able 
to receive oral methadone ‘take-home’ supplements and receive psychosocial 
interventions.
The clinics (with a capacity of 30–40 patients) are typically staffed by one consultant 
physician, one lead nurse (team leader) and four nursing staff with additional 
nurses (2.0 full-time equivalent (FTE)) for weekend cover and a pharmacist (0.5 FTE). 
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Each clinic shares reception staff with the larger general clinic. The smaller stand-
alone clinic in Brighton has no pharmacist and no reception staff. All nursing and 
medical staff receive training in cardiopulmonary resuscitation (including use of 
oxygen); preventing, recognising and treating intoxication and overdoses (including 
Naloxone); pre- and post-injection assessment; vein management and safer injecting; 
and first aid and treatment of anaphylaxis. The injecting room is supervised by at 
least two registered nurses (or medical staff) at all operating times, of whom at least 
one has received training in all identified procedures.
Doses are individualised with the aim of reducing illicit opiate use. Initial doses are 
converted from oral methadone to injectable heroin. Heroin doses are in the range 
of 300–500 mg per day. Patients have the option of also having supplementary 
prescribed oral methadone. Treatment with heroin typically involves two injections a 
day. Patients who are unable to attend for injectable opioid treatment (IOT) will have 
access to take-away doses of oral methadone according to contingency-based criteria.
To minimise the risk of adverse events due to the concomitant use of central nervous 
depressants (e.g. alcohol, benzodiazepines), patients are routinely assessed before 
and after dose administration. This may involve an instant drug-screen urine test 
(by means of a single-use, rapid, one-step test strip) or breath alcohol test using an 
alcometer. More extensive monitoring takes place when tolerance to the prescribed 
doses cannot be established.
The use of correct, safe and hygienic injecting practices is strictly monitored by the 
nursing team. Patients have the option to inject intravenously, intramuscularly and 
subcutaneously; however, the choice of route is subject to assessment by the nursing 
team and is guided by the condition of the client’s veins — deep vein injecting (e.g. 
groin) is prohibited. Although injecting in the femoral vein was originally permitted, 
this was reviewed following clinical concerns (Zador et al., 2008) and is no longer 
permitted in the RIOTT clinics.
Up to three clients are allowed in the injecting room at any one time. On average, 
the process of assessment, preparation and injection takes 10 minutes for each 
patient.
Patients are assigned a key worker, with weekly sessions during the initial three-
month period. Thereafter, the frequency of reviews may reduce to two weekly. All 
patients have reviews every three months with a physician and have access to other 
ancillary services (e.g. psychology, counselling) available at each site.
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Although clinical practice has been governed by the trial’s clinical protocols, not all clinical 
issues encountered by the staff were anticipated by these protocols, nor could they be 
given the unprecedented nature of this clinical service in the United Kingdom. Changes 
to clinical practice have been implemented as part of an ongoing process of service 
improvement guided by clinical/service review, clinical audit and review of untoward 
incidents. Such changes have been operationally led, not directed by policy and included, 
among others, the change from allowing groin injecting to excluding it after reflecting 
that it was impossible to have a safer groin-injecting practice (Zador et al., 2008), and 
moving from supervising four patients at one time to only three, owing to the change in 
diacetylmorphine preparation from multi-dose vials and pre-prepared syringes to single-
dose ampoules and the nurses having to prepare injections in the clinical room, and thus 
finding that they could safely supervise only a maximum of three patients at a time.
Supply, storage, preparation and administration of diacetylmorphine
There are locally agreed standard operating procedures for the supply, storage, 
preparation and administration of diacetylmorphine. Injectable diacetylmorphine 
stock is stored at the clinic pharmacy in a locked, controlled drugs cabinet, according 
to British controlled drug legal requirements and health trust regulations. All 
diacetylmorphine received and administered is recorded in a controlled drugs book.
Laboratory methods are used to differentiate pharmaceutical from ‘street’ heroin use
A special laboratory test, which can differentiate prescribed from illicit heroin in 
urine drug screens, has been developed and validated in the context of the trial, 
and thus provides the ability to establish whether the patient has been taking any 
supplementary ‘street’ heroin while in the injecting clinic. This laboratory test is able to 
identify ‘street’ heroin through its contaminants by looking for markers of metabolites 
such as papaverine and its derivatives, which are not present in pharmaceutical 
heroin. Both the method and the results from this new laboratory assay have been 
published (Paterson et al., 2005) and the laboratory test is applied in everyday 
clinical practice in the supervised injectable maintenance clinics.
Admission and discharge criteria
The supervised injecting clinics are reserved for treatment of the most difficult cases 
where ordinary first-line treatment has failed to deliver the expected benefits. Hence, 
it is typically the most severe and entrenched heroin addicts who are the patient 
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population of these clinics. The entry criteria include an age between 18 and 65 
years with a minimum 3-year history of injecting heroin use, regular injecting heroin 
use and no active significant medical or psychiatric condition, no severe alcohol 
dependence and not abusing benzodiazepines in an erratic manner — patients 
taking stable prescribed doses of benzodiazepines are not excluded.
The NTA expert working group estimated that SIH was probably applicable to the 
most severe 5 % of the heroin addict population.
Patients are regularly reviewed and, depending on their progress, will receive fewer 
restrictions or more intensive treatment with greater scrutiny.
Operational costs
The annual operating costs of the three clinics are EUR 1 683 088 (GBP 1 500 000) 
and individual costs fall into three main categories: buildings and corporate overheads 
at EUR 168 304 (GBP 150 000); staff costs at EUR 1 290 379 (GBP 1 150 000); and 
drug costs at EUR 224 405 (GBP 200 000). The cost per patient per annum is around 
EUR 16 830 (GBP 15 000).
Description of patient characteristics
The majority of patients attending the clinics are those who were eligible and 
successfully enrolled in the trial. Patients were heroin addicts with long histories of 
addiction and of previous treatments. The majority were male (73 %), white (96 %) and 
with a mean age of 37 years. They were most likely to be unemployed (95 %) — their 
main source of income was state benefit (96 %), with one-quarter (24 %) reporting 
family or partner as providing a main source of income. Nearly one-half of the patient 
sample lived alone (46 %) and one-quarter lived with a partner or spouse. Patients 
reported first using opiates at the age of 20 years and first injected at the age of 23 
years. They had used opiates for a mean of 17 years and had injected for a mean of 
14 years. Patients had first received drug treatment at the age of 27 years and had 
received treatment for a mean of 10 years. All had previously received oral methadone 
treatment and had a mean number of four previous opiate treatment episodes. At 
enrolment, all (100 %) were using ‘street’ heroin virtually daily (mean 28 days/month), 
nearly three-quarters (74 %) were using crack/cocaine (mean 10 days/month), over 
one-third (35 %) were using non-prescribed benzodiazepines (mean 7 days/month) and 
one-half were drinking alcohol 15 days per month. Nearly three-quarters (73 %) had 
previously been to prison, with a mean of six periods of past imprisonment.
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What works and what are the challenges for the implementation of SIH treatment 
in England?
The new supervised injectable maintenance clinics deliver a highly intensive, moderately 
expensive treatment. The supervised injecting clinics (all of which have contributed to the 
trial) have all been based on the design and approach of the German, Dutch, Swiss and 
Canadian clinics. While there is nothing new about prescribing heroin for the treatment 
of opiate addiction in the United Kingdom, the way heroin treatment is delivered — 
within these European-style supervised injecting clinics — is new and it is a radical 
departure from previous clinical practice in the United Kingdom. First, they are open 
365 days per year. Second, all injectable doses are supervised, so there is no potential 
for diversion or abuse. However, this makes the procedure more labour intensive for the 
clinic providing the treatment and more demanding on the patient. Patients must comply 
with the regular attendance schedule (typically, twice-daily injections of heroin).
In May 2011, the NTA and the Department of Health in England announced that, 
following the model demonstrated in the trial and the benefit observed for the identified 
extreme patient population, they would commence the process of establishing new 
supervised injectable opiate maintenance clinics.
At present, all three supervised injectable maintenance clinics in England are open 
for two sessions per day, every day. This appears to be acceptable to patients (with 
additional oral methadone), even with the long overnight interval between injecting 
sessions. However, it is possible that with more experience with this new type of 
treatment, it might be found that a more extended schedule of three opening sessions 
per day might be more effective (at the present time it is not possible to give an opinion 
on this, but this should be kept in mind as a possible means of achieving further 
improvement of benefit, especially as heroin is such a short-acting drug). 
Clinics in mainland Europe (Germany, the Netherlands and Switzerland) and Canada all 
use large-dose multi-use vials which are considered to be well suited to the supervised 
clinic situation, and which also reduce medication costs to less than half the British price. 
In the United Kingdom, the Swiss diacetylmorphine multi-dose vial has been used for 
much of the period of the RIOTT trial, and this has significantly reduced operating costs. 
While the clinics are now using British single-dose ampoules, it is hoped that it will be 
possible to establish a regular supply of multi-dose pharmaceutical heroin in the future.
The UK Government has given approval (January 2012) for cautious roll-out of Phase 
2 of such RIOTT-style clinics, specifically for the small number of individuals severely 
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affected by their chronic heroin addiction where all orthodox treatments have failed 
to have a significant impact: in the Department of Health’s own words, supervised 
injectable opiate treatment ‘is now evidenced as a clinically-effective second-line 
treatment for the small number of people who have repeatedly failed to respond to 
standard methadone treatment or residential rehabilitation’ (please see the Department 
of Health’s website: http://www.dh.gov.uk/health/2012/01/iotservice-provider-briefing 
(accessed in January 2012)).
Conclusion
SIH treatment clinics have been found to be feasible and effective in the United 
Kingdom. The next stage is to identify how best to expand this treatment to more opiate 
addicts with a clinical need for it and what models of service delivery might work best.
Denmark
Historical background
National policy/drug strategy/legal framework for substitution treatment/existing 
service provision/rationale for SIH treatment
In Denmark, substitution treatment of substance abusers is taken care of by the 
municipalities, and treatment with medically prescribed heroin is an integrated part 
of the overall treatment and care services for substance abusers in the individual 
municipality. Thus, there is continuity between the medical treatment and the 
interventions addressing the social problems of the individual substance user. Patients 
in SIH treatment are therefore encouraged to engage with local agencies offering help 
and support with life problems (e.g. housing), as well as with services dedicated to the 
psychological well-being and individual livelihood. At patient level, all medical and 
other treatment services are free of charge.
In 2007, there were approximately 6 500 patients in substitution treatment with 
methadone and about 1 000 with buprenorphine. Of the overall number of patients 
in long-term maintenance treatment, about 10 % were estimated to meet the criteria 
for SIH, with an actual target group set at 300 opioid-dependent individuals (National 
Board of Health, 2007).
As from May 2009, SIH has become available for a specially delimited target group of 
opioid-dependent individuals in Denmark (National Board of Health, 2010).
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Following the launch by the Danish government of a scheme for SIH provision as a 
second-line treatment for the most vulnerable heroin users who have failed to benefit 
sufficiently from long-term oral substitution treatments, a proposal was put forward by 
the Ministry of Health and Prevention for amendment of the Controlled Substances Act 
for SIH to become available for this select group of patients. Adoption of the proposal 
on 29 May 2008 and its coming into force on 1 July 2008 enabled SIH to be offered 
as a second-line treatment to opioid-dependent individuals in the country. Subsequently, 
the National Board of Health established rules around the prescription of and treatment 
with heroin (National Board of Health, 2009a).
According to current regulations, initiation of SIH may be undertaken only as part 
of treatment in services for opioid dependence that have a special permission from 
the Danish Medicines Agency, which has laid down rules with regard to safety 
measures, admission and accounts (National Board of Health, 2009b). Furthermore, 
the Medicines Agency has established a special guidance on ordering and storage of 
diacetylmorphine by the treatment institutions and on importation and delivery of this 
substance by companies (Medicines Agency, 2009).
Description of clinical practice and related issues
At present in Denmark, SIH treatment cannot be delivered in hospital settings or in 
institutions that are part of the prison service. SIH treatment is a specialised medical 
task that involves special requirements with regard to treatment and patient safety. 
These requirements are imposed by the complexity and the significantly greater risks 
in comparison with risk related to conventional oral substitution treatment, for which 
reason there are specific requirements as to professional competence and staffing.
The medical doctors who are allowed to prescribe heroin must be approved by the 
National Board of Health, and the doctor in charge of treatment must have experience 
of substance-misuse treatment. The doctor must be a specialist within a relevant medical 
field (e.g. general medicine, psychiatry, social medicine, internal medicine) and have 
documented clinical experience of substance-misuse (and co-morbidity) treatment.
The doctor in charge of treatment may use assistance from other healthcare 
professionals (e.g. nurses) who have knowledge and experience of substance-misuse 
treatment, including undertaking acute treatment of life-threatening conditions such as 
anaphylactic shock or overdose.
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Medically prescribed heroin may be taken only by self-administration and under 
supervision by the healthcare staff at the injecting clinics. Typically, patients attend 
the clinic twice per day, mornings and afternoons, and they are issued with oral 
methadone for the night. Doses of heroin are never given out for home use, and so the 
clinic is open to patients for 8–10 hours per day, each day of the year.
As a minimum requirement, the supervised injecting clinic is staffed at all times with one 
medical doctor and at least two authorised healthcare professionals.
Indications for SIH include:
• enduring intravenous misuse of prescribed or illegal opioids despite participation in 
long-term oral substitution treatment within the preceding 12 months;
• age of 18 years or over;
• no active or untreated severe psychiatric condition which would mean that the 
patient cannot participate in the injection treatment;
• no severe somatic disorder that contraindicates treatment;
• no significant alcohol abuse, that is the patient must be able to appear in person 
twice daily without symptoms of severe intoxication or withdrawal;
• no significant abuse of benzodiazepines. Patients in stable treatment with 
benzodiazepines are not excluded from injection treatment;
• no pregnancy, breastfeeding or current plans to become pregnant; and
• acceptance of the requirement to appear in person and undertake supervised self-
administration of injectable opioid treatment.
The medical doctor in charge of treatment submits electronic reports on a six-monthly 
basis to the National Board of Health. The reports cover patient treatment progress in 
three domains:
(i) continued substance misuse;
(ii) health (physical and psychological); and
(iii) social functioning (including criminal activity).
In 2008, the government and the political parties behind the parliamentary agreement 
on the ‘rate adjustment pool’ (Satspuljen) allocated to municipalities EUR 1 342 329.83 
(DKK 10 million) of the total 2008 budget towards preparation and implementation 
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of the SIH scheme (establishing the supervised injecting clinics, staff training) and the 
development of a coordinated monitoring system by the National Board of Health 
(National Board of Health, 2008). In 2009, the ‘rate adjustment pool’ included an 
agreement according to which EUR 8 322 035 (DKK 62 million) per year would be 
allocated yearly to a sustained funding stream for SIH provision in Denmark.
To date (July 2011), five clinics have been launched and SIH has been initiated in the 
municipalities of Copenhagen, Odense, Glostrup, Århus and Esbjerg.
The operating supervised injectable clinics are not seeing an overwhelming demand 
for their services. Since they became operational in April 2010, 120 patients have 
started SIH. It is estimated that by the end of 2012, the number of patients in SIH will 
reach 300 patients. The anticipation is that the clinic in Copenhagen Municipality 
will be looking after about 120 patients, and each of the remaining four clinics will 
see about 40 patients.
Belgium
(Translated and compiled from media publication and coverage)
Historical background
In Belgium, methadone substitution treatment was introduced in the late 1980s and 
buprenorphine was introduced in 2003. However, a royal decree on substitution 
treatment was adopted only in 2004. In the Dutch-speaking part of Belgium, most 
methadone maintenance programmes are provided by low-threshold drug services. 
In the French-speaking part of the country, general practitioners (GPs), outpatient 
specialist drug units and mental health facilities offer access to methadone, but 
GPs are the main providers. In 2007, 16 275 drug users were receiving substitute 
treatment, of whom 15 383 were receiving methadone.
Despite the presence of an extensive drug treatment and care network in Liège, 
a fraction of severely dependent heroin users is failing to benefit from treatment, 
experiencing negative health and social consequences. An application to introduce 
SIH and to develop an injectable maintenance clinic in Liège was relayed to the 
federal government. In 2007, initial governmental approval was given for SIH to be 
provided as a scientific experiment and granted the required funding.
The University of Liège is responsible for the scientific evaluation of the SIH treatment 
initiative. Since June 2007, a research protocol and a clinical project protocol have 
148
New heroin-assisted treatment
been developed, based on the research experience from the SIH RCTs conducted 
internationally. The SIH trial in Belgium has received ethical approval from the Liège 
University Ethics Committee and was begun in January 2011.
Description of clinical practice under the trial
SIH treatment in Liège takes place in a purpose-built secure ‘issuing clinic’. The 
treatment of each patient is supervised by a medical team, including an experienced 
psychiatrist, a GP and a team of nurses.
Medication doses are individually tailored by physicians at the supervised injectable 
maintenance clinic in consultation with the patient. Additional doses of oral 
methadone are available to patients on a daily basis.
At treatment entry, the medical team meet with the patient to explain the clinic 
rules and develop a weekly schedule for clinic attendance. Pharmaceutical heroin 
(obtained from the Netherlands) is available to patients for supervised self-
administration in an injectable or inhalable form.
A pharmacist prepares individual patient medication doses. Nurses give doses to the 
patients and provide pre- and post-dose assessment, supervision and monitoring, and 
assistance in case of medical emergency. They also liaise with external treatment and 
social care service providers and coordinate and follow-up the care of SIH patients.
Patients are free to withdraw from SIH at any time, and the medical team ensure best 
transition and care continuity within the Liège network of addiction services.
Aims of the SIH treatment pilot project in Liége
The pilot project seeks to add to the existing evidence base for SIH treatment by 
testing the efficacy of SIH treatment in comparison with optimised oral methadone 
(OOM), using an RCT design. This study also aims to evaluate the ideal conditions for 
implementation of this treatment in Belgium.
Number of patients and timescale for the pilot project
It is intended that the study will recruit 200 patients over a 12-month period. Following 
allocation, patients commence their randomised treatment as soon as possible to avoid 
early drop-out. Each patient is treated and followed up by an independent research 
team for 12 months after the start of treatment. Upon completion of the trial period, 
patients are to be directed by the medical team to another type of existing treatment.
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Selection criteria
Participating patients are entrenched heroin users (daily use for at least the last 5 years; 
injecting or inhaling), ≥ 20 years old and residents of Belgium (or with legal right to 
stay in the country) who have experienced failed treatment attempts in oral methadone 
maintenance (OMM) programmes.
Supervision of the project
Management and scientific monitoring and evaluation are entrusted to a research 
team at the University of Liège.
The clinical protocol has been developed with input from foreign experts in the 
field, and approved by the medical authorities in the country (Committee on Ethics, 
Commission Medicale Provinciale, College of Physicians).
In summary of the current clinical practice and service provision of SIH in Europe 
and Canada, Table 6 gives the prominent characteristics that describe this treatment:
Table 6: Key features of SIH clinical practice and service provision in Europe and 
Canada
Country Number 
of 
clinics
Total 
capacity 
(range)
Numbers in 
treatment  
(as of July 2011)
Catchment  
area
Number of 
block opening 
hours
SIH is part of 
routine clinical 
practice
Switzerland 23 1 454
(15–210)
1 356 German-speaking 
part 
(22 clinics)
and Geneva  
(1 clinic)
2–3 Yes
Netherlands 17 745 
(20–75)
650 (1) Country-wide 3 Yes
Spain 1 56 17 Granada city 2
(weekdays only)
No (2)
Germany 7 300 
(12–70)
300 Seven towns 
across Germany
2–3 Yes
Canada 2 140–180 0 Vancouver and 
Montreal
N/A No (2)
England 3 100
(24–40)
100 South-east 
London, Brighton 
and Darlington
2 Yes
Denmark 5 300 
(40–120)
120 Municipalities 
of Copenhagen, 
Odense, Glostrup, 
Århus and Esbjerg
2 Yes
(1) 590 inhaling and 60 injecting.
(2) SIH treatment is available under compassionate use.
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The aim of provision of supervised injectable heroin treatment (SIH) is often misunderstood 
and the method of provision of the treatment is also frequently described in a confusing 
manner. One of the important objectives of this Insights publication is to provide a clear 
account of the aims, the delivery of the treatment and the research findings.
Let us first consider the context for and history of the development of this new 
and controversial treatment, and then remind ourselves of the aims of treatment, 
after which we should identify the key consistent research findings, consider the 
implications for the evolution of policy and practice, and reflect on what the next 
steps could or should be.
Context and history
Supervised heroin treatment was developed and initially introduced in Switzerland 
during the 1990s, and subsequently in other European countries and beyond, as 
summarised in this publication. The approach was an adaptation of the previous heroin 
treatment which had been prescribed in the treatment of addiction, most notably in 
the United Kingdom (and hence was often referred to as the ‘British system’). However, 
the significance of the adaptation that was made for the Swiss clinics should not be 
underestimated — indeed, it could reasonably be argued that this was not merely the 
next incremental adaptation but was in fact a step change. In this Insights publication, 
we have concentrated on examining the research evidence and the clinical and policy 
experience with this new adaptation — supervised injectable heroin treatment.
At first glance, the notion of prescribing diacetylmorphine (pharmaceutical heroin) 
as a treatment of heroin addiction seems counterintuitive, or at least confusing. How 
can the drug of addiction itself be the treatment? However, across many areas of 
the addiction field, we encounter instances where there may be ways in which some 
degree of provision of the drug of addiction (or a closely related other agonist) may 
enable people to break with some particularly damaging aspect of their addictive 
behaviour, and thereby make significant progress in recovery. Examples include 
the provision of oral opiate substitution treatments (such as oral methadone and 
sublingual buprenorphine in many countries of the world, and also slow-release oral 
morphine in Austria, for example), where the provision of the substitution treatment 
enables significant other changes in behaviour and health to occur. Similarly, with 
tobacco smoking, the development and provision of a range of nicotine replacement 
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therapies (gum, tablet and nasal spray) has brought a pharmacological adjunct 
which leads to better rates of successful quitting of the harmful smoking behaviour. 
It is because our concern is not only about the physiological or psychological 
dependence, but is also importantly about the associated health and societal 
consequences of the heroin use. Thus, it is the reduction of risk of heart disease or 
stroke or of lung cancer, etc. in the former cigarette smoker which constitutes an 
important health gain, even while the replacement nicotine supply is maintained. 
And similarly with the injecting heroin user, it is the quitting of involvement with use 
of ‘street’ heroin, disengagement from criminal activities and improvements in health 
and social well-being which are some of the important gains sought.
Since the original introduction of SIH treatment in the mid-1990s in Switzerland, 
this clinical approach has been tested as new clinical practice, sometimes in the 
context of a randomised clinical trial, in more than half a dozen countries across 
Europe, plus Canada. The research findings from the structured randomised trials are 
described above, and we also present summaries of the important related clinical 
and policy experiences in these countries. The purpose is to inform the public debate 
and to make available a better understanding of the research, clinical and policy 
experiences to date so that future policymakers and practitioners can be best guided 
in their decisions.
Many of the data reported here are already available in other forms (such as 
the original research reports from the individual trials). However, the particular 
advantage of this Insights publication is that these findings are brought together in 
a single analysis, and are also accompanied by the clinical and policy perspectives 
from the relevant countries in which the treatment has recently been provided.
Besides the results of a meta-analysis of the main studies done on SIH treatment, the 
outcome of a Cochrane Review on this topic also has been included in this publication. 
A special section helpfully describes the Cochrane review process. Cochrane Reviews 
are held in high regard in the scientific community, and are primarily concerned with 
analyses of findings from robustly designed randomised trials which meet the stringent 
criteria of the Cochrane review process. On the negative side, these reviews have to be, 
by definition, very selective with respect to studies included owing to methodological 
shortcomings frequently found in them. Reading results from both our wider review and 
the Cochrane Review in parallel allows us to combine the strengths of both approaches.
Since the publication of the results from the first randomised trial of SIH in 
Switzerland (Perneger et al., 1998), there have now been five further randomised 
160
New heroin-assisted treatment
trials of SIH treatment, each of which has been in a different country (Germany, 
Spain, Netherlands, United Kingdom, Canada) and each of which generally builds 
on the growing scientific evidence base achieved by the previous work. To quote 
Isaac Newton (who was himself referring to Greek mythology and the blind giant 
Orion and his servant Cedalion), it is by standing on the shoulders of giants that 
each research group has been able to move forward. They have conducted an 
evolving series of studies, each building on the previous, and each adding a new 
aspect to our overall understanding. In contrast, the clinical practice has remained 
remarkably consistent and has, by and large, been replicated from one country 
to the next so that the series of trials (and the collective clinical experience) can 
reasonably be considered together.
Other approaches have also been investigated, such as the smokable heroin studied 
as parallel investigation in the trial in the Netherlands (van den Brink et al., 2003), 
the injectable hydromorphone studied in the Canadian North American Opiate 
Medication Initiative (NAOMI) trial (Oviedo-Joekes et al., 2009) and the injectable 
methadone studied in the UK Randomised Injecting Opoid Treatment Trial (Strang et 
al., 2010). However, even though these variations may legitimately warrant attention 
and possible further study, it is with the application of SIH treatment that we find the 
largest amounts of evidence from well-designed trials and with which we can look for 
generalisable robust conclusions. Furthermore, it is reassuring that, in this exercise, 
many of these publications have been judged to be of sufficiently high quality in 
the peer-review process and that they have appeared in high-impact high-quality 
scientific journals, such as the BMJ, New England Journal of Medicine and the Lancet.
Aims and objectives
If heroin itself is being prescribed, then what is the objective of the treatment? 
In fact, the answer to this question is remarkably similar to the answer for other 
medication-based treatments — it is the quitting of use of ‘street’ heroin, alongside 
other improvements in physical and psychological well-being, as well as the 
disengagement from any criminal activity and broader social integration. These 
might be considered the aims of most addiction treatments, and they are generally 
the aim of SIH treatment also.
So why do we need to utilise such a potentially controversial treatment approach, 
if other treatments already exist and are approved, and have the same therapeutic 
objectives? The answer is that there remains a substantial minority of patients who 
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fail to benefit from these treatments and for whom we may need to consider more 
intensive and alternative forms of treatment. For those patients who repeatedly fail 
with existing orthodox treatments, are they just ‘untreatable’ or might we be able to 
devise alternative and/or more intensive treatments which enable them to achieve 
the gains that have, thus far, been unattainable? Hence, this treatment is typically 
reserved as a second-line treatment (or third-line, etc., depending on the schematic), 
reserved as an expensive intensive treatment which might be considered for a patient 
population which otherwise appears unresponsive to conventional treatment. Thus, 
the typical patient population considered for SIH will be those with a long-standing 
history of injectable heroin use and an entrenched addiction, with major physical 
and social complications and who are treatment refractory. In many instances, these 
patients may have been considered as ‘heartsink patients’ and will often have had 
previous extensive involvement with the criminal justice system and prison, as well as 
diverse treatment and rehabilitation agencies.
The findings from these trials of SIH contribute much to the improvement of our 
understanding of effective treatments for opiate dependence — in particular, what 
can be achieved with a severely affected treatment population for whom previous 
treatments had appeared consistently unable to deliver benefit.
Research findings
A consistent finding from this series of randomised trials is of the substantial 
improvement in health and well-being of the patients receiving SIH compared 
with those provided with oral methadone treatment. This improvement includes, in 
particular, a major reduction in the extent of continued injecting of ‘street’ heroin, 
improvements in general health, psychological well-being and social functioning, as 
well as major disengagement from criminal activities (such as acquisitive crime to 
fund continued use of ‘street’ heroin and other street drugs).
Good retention rates are generally seen with SIH. However, evidence of good 
retention in treatment can only be a benefit if there is a strong relationship between 
retention and the health and social benefit sought. Better retention rates in the 
supervised heroin treatment compared with oral methadone were not observed 
across all trials, although the SIH itself achieves good retention for the different 
randomised trial periods that were studied (ranging from 6 to 12 months).
While mortality is lower for persons in SIH treatment than for those in oral 
methadone treatment, the risk of adverse events — including death directly related 
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to medication — are higher. Even if the absolute numbers are small, this means that 
precautions have to be taken through adequate staff and equipment in the treatment 
centre. The substance also requires more efforts on the side of security. This explains 
to a large extent why treatment costs for heroin treatment are well above methadone 
even in routine application: EUR 12 700–20 400 per patient per year compared 
with EUR 1 600–3 500. However, if an analysis of cost utility takes into account 
all relevant parameters, especially related to criminal behaviour, SIH saves money. 
Figures from the United Kingdom debate, of EUR 18 300 per year for SIH treatment 
still compare positively with EUR 50 400 per year for imprisonment (approximate 
data obtained from different analyses, presented merely to illustrate).
Implications for policy and practice
While SIH has developed to become a useful addition to our treatment ‘toolbox’ 
for opiate addicts, it seems unlikely to become the solution for the heroin problem. 
The objective to provide a second-line intervention for hard-to-reach and highly 
problematic heroin users is reflected by the small number of persons in such 
treatment. In 2011 all across Europe, only 2 500 clients were enrolled in SIH 
treatment — approximately 0.5 % of all those enrolled in substitution treatments in 
Europe. In those countries where application is already well established, these figures 
were stable at between 5 % and 8 %.
Let us also examine the clinical practice as it is actually delivered. There is strong 
consistency between countries regarding the delivery and clinical practice of 
SIH treatment. The treatment is strongly structured, with the patient having to attend for 
all injected doses, which are taken under direct medical supervision within the clinic. 
The treatment is also embedded within the provision of wider psychosocial support and 
rehabilitation, with attention to family reunion, criminal charges and debt, etc., as well 
as to outstanding health and psychological disorders. In conversation with patients in 
this treatment, the provision of the prescribed heroin is seen as one component part — 
perhaps an important part, but just one part nevertheless — and the wider therapeutic 
engagement and rehabilitative effort is considered to be of equal importance.
Clinical precautions remain vital, however, since occasional life-threatening adverse 
events are seen, often unexpectedly. While these events are rare, they are enormously 
important given their severity. These include, in particular, instances of overdose, often 
for reasons which are not immediately apparent and in a number of cases are very 
hard to predict even with a carefully applied standard practice of testing. If we consider 
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these events to be unpredictable (or at least difficult to predict), and if they occur in 
the region of one in every 6 000 injections, then it is important for clinical teams to be 
appropriately trained and resourced to deal with such occasional emergencies and for 
clinical protocols, training and facilities to be established in advance.
The high costs of the provision of this intensive treatment, especially alongside the 
potentially controversial status of the medication being prescribed (pharmaceutical 
diacetylmorphine), may be a potentially major limiting factor. The extent to which 
these factors are obstacles will vary according to the audience considering them 
and the national and international context. However, it must be remembered that 
diacetylmorphine is a medicinal product prepared by the pharmaceutical industry in 
accordance with all of the usual quality and safety controls. Also, the costs have to be 
compared with the gains and, notwithstanding the greater cost of SIH treatment, the 
cheaper oral opiate substitution treatments can never be cost-effective for this selected 
group of heroin addicts if they do not derive the expected benefits from these treatments, 
as clearly articulated by many observers, including Archie Cochrane himself (1972).
Different pharmaceutical companies are now involved with the production of 
pharmaceutical diacetylmorphine in Europe, and an overview of the situation is 
presented in this book. For more than a century, there has been a pharmaceutical 
industry producing diacetylmorphine, from the late nineteenth century onwards 
(synthesised in 1874 and brought to market by Bayer in 1898). However, until the 
1970s there was not a great deal of interest in the production (with pharmaceutical 
supply continuing in the United Kingdom). During the 1990s, new Swiss clinics 
required their own supply of diacetylmorphine, and a new pharmaceutical industry 
was established; since this time, particularly in recent years, several further companies 
have established their own supply. As far as we are aware, the active pharmaceutical 
ingredients of all of these different formulations are exactly the same. However, their 
preparation in different formulations varies, and this will have a direct bearing on 
their use within clinical practice of the future according to the fit with the operational 
practice of the clinics.
Next steps
Where next?
An important clinical and policy step forward has been achieved. A patient 
population that was previously considered to be resistant to treatment and with 
whom it appeared impossible to achieve therapeutic benefit has now been found to 
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be responsive to this intensive SIH. Not all of the refractory heroin addict patients 
respond to this treatment, and not all will find it acceptable. But for those among 
whom the benefit is observed, there are major benefits for themselves, their families 
and society. The challenge will be to establish a viable operational system of 
provision of this form of treatment in such a way that makes it available to severely 
affected heroin addicts, while not inadvertently undermining the commitment 
of other patients to orthodox forms of opiate addiction treatment. Retention in 
treatment is high for heroin treatment, but field studies showed in some of the 
countries that after 2 years of treatment about one-third of clients had left, and at 
least half of them went back to methadone substitution treatment in a better and 
more stable shape than before.
Other injectable opiate maintenance medications should also be explored further, 
especially in light of the encouraging preliminary results with supervised injectable 
hydromorphone seen with the small subset of the Canadian NAOMI trial, but more 
serious robust study in this area will be required.
Future clinical and research studies are likely to involve further investigation of 
administration of diacetylmorphine by different possible routes, including the 
study of heroin by smoking/chasing the dragon (as in the Dutch trial; van den 
Brink et al., 2003), and also the recent descriptions of the provision of oral heroin 
(Frick et al., 2006, 2010) as well as the small preliminary report of the potential 
of intranasal diacetylmorphine (Mitchell et al., 2006). These approaches are 
also highly relevant because, in some countries, particularly in Spain and the 
Netherlands, today the majority of heroin users do not use heroin intravenously.
Much has been achieved, and there is still much to be explored — as always. 
However, it is important to be clear that sufficient knowledge has now been gained 
from a series of well-designed randomised trials from different groups in different 
countries to conclude that real clinical benefits can be achieved through the provision 
of SIH to this patient population that was previously considered untreatable. Future 
work will build on the success of SIH and include the study of the longer-term 
outcome of patients receiving this treatment, and potential methods of securing 
further continuing gains. These will inform future reviews and later editions of this 
Insights series.
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Benzodiazepine: a class of drugs that have a hypnotic and sedative action, and are 
prescribed mainly as tranquillisers to control symptoms of anxiety, but are also used 
for recreational purposes.
Cost–benefit analysis: a type of economic evaluation that compares treatment 
interventions by exploring the relationship between the value of the resources used 
for each intervention and the value of a single or multiple benefits (e.g. victimisation, 
criminal justice expenses, lost work due to illness, etc.) produced by the same 
interventions.
Cost–utility analysis: a type of economic evaluation that compares competing 
treatment interventions in terms of both quantity and quality of life, expressed by 
utilities (e.g. cost per quality-adjusted life year).
Diacetylmorphine (the principal psychoactive constituent of heroin): a short-acting 
opiate agonist. Illicit (‘street’) heroin may be smoked or solubilised with a weak acid 
and injected.
Hydromorphone: a centrally acting opioid, derivative of morphine, three to four 
times stronger than morphine but with a lower risk of dependency.
Intention-to-treat (ITT) analysis: a method of analysing results of a randomised 
controlled trial that includes in the analysis all those cases that should have received 
a treatment regimen but for whatever reason did not. All cases allocated to each 
arm of the trial are analysed together as representing that treatment arm, regardless 
of whether they received or completed the prescribed regimen.
Liquid chromatography-mass spectrometry: an analytical chemistry technique used 
for the specific detection and potential identification of chemicals in the presence 
of other chemicals (in a complex mixture) whereby compounds are separated 
chromatographically, usually in a mixture of water and organic solvents, before they 
are introduced to an ion source and mass spectrometer.
Morphine: a naturally occurring alkaloid extracted from opium; a powerful narcotic 
substance with strong analgesic (painkilling) action and other significant effects on 
the central nervous system.
Noscopine: a naturally occurring substance, a non-addictive derivative of opium.
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Opiate: one of a group of alkaloids derived from the opium poppy (Papaver 
somniferum) with the ability to induce analgesia, euphoria and, in higher doses, 
respiratory depression and coma. The term excludes synthetic opioids.
Opioid: a generic term applied to alkaloids from the opium poppy (Papaver 
somniferum), their synthetic analogues and compounds synthesised in the body which 
interact with specific receptors in the brain and have the ability to induce analgesia, 
euphoria (a sense of well-being) and, in higher doses, respiratory depression and 
coma.
Opioid agonist: any morphine-like substance that produces effects that mimic 
the action of the naturally occurring substance, including pain relief, respiratory 
depression, etc.
Opioid antagonist: a substance (e.g. naloxone, naltrexone) that blocks mu, kappa or 
delta opioid receptors, used primarily in the treatment of opioid-induced respiratory 
depression.
Overdose: an accidental or intentional use of any drug in an amount that produces 
acute adverse physical or mental reactions — transient or lasting — or death; the 
lethal dose of a particular drug varies with the individual and with circumstances.
Papaverine: a non-addictive opium derivative.
Quality-adjusted life year (QALY): a numerical description of the values, in terms 
of quantity and quality of life, that treatment clients consider to be gaining during a 
treatment episode.
Randomised controlled trial (RCT): a study in which people are allocated at random 
(by chance alone) to receive one of several clinical interventions. One of these 
interventions is the standard of comparison or control. Someone who takes part in 
an RCT is called a participant or subject. RCTs seek to measure and compare the 
outcomes after the participants receive the interventions. The RCT is one of the most 
powerful tools in clinical research.
Relapse: in addiction, relapse is the resumption of drug use after trying to stop 
taking drugs. It is a common occurrence in many chronic disorders, including 
addiction, that requires behavioural adjustments to treat effectively.
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